Improved reprogramming, maintenance and preservation for induced pluripotent stem cells

A composition of TGFβ family proteins, ROCK inhibitors, and WNT activators in transient expression systems addresses genomic instability in iPSC generation, achieving stable and viable iPSCs for banking and redifferentiation.

KR1020260164643APending Publication Date: 2026-11-17FATE THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020267036944
Authority / Receiving Office
KR · KR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-10-02
Filing Date
2021-10-01
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing methods for generating induced pluripotent stem cells (iPSCs) using viral systems result in permanent genomic changes and exogenous gene reactivation, leading to instability and potential tumor formation, and current cell expansion and cryopreservation processes affect cell viability and function.

Method used

A composition comprising TGFβ family proteins, ROCK inhibitors, MEK inhibitors, and WNT activators, along with transient expression systems, is used to generate footprint-free iPSCs with improved pluripotency and genomic stability, including stages like single-cell dissociation, sorting, expansion, and cryopreservation.

Benefits of technology

The method produces iPSCs with high clonal regeneration, sustainable self-renewal, and minimal differentiation, maintaining genomic stability and viability through transient expression systems, suitable for banking and directed redifferentiation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PAT00004_ABST
    Figure PAT00004_ABST
Patent Text Reader

Abstract

The present invention provides a method and composition for providing iPSCs with desired characteristics with high efficiency by inducing reprogramming of non-pluripotent cells using a small molecule support vector system. Additionally, the present invention provides reprogrammed cells and iPSC populations or clonal cell lines using the provided reprogramming method and composition. Furthermore, the present invention provides compositions and methods for maintaining and preserving iPSCs while achieving genomic stability of the cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] Related applications

[0002] This application claims priority to U.S. Provisional Application No. 63 / 087,119 filed on October 2, 2020, the entire disclosure of which is incorporated herein by reference.

[0003] Technology field

[0004] The present disclosure relates broadly to the field of generating human induced pluripotent stem cells (iPSCs or iPS cells). More specifically, the present disclosure relates to the use of combinations of plasmid vectors to obtain footprint-free iPSCs having desirable characteristics with higher efficiency and increased reliability. Background Technology

[0005] iPSCs were originally generated by incorporating viral systems to express key transcription factors. Retroviral and lentiviral systems, including polycistrons and inducible systems, are now successfully used for iPSC generation. However, permanent genomic changes resulting from insertion mutagenesis and the potential for exogenous gene reactivation after iPSC differentiation may present potential challenges for the subsequent drug screening and therapeutic application of cells generated by these methods. Indeed, significant differences have been reported between iPSC clones generated using the same viral system, and a large percentage of clones have been reported to form tumors in rodents when transplanted into differentiated neurospheres. Studies suggest that iPSCs generated using the same viral method may behave differently upon differentiation. Differences in ectopic gene integration sites can lead to different insertion mutagenesis and epigenetic regulation of transplanted gene expression. For iPSC generation methods involving integration systems, it may be necessary to derive and screen a large number of clones to identify clones that are stable in both pluripotent and differentiated states.

[0006] Among the many key aspects of the cell therapy manufacturing process, cell expansion and cryopreservation have been identified as important areas of interest; cell viability and function are significantly affected during freeze-thaw cycles, and the in vivo cellular efficacy and persistence of effector cells derived from iPSC differentiation are complexly influenced during the effector cell expansion stage after iPSC differentiation. The problem to be solved

[0007] In light of the foregoing, there is a substantial need in the art to efficiently produce a homogeneous population of footprint-free iPSCs under defined culture conditions, preferably in a pluripotent "naive" or "grounded" state. A pluripotent "naive" or "grounded" state imparts to iPSCs characteristics including, but not limited to, high clonal regeneration, sustainable self-renewal, minimal spontaneous differentiation, and high viability as a genomic abnormality, dissociated single cell. The methods and compositions of the embodiments according to the present disclosure, in particular the novel culture media and plasmid vector systems, address this need and provide other related advantages in the field of cell reprogramming.

[0008] By using an efficient but transitional and transient expression system that minimizes the presence of exogenous genes to reduce the potential for host genome integration, the object of the present disclosure is to provide a method and composition efficient for generating iPSCs without containing exogenous DNA introduced into non-pluripotent cells for the induction of reprogramming. The object of the present disclosure is to provide a combination plasmid system for efficiently producing iPSCs having a "naive" or "bottom" state of pluripotency and / or high clonality. Since iPSCs having bottom-state pluripotency enable long-term survival and genetic stability of single-cell dissociated iPSCs, they can generate clonal iPSC lines suitable for banking and operations such as single-cell sorting and / or depletion, clonal iPSC targeted genome editing, and directed redifferentiation of iPSC homogeneous populations. Accordingly, the object of the present disclosure is to provide a method and composition for generating a single-cell derived iPSC clone line or a derivative cell therefrom, comprising one or several genetic modifications at selected sites, which include polynucleotide insertions, deletions, and substitutions, wherein such modifications retain and maintain function in subsequently derived cells even after differentiation, dedifferentiation, reprogramming, expansion, passaging, and / or transplantation.

[0009] One aspect of the present application provides a composition (e.g., FMM2) for the production of induced pluripotent stem cells (iPSCs), wherein the composition comprises (i) a TGFβ family protein, (ii) a ROCK inhibitor, and (iii) a MEK inhibitor and a WNT activator, wherein the composition does not comprise a TGFβ inhibitor, and the composition is effective in improving iPSC pluripotency and genomic stability in long-term iPSC maintenance. In some embodiments, long-term iPSC maintenance comprises one or more stages including single-cell dissociation of iPSC colonies, single-cell sorting of dissociated iPSCs, iPSC single-cell clonal expansion, cryopreservation of a clonal iPSC master cell bank (MCB), thawing of the iPSC MCB, and optionally additional cryopreservation-thaw cycles of the iPSC MCB; or the TGFβ family protein is optionally added to the composition at the single-cell dissociation of iPSC colonies, at the iPSC single-cell clonal expansion, or at any stage in between; MEK inhibitors and / or WNT activators constitute 30 to 60% of the amount used in the reprogramming composition for reprogramming non-pluripotent cells into iPSCs. In some embodiments, TGFβ family proteins comprise at least one of activin A, TGFβ, nodal, and functional variants or fragments thereof; and WNT activators comprise GSK3 inhibitors. In some embodiments, non-pluripotent cells comprise somatic cells, progenitor cells, or pluripotent cells; non-pluripotent cells comprise T cells; and the reprogramming composition comprises a ROCK inhibitor, a MEK inhibitor, a WNT activator, a TGFβ inhibitor, and optionally an HDAC inhibitor, wherein the TGFβ inhibitor and the HDAC inhibitor are included in the reprogramming composition at a specific stage during reprogramming.

[0010] In some embodiments, improved long-term iPSC pluripotency is indicated by reduced pluripotency recovery or reduced spontaneous differentiation compared to iPSCs not in contact with the composition; and improved genomic stability is indicated by a lower propensity for genomic abnormalities compared to iPSCs not in contact with the composition. In some embodiments, improved genomic stability includes a reduction or prevention of trisomy or karyotype abnormalities in iPSCs obtained by reprogramming T cells. In some embodiments, the composition further comprises iPSCs, and optionally, the iPSCs comprise at least one genome edit.

[0011] In some embodiments, iPSC maintenance further comprises iPSC genome editing to obtain an engineered iPSC pool, single-cell sorting of the engineered iPSC pool, engineered iPSC single-cell clone expansion, cryopreservation of a cloned engineered iPSC master cell bank (MCB), thawing of the engineered iPSC MCB, and optionally additional cryopreservation-thaw cycles of the engineered iPSC MCB; the engineered iPSC comprises at least one genome edit.

[0012] In another aspect, the present invention provides a composition (e.g., FRM2) for producing induced pluripotent stem cells (iPSCs), wherein the composition comprises (i) a ROCK inhibitor, a MEK inhibitor, and a WNT activator; (ii) an HDAC inhibitor; and (iii) a TGFβ inhibitor, wherein the composition is effective in improving the reprogramming of non-pluripotent cells to obtain iPSCs with established pluripotency and improved genomic stability, and optionally, the addition of (i), (ii), or (iii) to the composition is stage-specific during the reprogramming of non-pluripotent cells for increased reprogramming efficiency. In some embodiments, the reprogramming of non-pluripotent cells comprises one or more stages including somatic cell transfection (day 0), exogenous gene expression, increase in heterochromatin, loss of somatic identity, and iPSC colony formation; or the addition of the HDAC inhibitor is optionally made at chromatin reconstruction or about 2-3 days (after transfection); The addition of a TGFβ inhibitor is selectively performed at the time of loss of somatic identity or about 6-8 days (after transfection), and one or more stages of reprogramming are indicated by cell morphological changes and / or marker gene profiling.

[0013] In some embodiments, the HDAC inhibitor comprises valproic acid (VPA) or a functional variant or derivative thereof; and the WNT activator comprises a GSK3 inhibitor. In some embodiments, the non-pluripotent cells comprise somatic cells, progenitor cells, or pluripotent cells; and the non-pluripotent cells comprise T cells. In some embodiments, established pluripotency comprises ground-state pluripotency and / or; established pluripotency is expressed by increased naive-specific gene expression comprising one or more of MAEL, KLF4, DNMT3L, DPPA5, PRDM14, FGF4, UTF1, TFCP2L1, and TBX3; and improved genomic stability is indicated by a lower propensity for genomic abnormalities than iPSCs obtained without contact with the composition during reprogramming; Increased reprogramming efficiency is indicated by a higher percentage of cells expressing pluripotency marker genes in the iPSC pool after reprogramming compared to the iPSC pool obtained without contact with the composition during reprogramming.

[0014] In another aspect, the present invention provides a method for producing induced pluripotent stem cells (iPSCs), comprising the step of cryopreserving a population of induced pluripotent stem cells (iPSCs), wherein the iPSCs are in contact with a composition (e.g., FRM2) as described herein, and the pluripotency and genomic stability of the iPSCs are maintained during cryopreservation; optionally, an iPSC population comprising homogeneous iPSCs is expanded from a single clonal iPSC cell.

[0015] In some embodiments, a method for producing induced pluripotent stem cells (iPSCs) further comprises the step of expanding a single-cell iPSC clone to obtain a population of cloned iPSCs, wherein the iPSCs come into contact with the composition described herein (e.g., FMM2), and the pluripotency and genomic stability of the iPSCs are maintained during expansion.

[0016] In some embodiments, a method for producing induced pluripotent stem cells (iPSCs) further comprises a single-cell sorting step of dissociated iPSCs to obtain single-cell iPSC clones, wherein the iPSCs are in contact with a composition as described herein (e.g., FMM2), and the pluripotency and genomic stability of the iPSCs are maintained during single-cell sorting.

[0017] In some embodiments, a method for producing induced pluripotent stem cells (iPSCs) further comprises the step of dissociating iPSC colonies into single-cell iPSCs, wherein the iPSCs come into contact with a composition described herein (e.g., FMM2), and the pluripotency and genomic stability of the iPSCs are maintained during iPSC single-cell dissociation.

[0018] In some embodiments, the method for producing induced pluripotent stem cells (iPSCs) further comprises the step of obtaining at least one colony comprising iPSCs produced by reprogramming non-pluripotent cells.

[0019] In various embodiments of the method for producing induced pluripotent stem cells, iPSCs are reprogrammed from somatic cells, progenitor cells, or pluripotent cells, or iPSCs are reprogrammed from T cells. In various embodiments, pluripotency comprises and / or comprises ground-state pluripotency; pluripotency is expressed by increased naive-specific gene expression comprising one or more of MAEL, KLF4, DNMT3L, DPPA5, PRDM14, FGF4, UTF1, TFCP2L1, and TBX3; and genomic stability comprises a lower tendency for genomic abnormalities than iPSCs in the above steps without contact with the composition described herein.

[0020] In another aspect, the present invention provides a method for producing induced pluripotent stem cells (iPSCs), the method comprising: (i) initiating cell reprogramming by delivering one or more reprogramming factors to non-pluripotent cells; and (ii) generating at least one colony comprising iPSCs by reprogramming non-pluripotent cells by contacting the cells after step (i) with a composition described herein (e.g., FRM2) for a sufficient time. In some embodiments, the delivery step comprises introducing the following into non-pluripotent cells: (i) one or more first plasmids, each first plasmid comprising a polynucleotide encoding a replication origin and one or more reprogramming factors, but not a polynucleotide encoding EBNA or a variant thereof; and one or more first plasmids comprising at least OCT4, or at least a polynucleotide encoding OCT4, YAP1, SOX2, and large T antigen (LTag) collectively; The introduction of one or more first plasmids induces a reprogramming process; and (ii) (1) a second plasmid comprising a nucleotide sequence encoding EBNA, wherein the second plasmid does not comprise polynucleotide(s) encoding a replication origin or reprogramming factor(s); (2) EBNA mRNA; and (3) one of an EBNA protein. In some embodiments, one or more first plasmids further comprise polynucleotides collectively encoding one or both of SOX2 and KLF, or one or more of MYC, LIN28, ESRRB and ZIC3.

[0021] In some embodiments, the contact step further comprises the step of culturing cells in the presence of a ROCK inhibitor, a MEK inhibitor, a WNT activator, an HDAC inhibitor, and a TGFβ inhibitor. In certain embodiments, the contact step comprises: (a) selectively contacting cells after step (i) with a combination comprising a ROCK inhibitor, a MEK inhibitor, and a WNT activator at the stage of exogenous reprogramming factor expression, or 1 to 2 days after reprogramming factor delivery (day 0); (b) selectively contacting cells from step (a) with an HDAC inhibitor at the chromatin restructuring stage, or about 2 to 3 days after reprogramming factor delivery; and (c) selectively contacting cells from step (b) with a TGFβ inhibitor at the stage of loss of somatic identity, or about 6 to 8 days (after transfection) to generate at least one colony comprising iPSCs; said stages are indicated by cell morphological changes and / or marker gene profiling; iPSCs have no footprint, pluripotency is established, genomic stability is improved, and are produced with higher efficiency compared to reprogramming without steps (a), (b), and (c). In some embodiments, non-pluripotent cells include somatic cells, progenitor cells, or pluripotent cells; or non-pluripotent cells include T cells.In some embodiments, established pluripotency comprises ground-state pluripotency and / or; established pluripotency is expressed by increased naive-specific gene expression comprising one or more of MAEL, KLF4, DNMT3L, DPPA5, PRDM14, FGF4, UTF1, TFCP2L1, and TBX3 and / or; improved genomic stability comprises a lower propensity for genomic abnormalities than iPSCs from reprogramming without steps (a), (b), and (c); and increased reprogramming efficiency is indicated by a higher percentage of cells expressing pluripotency marker genes in the iPSC pool after reprogramming than in the iPSC pool obtained without contact with the composition during reprogramming. In some embodiments, improved genomic stability further comprises a reduction or prevention of trisomy or karyotype abnormalities in iPSCs obtained by reprogramming T cells.

[0022] In another aspect, the present invention provides a method for producing induced pluripotent stem cells (iPSCs), the method comprising: (i) initiating cell reprogramming by delivering one or more reprogramming factors to non-pluripotent cells; (ii) contacting the cells after step (i) with a composition described herein (e.g., FRM2) for a sufficient period of time to produce at least one colony containing iPSCs, wherein the pluripotency and genomic stability of the iPSCs are established; (iii) dissociating the iPSC colony of step (ii) into dissociated iPSCs, wherein the iPSCs are in contact with a composition described herein (e.g., FMM2); (iv) sorting the dissociated iPSCs to obtain one or more single-cell iPSC clones, wherein the single-cell iPSC clones are in contact with a composition described herein (e.g., FMM2); and optionally, (v) a step of expanding a single-cell iPSC clone into a population of clonal iPSCs, wherein the population of clonal iPSCs is in contact with a composition described herein (e.g., FMM2); and optionally, (vi) a step of cryopreserving a population of clonal iPSCs, wherein the cryopreserved population is in contact with a composition described herein (e.g., FMM2), and the pluripotency and genomic stability of the iPSCs are maintained during the steps of dissociation, sorting, expansion, cryopreservation, or thawing. In some embodiments, one or more reprogramming factors comprise at least OCT4.

[0023] In various embodiments, the delivery step (i) comprises introducing the following into a non-pluripotent cell: (a) one or more first plasmids, each first plasmid comprising a polynucleotide encoding a replication origin and one or more reprogramming factors, but not a polynucleotide encoding EBNA or a variant thereof; one or more first plasmids comprising at least OCT4, or at least polynucleotides encoding OCT4, YAP1, SOX2, and large T antigen (LTag) collectively; and the introduction of one or more first plasmids induces a reprogramming process; and (b) one of (1) a second plasmid comprising a nucleotide sequence encoding EBNA, wherein the second plasmid does not contain polynucleotide(s) encoding a replication origin or reprogramming factors; (2) EBNA mRNA; and (3) EBNA protein. In some embodiments, one or more first plasmids collectively additionally comprise a polynucleotide encoding one or both of SOX2 and KLF, or one or more of MYC, LIN28, ESRRB and ZIC3.

[0024] In some embodiments, the contact step (ii) further comprises the step of culturing cells in the presence of a ROCK inhibitor, a MEK inhibitor, a WNT activator, an HDAC inhibitor, and a TGFβ inhibitor. In certain embodiments, the contact step (ii) comprises: (a) selectively contacting cells after step (i) with a combination comprising a ROCK inhibitor, a MEK inhibitor, and a WNT activator at the stage of exogenous reprogramming factor expression, or 1 to 2 days after reprogramming factor delivery (day 0); (b) selectively contacting cells from step (a) with an HDAC inhibitor at the chromatin restructuring stage, or about 2 to 3 days after reprogramming factor delivery; and (c) selectively contacting cells from step (b) with a TGFβ inhibitor at the stage of loss of somatic identity, or about 6 to 8 days (after delivery) to generate at least one colony comprising iPSCs; said stages are indicated by cell morphological changes and / or marker gene profiling; iPSCs have established pluripotency and improved genomic stability and are produced with higher efficiency compared to reprogramming without steps (a), (b), and (c). In some embodiments, the method comprises: (1) a step of contacting cells of the sorting step (iv), expansion step (v), cryopreservation step (vi), and optionally the dissociation step (iii) with a ROCK inhibitor, a MEK inhibitor, and a WNT activator, wherein the concentration of one or both of the MEK inhibitor and the WNT activator is 30% to 60% of the concentration in step (ii); (2) a step of further contacting cells of the expansion step (v) and cryopreservation step (vi), and optionally the dissociation step (iii) and / or sorting step (iv) with a TGFβ family protein; and the cells of steps (iii), (iv), (v), and (vi) are not contacted with a TGFβ inhibitor or an HDAC inhibitor.

[0025] In various embodiments, non-pluripotent cells comprise somatic cells, progenitor cells, or pluripotent cells; or non-pluripotent cells comprise T cells. In some embodiments, pluripotency comprises ground-state pluripotency and / or; pluripotency is expressed by increased naive-specific gene expression comprising one or more of MAEL, KLF4, DNMT3L, DPPA5, PRDM14, FGF4, UTF1, TFCP2L1, and TBX3; iPSCs comprise at least one genome edit and / or; and genomic stability comprises a lower tendency for genomic abnormalities. In some embodiments, genomic stability further comprises a reduction or prevention of trisomy or karyotype abnormalities in iPSCs obtained by reprogramming T cells.

[0026] In some embodiments, the process further comprises genome editing of iPSCs to obtain a pool of engineered iPSCs, single-cell sorting of the pool of engineered iPSCs, single-cell clonal expansion of engineered iPSCs, cryopreservation of a cloned engineered iPSC master cell bank (MCB), thawing of the engineered iPSC MCB, and optionally additional cryopreservation-thaw cycles of the engineered iPSC MCB; the engineered iPSCs comprise at least one genome edit. In some embodiments, in the iPSCs or iPSC-derived effector cells, the genome edit is a deletion or reduced expression of B2M, TAP1, TAP2, Tafacin, NLRC5, PD1, LAG3, TIM3, RFXANK, CITTA, RFX5, or RFXAP; or HLA-E, HLA-G, CD16, 4-1BBL, CD3, CD4, CD8, CD47, CD137, CD80, PDL1, A 2A It causes the introduction or increased expression of R, CAR, TCR, engager, or surface-induced receptors for engagers.

[0027] In another aspect, the present invention provides a composition comprising induced pluripotent cells (iPSCs), a cell line, a clonal population, or a master cell bank thereof, wherein the iPSCs are contacted by a combination of a ROCK inhibitor, a MEK inhibitor, a WNT activator, and a TGFβ family protein, and the iPSCs have increased naive-specific gene expression comprising one or more of MAEL, KLF4, DNMT3L, DPPA5, PRDM14, FGF4, UTF1, TFCP2L1, and TBX3; optionally, the iPSCs provide a composition having at least one of high clonality, genetic stability, and ground-state pluripotency. In some embodiments, the TGFβ family protein comprises and / or comprises at least one of activin A, TGFβ, nodal, and functional variants or fragments thereof; and the WNT activator comprises a GSK3 inhibitor. In some embodiments, the iPSCs are generated from the reprogramming of non-pluripotent cells. In some embodiments, the non-pluripotent cells comprise somatic cells, progenitor cells, or pluripotent cells; or the non-pluripotent cells comprise T cells. In some embodiments, the iPSC comprises at least genome editing. In some embodiments, the composition further comprises a medium, and the medium is feeder-free.

[0028] In another aspect, the present invention provides induced pluripotent cells (iPSCs) produced by the method described herein, cell lines, clonal populations, or master cell banks thereof. In some embodiments, the iPSCs comprise at least genome editing.

[0029] In another aspect, the present invention provides non-natural cells or a population thereof derived from the in vitro differentiation of the pluripotent cells or cell lines described herein. In some embodiments, the cells are immune effector cells, and optionally, the immune effector cells comprise at least a genome edit contained in the iPSCs. In some embodiments, the cells comprise CD34 cells, hematopoietic endothelial cells, hematopoietic stem or progenitor cells, hematopoietic pluripotent progenitor cells, T cell progenitors, NK cell progenitors, T cells, NKT cells, NK cells, B cells, or immunomodulatory cells. In some embodiments, the cells are rejuvenated cells comprising at least one of the following characteristics compared to their natural cell counterparts: an overall increase in heterochromatin; improved mitochondrial function; an increased DNA damage response; telomere elongation and a decrease in the percentage of short telomeres; a decrease in the proportion of senescent cells; and a higher potential for proliferation, survival, persistence, or memory-like functions.

[0030] In another aspect, the present invention comprises pluripotent cells produced by the method described herein, as a composition for use in producing pluripotent cells for application in cell-based therapy. In some embodiments, the pluripotent cells are allogeneic or autologous cells. In another aspect, the present invention provides a pharmaceutical kit comprising pluripotent cells obtained by the method described herein. In another aspect, the present invention provides a pharmaceutical kit comprising the induced pluripotent cells described herein or the induced non-natural cells described herein.

[0031] Another aspect of the present application provides an in vitro system for initiating reprogramming in non-pluripotent cells, the system comprising: one or more first plasmids, each first plasmid comprising a replication origin and a polynucleotide encoding one or more reprogramming factors but not coding for EBNA or a variant thereof; one or more first plasmids collectively comprising polynucleotides encoding OCT4, YAP1, SOX2 and LTag; and optionally (1) a second plasmid comprising a nucleotide sequence encoding EBNA, wherein the second plasmid does not comprise polynucleotide(s) encoding the replication origin or reprogramming factors; (2) EBNA mRNA; and (3) one of EBNA proteins. In some embodiments, the second plasmid of the system has a high loss rate; and the expression of EBNA by the second plasmid is short-lived, transient, and transient. In some other embodiments, EBNA replication and / or continuous expression in the nucleus is not provided. In one embodiment, the system enables transient / cytoplasmic expression of EBNA for a short period prior to the emergence of a pluripotent cell form and the induced expression of an endogenous pluripotent gene. In some embodiments, the system enables transient / cytoplasmic expression of one or more reprogramming factors contained in the first plasmid(s) for a short period prior to the emergence of a pluripotent cell form and the induced expression of an endogenous pluripotent gene.

[0032] In one embodiment of the system, the replication origin of the first plasmid(s) is one selected from the group consisting of polyomavirinae virus, papillomavirus, and gamma herpesvirus. In some embodiments, the replication origin is selected from the group consisting of SV40, BK virus (BKV), bovine papillomavirus (BPV), or Epstein-Barr virus (EBV). In one specific embodiment, the replication origin corresponds to or is derived from the wild-type replication origin of EBV. In some other embodiments, the EBNA of the second plasmid in the system is EBV-based. In some embodiments, the system comprises (i) one or more of NANOG, KLF, LIN28, MYC, ECAT1, UTF1, ESRRB, HESRG, CDH1, TDGF1, DPPA4, DNMT3B, ZIC3, and L1TD1; or (ii) provide one or more first plasmids collectively comprising polynucleotides encoding reprogramming factor(s) including MYC, LIN28, ESRRB, and ZIC3. In some embodiments, the polynucleotides encoding the reprogramming factor are included in the first plasmids in a polycistron construct or a non-polycistron construct. In one embodiment of the polycistron construct, the polycistron construct comprises a single open read frame or multiple open read frames. In an embodiment in which the system comprises two or more first plasmids, each first plasmid may comprise the same or different reprogramming factor encoded by at least one polynucleotide copy. In some embodiments, the system comprises four first plasmids, each first plasmid comprising the same or different reprogramming factor encoded by at least one polynucleotide copy.In an embodiment in which the system comprises four first plasmids, each first plasmid comprises at least one copy of a polynucleotide encoding OCT4 and YAP1, SOX2 and MYC, LIN28 and LTag, and ESRRB and ZIC3.

[0033] In some embodiments, the first plasmid comprises one or more polynucleotides encoding a reprogramming factor, and adjacent polynucleotides are operably linked by a linker sequence encoding a self-cleaving peptide or an IRES. In one embodiment, the self-cleaving peptide is a 2A peptide and is selected from the group comprising F2A, E2A, P2A, and T2A. In another embodiment, the 2A peptides included in the first plasmid construct may be the same or different. In another embodiment in which the plasmid of the system comprises a plurality of 2A peptides, two 2A peptides at adjacent positions are different. In some other embodiments, the first and second plasmids each comprise one or more promoters for the expression of the reprogramming factor and EBNA, and the one or more promoters comprise at least one of CMV, EF1α, PGK, CAG, UBC, and other suitable promoters that are constitutive, inducible, endogenous regulatory, or transient, tissue or cell type specific. In one embodiment, the first and second plasmids each include a CAG promoter.

[0034] In one aspect, the present disclosure provides a kit. In some embodiments, the kit comprises one or more compositions disclosed herein, such as (i) a first composition for iPSC production and a second composition for iPSC production, and / or (ii) a first composition for iPSC production and a second composition for iPSC retention. A kit comprising an in vitro system described herein is also provided.

[0035] Various purposes and advantages of using the method and composition will become apparent from the following description taken together with the accompanying drawings, which present specific embodiments of the invention as examples. Brief explanation of the drawing

[0036] Figures 1a and 1b show that supplementing FMM with members of the TGFβ family (e.g., activin A, TGFβ, and / or nodal) or reducing the concentrations of MEK and GSK3 inhibitors in FMM improves the long-term stability of iPSCs. Figure 1a. The figure shows an exemplary experimental design for testing various formulations of FMM-based media for long-term iPSC culture. Figure 1b. Summary of ddPCR and karyotype results for one engineered clone derived from T cell donor 1 and two unengineered clones derived from T cell donor 2 tested using the experimental design of Figure 1a. Figure 2 shows the PCA analysis results of three TiPSC clones maintained in E8, FMM, or FMM2 for more than 10 passages. Figures 3a and 3b show the heatmaps of the major pluripotency markers of the three TiPSC clones of Figure 2, where the common pluripotency marker was expressed under all tested conditions (Figure 3a), and the expression of the naive-specific marker was further increased by the addition of activin A (Figure 3b). Figures 4A through 4C are schematic and graphic representations showing that FMM supplemented with Activin A prevents stress-induced genomic abnormalities. Figure 4A shows an exemplary experimental design for inducing stress (manipulation and / or screening / expansion) in iPSC clones. Figure 4B shows a comparison of abnormal cells in iPSC populations generated using FMM and FMM2 (FMM + ActA). Figure 4C shows a comparison of abnormal clones after cryopreservation in iPSC populations generated using FMM and FMM2 (FMM + ActA). Figures 5a and 5b show that applying a new FMM formulation early in the iPSC generation process improves the genomic stability of iPSCs. Figure 5a is a diagram showing an exemplary experimental design for generating iPSCs from primary T cells. Figure 5b shows the results of evaluating the genomic stability of iPSC clones generated with FMM compared to the new FMM formulation. FIG. 6 is a diagram showing exemplary DNA constructs of vector 1 (1), vector 1 (2)… vector 1 (n), vector 1 (n+1), and vector 2 used in a short-term transient and temporary reprogramming (STTR) system. Figures 7a and 7b show that the addition of valproic acid (VPA) to the STTR system improves the reprogramming efficiency of STTR. Figure 7a shows the flow cytometry analysis of the expression of iPSC surface markers (SSEA4, TRA-1-81, and CD30) in T cells reprogrammed using the STTR2 system with or without VPA treatment. Figure 7b shows that VPA treatment enhances STTR2 reprogramming of T cells derived from three different donors. Figures 8a through 8c demonstrate STTR2-induced stable pluripotent cultures derived from multiple donor T cells. Figure 8a shows an image of iPSC colonies induced by the STTR2 system from T cells of two different donors. Figure 8b shows that a portion of the iPSC population increases over successive passages, indicating stable pluripotent cultures derived from multiple donors. Figure 8c shows a representative flow cytometry profile of the reprogramming pool from T cells of two different donors. Figure 9 is a diagram illustrating an exemplary workflow for improved reprogramming and iPSC retention using stage-specific badges. Figures 10a through 10c show that reprogramming T cells using the STTR2 system generated potent iPSC clones without transplant genes. Figure 10a shows an example of the position of the TaqMan probe (black bar) for the detection of the reprogramming vector. Figure 10b shows an example of the mean Ct values ​​from the TaqMan assay; positive control 1 is an iPSC clone with multiple transplant gene integration (positive for EBNA1 and P2A); positive control 2 is an iPSC clone with a plasmid backbone (positive for KanR) integrated; ND: not detected. Figure 10c shows a summary of the vector clearance results for STTR2 clones derived from T cells from two different donors. Figure 11 demonstrates the flow cytometry profile of an STTR2-generated iPSC clone showing homogeneous expression of iPSC surface markers (SSEA4, TRA-1-81, and CD30). Figures 12a through 12c demonstrate that STTR2-generated iPSC clones maintain a high propensity to differentiate into cell types representing all three germ layers. Figure 12a shows the expression of the indicated lineage markers (pancreatic progenitor marker SOX17 for the endoderm, mesenchymal marker CD56 for the mesoderm, and neural progenitor marker SOX2 for the ectoderm). Figure 12b shows flow cytometry analysis at the indicated time points demonstrating that STTR2-generated iPSCs differentiated into mature T cells similarly to control iPSCs generated using a conventional episomal system. Figure 12c provides images of tissue sections from each of the three germ layers formed in STTR2-generated iPSC teratomas. Figure 13 demonstrates the flow cytometry profile of STTR2-generated, CAR-engineered iPSCs showing uniform expression of pluripotent surface markers. Figures 14a and 14b demonstrate the phenotypic and functional characteristics of T cells derived from CAR-engineered STTR2-generated iPSCs. Specific details for implementing the invention

[0037] definition

[0038] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as generally understood by a person skilled in the art to which this invention pertains. For the purposes of this invention, the following terms are defined below. The articles “a,” “an,” and “the” are used herein to refer to one or more than one (i.e., at least one) of grammatical objects. For example, “element” means one element or more than one element.

[0039] The use of alternatives (e.g., "or") should be understood to mean one, both, or any combination thereof. The term "and / or" should be understood to mean one or both of the alternatives.

[0040] As used herein, the term “about” or “approximately” refers to a quantity, level, value, number, frequency, percentage, dimension, size, quantity, weight, or length that varies by 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% relative to a reference quantity, level, value, number, frequency, percentage, dimension, size, quantity, weight, or length. In one embodiment, the term “about” or “approximately” refers to a range of ± 15%, ± 10%, ± 9%, ± 8%, ± 7%, ± 6%, ± 5%, ± 4%, ± 3%, ± 2%, or ± 1% relative to a reference quantity, level, value, number, frequency, percentage, dimension, size, quantity, weight, or length.

[0041] As used herein, the terms “substantially” or “essentially” refer to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that is about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more of a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length. In one embodiment, the terms “essentially identical” or “substantially identical” refer to a range of quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that is nearly identical to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length.

[0042] The terms “substantially absent” and “essentially absent” as used herein are used interchangeably and, when used to describe a composition, e.g., a cell population or a culture medium, refer to a composition in which a specific substance or its source is absent, e.g., 95%, 96%, 97%, 98%, 99%, or undetectable by measurement by conventional means. The term “absent” or “essentially absent” of a specific component or substance of a composition also means that such component or substance is (1) included in the composition at any concentration or (2) not included in the composition at a low concentration that is functionally inert. A similar meaning may be applied to the term “absence of” when referring to the absence of a specific substance or its source of a composition.

[0043] As used herein, terms such as “isolated” refer to a cell or group of cells separated from its original environment, that is, the environment of the isolated cell is substantially devoid of at least one component as found in the environment where the “non-isolated” reference cell exists. The term includes cells removed from some or all components found in a natural environment (e.g., tissue, biopsy). The term also includes cells removed from at least one, some or all components because the cell is found in a non-natural environment, e.g., a culture, a cell suspension. Thus, the isolated cell is partially or completely separated from at least one component, including other material, cells, or cell populations, as it is found in nature or as it is grown, stored, or exists in a non-natural environment. Specific examples of isolated cells include partially pure cells, substantially pure cells, and cells cultured in a non-natural medium. Isolated cells may be obtained by separating the desired cell or group thereof from other material or cells in the environment, or by removing one or more other cell populations or subgroups from the environment.

[0044] Terms used herein, such as "purify," refer to increasing purity. For example, purity can be increased to at least 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%.

[0045] Throughout this specification, unless otherwise required by the context, the words “include,” “comprising,” and “comprising” are to be understood as meaning the inclusion of a specified step or element or group of steps or elements, but not excluding any other step or element or group of steps or elements. In certain embodiments, the terms “include, comprise,” “has,” and “contain” are used as synonyms.

[0046] The phrase "consisting of" means that it includes and is limited to whatever precedes it. Therefore, the phrase "consisting of" indicates that the enumerated elements are necessary or essential and that no other elements can exist.

[0047] "Essentially composed of" means that it includes any element enumerated following the phrase and is limited to other elements that do not interfere with or contribute to the activity or function specified in the disclosure with respect to the enumerated element. Accordingly, the phrase "essentially composed of" indicates that the enumerated element is necessary or essential, but other elements are not optional and may or may not be provided depending on whether they affect the activity or function of the enumerated element.

[0048] Throughout this specification, references to “one embodiment,” “an embodiment,” “a specific embodiment,” “related embodiment,” “specific embodiment,” “additional embodiment,” or “additional embodiment,” or any combination thereof, mean that a specific characteristic, structure, or feature described in relation to an embodiment is included in at least one embodiment of the present invention. Accordingly, the appearance of the foregoing phrases in various places throughout this specification does not necessarily refer to the same embodiment. Furthermore, a specific characteristic, structure, or feature may be combined in any suitable manner in one or more embodiments.

[0049] The term “in vitro” generally refers to activity occurring in experiments or measurements performed in or on living tissue outside of an organism, such as in an artificial environment outside the organism that has minimal modifications to natural conditions. In certain embodiments, “in vitro” procedures involve living cells or tissues taken from an organism and cultured, typically in an experimental apparatus under sterile conditions, for several hours or up to about 24 hours (including 48 hours or 72 hours or more), depending on the environment. In certain embodiments, such tissues or cells may be collected, frozen, and subsequently thawed for in vitro processing. Tissue culture experiments or procedures using living cells or tissues that last longer than a few days are typically considered to be “in vitro” (although in certain embodiments, this term may be used interchangeably with “in vitro”).

[0050] The term "in vivo" generally refers to activities that occur within an organism.

[0051] As used herein, the terms “reprogramming,” “dedifferentiation,” “increased cell efficacy,” or “increased developmental efficacy” refer to methods or processes of increasing the pluripotency of cells or dedifferentiating cells into a less differentiated state. For example, cells with increased pluripotency possess greater plasticity (i.e., can differentiate into more cell types) compared to the same cells in a non-reprogramming state. In other words, reprogrammed cells are in a less differentiated state than the same cells in a non-reprogramming state. “Reprogramming cells,” as opposed to reprogrammed cells, refer to non-pluripotent cells undergoing reprogramming / dedifferentiation into a pluripotent state, representing a transitional form (i.e., a change in form) that lacks the characteristics of pluripotent cells, including a pluripotent stem cell form or stable endogenous pluripotent gene expression such as OCT4, NANOG, SOX2, SSEA4, TRA181, CD30, and / or CD50. The transitional form of "reprogramming cell" is distinguished from the initiating non-pluripotent cells prior to reprogramming induction and from reprogrammed cells having embryonic stem cell characteristic forms. For example, when reprogramming fibroblasts, the morphological changes of the reprogramming cell include MET (Mesenchymal-to-Epithelial Transition). Those skilled in the art readily understand and identify these transitional forms for various types of somatic cells induced to reprogram. In some embodiments, the reprogramming cell is an intermediate cell induced to reprogram for at least 1, 2, 3, 4, 5, 6, 7, 8 days but 21, 22, 24, 26, 28, 30, 32, 35, 40 days or less, or a number of days in between, and the cell has not entered a self-maintaining or self-sustaining pluripotent state. Non-pluripotent cells are induced to reprogram when one or more reprogramming factors are introduced into the cells.Reprogramming cells induced to reprogram for 1, 2, 3, or 4 days are cells 1, 2, 3, or 4 days (transduction day 0) after transduction of the reprogramming factor. Unlike somatic cells before exposure to exogenous expression of the reprogramming factor, reprogramming cells can proceed within the reprogramming process and reach a stable pluripotent state, and as long as sufficient time is given, they become reprogrammed cells even without exogenous expression of the reprogramming factor.

[0052] The term "induced pluripotent stem cell" or iPSC as used herein means that stem cells are generated from differentiated adult, neonatal, or fetal cells that have been induced or altered, that is, reprogrammed into cells capable of differentiating into all three germ layers or dermal layers (mesoderm, endoderm, and ectoderm).

[0053] As used herein, the term "embryonic stem cell" refers to naturally occurring pluripotent stem cells of the inner cell colony of an embryonic blastocyst. Embryonic stem cells are pluripotent and arise during development into all derivatives of the three primary germ layers (ectoderm, endoderm, and mesoderm). They do not contribute to the extraembryonic membrane or placenta (i.e., they are not totipotent).

[0054] As used herein, the term "pluripotent stem cell" refers to a cell that has the potential to differentiate into cells of one or more germ layers (ectoderm, mesoderm, and endoderm) (but not all three). Therefore, pluripotent cells may also be referred to as "partially differentiated cells." Pluripotent cells are well known in the relevant art, and examples of pluripotent cells include adult stem cells, e.g., hematopoietic stem cells and neural stem cells. "Pluripotency" indicates that a cell can form multiple types of cells within a given lineage (but not cells of other lineages). For example, pluripotent hematopoietic cells can form multiple different types of blood cells (red blood cells, white blood cells, platelets, etc.) but cannot form neurons. Therefore, the term "pluripotency" refers to a cell state that has a lower degree of potential for development than pluripotency and pluripotency.

[0055] As used herein, the term "pluripotency" refers to the ability of a cell to form all lineages of a body or somatic cell (i.e., embryonic suitability). For example, embryonic stem cells are a type of pluripotent stem cell capable of forming cells from each of the three germ layers (ectoderm, mesoderm, and endoderm). Pluripotency is a continuum of developmental efficacy ranging from incompletely or partially pluripotent cells (e.g., protoderm stem cells or EpiSCs) that cannot produce a complete organism more primitively, to more pluripotent cells that can produce a complete organism (e.g., embryonic stem cells).

[0056] Pluripotency can be determined in part by evaluating the pluripotency characteristics of the cell. Pluripotency characteristics include, but are not limited to: (i) pluripotent stem cell morphology; (ii) unlimited self-renewal potential; (iii) expression of pluripotent stem cell markers including, but not limited to, SSEA1 (mouse only), SSEA3 / 4, SSEA5, TRA1-60, TRA1-81, TRA1-85, TRA2-54, GCTM-2, TG343, TG30, CD9, CD29, CD133 / prominin, CD140a, CD56, CD73, CD90, CD105, OCT4, NANOG, SOX2, CD30, and / or CD50; (iv) ability to differentiate into all three somatic lineages (ectoderm, mesoderm, and endoderm); (v) teratoma formation consisting of the three somatic lineages; and (vi) formation of an embryoid body composed of cells of three somatic lineages.

[0057] Two types of pluripotency have been previously described: a "primed" or "metastable" state of pluripotency similar to ectoblastic stem cells (EpiSCs) of late blastocysts, and a "naive" or "bottom" state of pluripotency similar to inner cell colonies of early / preimplantation blastocysts. Both pluripotency states exhibit the characteristics described above, but the naive or bottom state additionally exhibits: (i) pre-inactivation or reactivation of the X-chromosome in female cells; (ii) improved clonality and survival during single-cell culture; (iii) overall reduction in DNA methylation; (iv) reduced deposition of H3K27me3 repressive chromatin markers for developmental regulatory gene promoters; and (v) reduced expression of differentiation markers compared to primed-state pluripotency cells. The standard method of cell reprogramming in which an exogenous pluripotency gene is introduced into somatic cells, expressed, and subsequently silenced or removed from the acquired pluripotency cells appears to generally possess the characteristics of the primed-state of pluripotency. Under standard pluripotent cell culture conditions, unless exogenous transplant gene expression is maintained, these cells remain in a primed state, but ground state characteristics are observed.

[0058] Pluripotency exists as a continuum, and induced pluripotent stem cells appear to exist in both "primed" and "naive" states, with cells in the naive state likely possessing greater differentiation potential. Induced pluripotent stem cells generated in conventional culture media exist in a primed state and are more similar to cells derived from post-implantation blastocysts, while naive iPSCs exhibit pluripotency characteristics more similar to mouse embryonic stem cells or cells derived from pre-implantation blastocysts. The primed and naive cell states can be defined by various differences, including differences in colony morphology, cellular responses to the inhibition or activation of major signaling pathways, gene expression signatures, and the ability to reactivate genes associated with extraembryonic cells. For example, conventional iPSCs exhibiting a primed pluripotency state display a flat colony morphology, while naive iPSCs display a small dome-shaped colony morphology similar to mouse embryonic stem cells. As used herein, the term "pluripotent stem cell morphology" refers to the classical morphological characteristics of embryonic stem cells. Normal embryonic stem cell morphology is characterized by a round and small shape, along with a high nucleus-to-cytoplasm ratio, the notable presence of nucleoli, and typical intracellular spaces.

[0059] "Pluripotency factor" or "reprogramming factor" refers to an agent or combination of agents used to induce or increase the developmental efficacy of a cell. Pluripotency factors include, but are not limited to, polynucleotides, polypeptides, and small molecules capable of increasing the developmental efficacy of a cell. Exemplary pluripotency factors include, for example, transcription factors OCT4 and SOX2, and small molecule reprogramming agents, for example, TGFβ inhibitors, GSK3 inhibitors, MEK inhibitors, and ROCK inhibitors.

[0060] The term “differentiation” as used herein is the process by which unspecialized (“uncommitted”) or less specialized cells acquire the characteristics of specialized cells, e.g., blood cells or muscle cells. Differentiated or differentiation-induced cells are those taken at a more specialized (“committed”) position within a cell lineage. When applied to the differentiation process, the term “committed” refers to a cell that progresses in the differentiation pathway to a point where, under normal conditions, it can continue to differentiate into a specific cell type or a subset of cell types, or to a point where, under normal conditions, it can differentiate into a different cell type or revert to a less differentiated cell type.

[0061] The differentiation of pluripotent stem cells requires changes in the culture system, such as stimulants in the culture medium or alterations to the physical state of the cells. The most traditional strategy utilizes the formation of embryonic bodies (EBs) as a common and important intermediate to initiate lineage-specific differentiation. "Embryonic bodies" are three-dimensional clusters that have been shown to mimic embryonic development because they generate numerous lineages within their three-dimensional area. During the differentiation process, typically over a few hours to a few days, simple EBs (e.g., aggregated pluripotent stem cells are induced to differentiate) continue to mature, and during the time it takes for them to continue further differentiation, typically over a few weeks, they develop into cystic EBs. EB formation is initiated by bringing pluripotent stem cells into close proximity to each other in a three-dimensional multilayer cluster of cells, which is typically achieved by one of several methods including a step of allowing pluripotent cells to settle in a droplet, settling the cells into a "U"-shaped bottom well-plate, or by mechanical stirring. To promote EB development, pluripotent stem cell aggregates require additional differentiation signals because aggregates maintained in the pluripotent culture maintenance medium do not form appropriate EBs. Thus, pluripotent stem cell aggregates need to be transferred to a differentiation medium that provides inducing signals for selected lineages. EB-based cultures of pluripotent stem cells typically result in the generation of differentiated cell populations (epoderm, mesoderm, and endoderm germ layers) with moderate proliferation within the EB cell clusters. Although proven to facilitate cell differentiation, EBs cause heterogeneous cells to develop into variable differentiation states due to inconsistent exposure to differentiation signals from the cell environment within the three-dimensional structure. Additionally, EBs are labor-intensive to generate and maintain. Furthermore, cell differentiation via EBs usually entails cell expansion, which also contributes to low differentiation efficiency.

[0062] In comparison, "aggregate formation," distinct from "EB formation," can be used to expand populations of pluripotent stem cell-derived cells. For example, during aggregate-based pluripotent stem cell expansion, the culture medium is selected to maintain proliferation and pluripotency. Cell proliferation generally increases the size of aggregates to form larger aggregates, and these aggregates can typically be mechanically or enzymatically dissociated into smaller aggregates to maintain cell proliferation within the culture and increase the cell number. Apart from EB cultures, cells cultured within aggregates in the maintenance culture retain pluripotency markers. Pluripotent stem cell aggregates require additional differentiation signals to induce differentiation.

[0063] As used herein, “monolayer differentiation” is a term referring to a method of differentiation through a three-dimensional multilayer cluster of cells, namely “embryo,” “EB,” or “EB formation.” Among other advantages disclosed herein, monolayer differentiation avoids the need for EB formation in initiating differentiation. Since monolayer culture does not mimic embryonic development such as EB formation, monolayer differentiation is directed toward a specific lineage as desired, compared to all three germ layer differentiations of EB.

[0064] As used herein, "dissociated" cells refer to cells that are substantially separated from other cells or from a surface (e.g., the surface of a culture plate) or purified. For example, cells may be dissociated from animals or tissues by mechanical or enzymatic methods. Alternatively, cells that aggregate in vitro may be dissociated enzymatically or mechanically by dissociation from each other, for example, into a suspension of a cluster, a single cell, or a mixture of a single cell and a cluster. In another alternative embodiment, adherent cells are dissociated from a culture plate or another surface. Thus, dissociation may involve disrupting cell interactions with the extracellular matrix (ECM) and the substrate (e.g., the culture surface) or disrupting the ECM between cells.

[0065] As used herein, “feeder cell” or “feeder” is a term describing one type of cell that is co-cultured with a second type of cell, which provides an environment in which the second type of cell can grow because the feeder cell provides growth factors and nutrients to the support of the second type of cell. Feeder cells are selectively derived from a different species than their supporting cells. For example, certain types of human cells, including stem cells, may be supported by a primary culture of mouse embryonic fibroblasts or immortal mouse embryonic fibroblasts. Feeder cells may typically be inactivated when co-cultured with other cells by irradiation or treatment with an anti-mitotic agent, such as mitomycin, to prevent them from growing larger than their supporting cells. Feeder cells may include endothelial cells, stromal cells (e.g., epithelial cells or fibroblasts), and leukemia cells. Without being limited to those foregoing, one specific type of feeder cell may be a human feeder, such as a human skin fibroblast. Other feeder cell types may be mouse embryonic fibroblasts (MEFs). Generally, various feeder cells can be partially used to maintain pluripotency, direct differentiation into specific lineages, and promote maturation into specialized cell types, such as effector cells.

[0066] As used herein, a "feeder-free (FF) environment" refers to an environment, such as a culture condition, cell culture, or culture medium, in which there are essentially no feeder cells and / or it is not pre-conditioned by the culture of feeder cells. A "pre-conditioned" medium refers to a medium taken after feeder cells have been cultured in the medium for a period of time, e.g., at least one day. Pre-conditioned media contain many mediators, including growth factors and cytokines secreted by feeder cells. In some embodiments, a feeder-free environment is in which there are neither feeder cells and it is not pre-conditioned by the culture of feeder cells. Feeder cells include, but are not limited to, stromal cells, mouse embryonic fibroblasts, human fibroblasts, keratinocytes, and embryonic stem cells.

[0067] "Culture" or "cell culture" refers to the maintenance, growth, and / or differentiation of cells in an in vitro environment. "Cell culture medium," "culture medium" (single "medium" in each case), "supplement," and "medium supplement" refer to nutrient compositions for culturing cell cultures.

[0068] "Cultivate" or "maintain" refers to sustaining, / or proliferating (growing), or differentiating cells outside of tissue or the body, for example, in a sterile plastic (or coated plastic) cell culture dish or flask. "Cultivate" or "maintain" may utilize a culture medium as a source of nutrients, hormones, and / or other factors to aid in proliferating and / or sustaining cells.

[0069] As used herein, “passage” or “subculture” refers to the act of subdividing cultured cells by subdividing and plating the cells into multiple cell culture surfaces or containers when the cells have proliferated to a desired degree. In some embodiments, “passage” or “subculture” means subdividing, diluting, and plating the cells. As cells are subdivided from a primary culture surface or container to a subsequent set of surfaces or containers, the subsequent culture may be referred herein to as “secondary culture” or “primary passage,” etc. Each act of subdividing and plating into a new culture container is considered one passage. In some embodiments, cultured cells are subdivided every 1, 2, 3, 4, 5, 6, 7 days or more. In some embodiments, iPSCs initially selected after reprogramming are subdivided once every 3 to 7 days.

[0070] The term “functionality” as used in the context of genome editing or modification of iPSCs and non-pluripotent cells derived from them, or genome editing or modification of non-pluripotent cells and iPSCs derived from them reprogrammed therefrom indicates the following: (1) at the gene level – successful knock-in, knock-out, knock-down gene expression, transgenic or controlled gene expression, e.g., inducible or transient expression at a desired cell developmental stage, which is achieved through direct genome editing or modification, or through “transfer” via differentiation or reprogramming from a starter cell that was initially genome-engineered; or (2) at the cell level – (i) gene expression modification obtained in said cell through direct genome editing, (ii) gene expression modification maintained in said cell through “transfer” via differentiation or reprogramming from a starter cell that was initially genome-engineered; (iii) downstream gene regulation in said cell as a result of gene expression modification that appears only at the early developmental stage of said cell, or only in the starter cell that gives rise to said cell through differentiation or reprogramming; or (iv) successfully removing, adding, or altering cell functions / characteristics through enhanced or newly achieved cell functions or properties displayed within mature cell products initially derived from genome editing or modifications performed on iPSCs, precursors, or dedifferentiated cell origins.

[0071] As used herein, the term “genetic imprint” refers to genetic or epigenetic information that contributes to preferential therapeutic properties in source cells or iPSCs and may be maintained in source cell-derived iPSCs and / or iPSC-derived non-natural hematopoietic lineage cells. As used herein, “source cell” refers to a pluripotent cell that can be used to generate iPSCs through reprogramming, and source cell-derived iPSCs may further differentiate into specific cell types, including any hematopoietic lineage cells. Source cell-derived iPSCs and cells differentiated therefrom are sometimes collectively referred to as “derived cells” depending on the context. The genetic imprint(s) as used herein conferring preferential therapeutic properties are incorporated into the iPSC through the reprogramming of selected source cells specific to the donor, disease, or treatment response, or by introducing genetically modified aspects into the iPSC using genome editing. Specifically, regarding source cells obtained from a selected donor, disease, or treatment content, the genetic imprint contributing to the preferential therapeutic attribute may include any content-specific genetic or epigenetic modifications that exhibit the preferential therapeutic attribute, i.e., a maintainable phenotype passed on the inducible cells of the selected source cell, regardless of whether or not the underlying molecular event is identified. Donor-, disease-, or treatment-response-specific source cells may include genetic imprints that may be maintained in iPSCs and derived hematopoietic lineage cells, and these genetic imprints include, but are not limited to:, for example, a pre-arranged monospecific TCR from virus-specific T cells or immutable natural killer T (iNKT) cells; for example, a traceable and desirable genetic polymorph that is homozygous for a point mutation encoding a high-affinity CD16 receptor in a selected donor; and selected HLA-matched donor cells exhibiting a haplotype with a planned HLA requirement, i.e., an increased population.The preferred therapeutic attributes used herein include improved engraftment, transport, homing, viability, self-renewal, persistence, modulation and coordination of immune responses, survival, and cytotoxicity of derived cells. Preferred therapeutic attributes may also be associated with antigen-targeting receptor expression; HLA labeling or lack thereof; resistance to the tumor microenvironment; induction and immunomodulation of bystander immune cells; improved target specificity with reduced off-tumor effects; and resistance to treatments such as chemotherapy.

[0072] As used herein, “genetic modification” means genetic editing, including (1) those naturally derived from rearrangements, mutations, genetic imprints, and / or epigenetic modifications occurring in a cell or cell development, or (2) those obtained through genome engineering via cell manipulation, including but not limited to insertions, deletions, or substitutions of the cell genome. As used herein, genetic modification also includes one or more sustainable therapeutic properties of donor-, disease-, or treatment-response-specific source-specific immune cells. Genetically modified cells are cells containing genetic modification (e.g., genetic editing) compared to a corresponding wild-type cell that does not have such genetic modification.

[0073] As used herein, the term "enhanced therapeutic properties" refers to the therapeutic properties of cells that are enhanced compared to typical cells of the same general cell type. For example, with respect to immune cells, NK cells having "enhanced therapeutic properties" will possess enhanced, improved, and / or augmented therapeutic properties compared to typical unmodified and / or naturally occurring NK cells. The therapeutic properties of immune cells may include, but are not limited to, cell engraftment, transport, homing, viability, self-renewal, persistence, modulation and coordination of immune responses, survival, and cytotoxicity. The therapeutic properties of immune cells are also manifested by antigen-targeting receptor expression; HLA labeling or lack thereof; tolerance to the tumor microenvironment; induction and immunomodulation of bystander immune cells; enhanced target specificity with reduced off-tumor effects; and tolerance to treatments such as chemotherapy.

[0074] “Integration” means the stable insertion of one or more nucleotides of a construct into the cell genome, that is, covalent linkage to a nucleic acid sequence within the cell’s chromosomal DNA. “Targeted integration” means the insertion of nucleotide(s) of a construct into the cell’s chromosomal or mitochondrial DNA at a pre-selected site or “integration site.” The term “integration” further refers to the process involving the insertion of one or more exogenous sequences or nucleotides of a construct at the integration site used herein, with or without deletion of the endogenous sequence or nucleotide. In this case, if a deletion is present within the insertion site, “integration” may further include the replacement of one or more inserted nucleotides with the deleted endogenous sequence or nucleotide.

[0075] "Construct" refers to a macromolecule or complex of molecules containing a polynucleotide to be delivered to a host cell in vitro or in vivo. "Vector" refers to any nucleic acid construct capable of guiding the delivery or transport of external genetic material to a target cell as used herein, wherein it may be replicated and / or expressed. The term "vector" includes the construct to be delivered as used herein. A vector may be a linear or circular molecule. A vector may be incorporated or non-incorporated. Major types of vectors include, but are not limited to, plasmids, episomal vectors, viral vectors, cosmids, and artificial chromosomes. Viral vectors include, but are not limited to, adenovirus vectors, adeno-associated virus vectors, retrovirus vectors, lentivirus vectors, Sendai virus vectors, etc.

[0076] As used herein, the term “encoding” refers to the specific characteristics of a specific sequence of nucleotides in a polynucleotide, such as a gene, cDNA, or mRNA, which functions as a template for the synthesis of other polymers and macromolecules in biological processes having any of the defined sequences of nucleotides (i.e., rRNA, tRNA, and mRNA) or defined sequences of amino acids and biological characteristics derived therefrom. Thus, a gene codes for a protein when the transcription and translation of the mRNA corresponding to the gene produce a protein in a cell or other biological system. Both the coding strand and the non-coding strand, which are used as templates for the transcription of a gene or cDNA and whose nucleotide sequences are identical to the mRNA sequence and are typically provided as sequence lists, may be referred to as encoding the protein or other product of that gene or cDNA.

[0077] As used herein, the term "exogenous" is intended to mean that a reference molecule or reference activity is introduced into a host cell. The molecule may be introduced, for example, by introducing coding nucleic acids into host genetic material, such as into a host chromosome, or by incorporating them into non-chromosomal genetic material, such as a plasmid. Thus, as used in relation to the expression of coding nucleic acids, this term refers to the introduction of an expressive form of coding nucleic acid into a cell. The term "endogenous" refers to the mentioned molecule or activity present in the host cell. Similarly, when used in relation to the expression of coding nucleic acids, this term refers to the expression of coding nucleic acids contained within the cell that were not introduced exogenously.

[0078] As used herein, “gene of interest” or “polynucleotide sequence of interest” is a DNA sequence that is transcribed into RNA and, in some examples, translated into a polypeptide in vivo when occurring under the control of an appropriate regulatory sequence. The gene of interest or polynucleotide may include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g. mammalian) DNA, and synthetic DNA sequences. For example, the gene of interest may code for miRNA, shRNA, natural polypeptides (i.e., polypeptides found in nature) or fragments thereof; variant polypeptides (i.e., mutants of natural polypeptides having less than 100% sequence identity with the natural polypeptide) or fragments thereof; engineered polypeptides or peptide fragments, therapeutic peptides or polypeptides, imaging markers, screening markers, etc.

[0079] As used herein, the term “polynucleotide” refers to a polymeric form of nucleotides of any length that are deoxyribonucleotides or ribonucleotides or analogs thereof. The sequence of a polynucleotide consists of four nucleotide bases: adenine (A); cytosine (C); guanine (G); thymine (T); and, if the polynucleotide is RNA, uracil (U) for thymine. Polynucleotides may include genes or gene fragments (e.g., probes, primers, EST or SAGE tags), exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. Polynucleotides also refer to both double and single-stranded molecules.

[0080] As used herein, the terms “peptide,” “polypeptide,” and “protein” are used interchangeably and refer to molecules having amino acid residues covalently linked by peptide bonds. A polypeptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids in a polypeptide. As used herein, the terms also refer to both short chains, generally referred to in the relevant art, e.g., peptides, oligopeptides, and oligomers, and long chains, generally referred to in the relevant art, e.g., polypeptides or proteins. “Polypeptide” includes, e.g., biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, and fusion proteins. Polypeptides include natural polypeptides, recombinant polypeptides, synthetic polypeptides, or combinations thereof.

[0081] As used herein, "operably linked" refers to an association of nucleic acid sequences on a single nucleic acid fragment such that one function influences the other. For example, a promoter is operably linked to a coding sequence or functional RNA if it can influence the expression of that coding sequence or functional RNA (i.e., if the coding sequence or functional RNA is under the transcriptional control of the promoter). The coding sequence may be operably linked to a regulatory sequence in a sense or antisense direction.

[0082] The term “engager” as used herein refers to a molecule, e.g., a fusion polypeptide, that can form a link between immune cells (e.g., T cells, NK cells, NKT cells, B cells, macrophages, neutrophils) and tumor cells and can activate immune cells. Examples of engagers include, but are not limited to, bispecific T cell engagers (BiTE), bispecific killer cell engagers (BiKE), trispecific killer cell engagers or multispecific killer cell engagers or universal engagers compatible with multiple immune cell types.

[0083] As used herein, the term “surface-triggered receptor” refers to a receptor capable of triggering or initiating an immune response, e.g., a cytotoxic response. Surface-triggered receptors can be engineered and expressed on effector cells, e.g., T cells, NK cells, NKT cells, B cells, macrophages, or neutrophils. In some embodiments, surface-triggered receptors facilitate dual- or multi-specific antibody coupling between effector cells and specific target cells, e.g., tumor cells, independent of the effector cells' natural receptors and cell types. Using this approach, iPSCs containing universal surface-triggered receptors can be generated and subsequently differentiated into a population of various effector cell types expressing universal surface-triggered receptors. "Universal" means that the surface-triggered receptor can be expressed and activated in any effector cell regardless of cell type, and that any effector cell expressing the universal receptor can bind to or be linked to an engager having the same epitope that can be recognized by the surface-triggered receptor, regardless of the engager's tumor binding specificity. In some embodiments, an engager having the same tumor targeting specificity is used to bind to the universal surface-triggered receptor. In some embodiments, an engager having different tumor targeting specificities is used to bind to the universal surface-triggered receptor. Thus, one or multiple effector cell types may be involved to kill one specific type of tumor cell in some cases and to kill two or more types of tumors in some other cases. The surface-triggered receptor generally comprises a co-stimulatory domain for effector cell activation and an anti-epitope specific to the epitope of the engager. The bispecific engager is specific to the anti-epitope of a surface-triggered receptor on one end and specific to the tumor antigen on the other end.

[0084] As used herein, the term "safety switch protein" refers to an engineered protein designed to prevent potential toxicity or other adverse effects of cell therapy. In some situations, safety switch protein expression is conditionally controlled to address safety issues for transplanted engineered cells in which the safety switch protein is permanently introduced within the gene encoding it in its genome. This conditional control may be variable and may include control through small molecule-mediated post-translational activation and tissue-specific and / or transient transcriptional regulation. Safety switches have been able to mediate the induction of apoptosis, inhibition of protein synthesis, DNA replication, inhibition of growth, transcriptional and post-transcriptional genetic regulation, and / or antibody-mediated depletion. In some examples, safety switch proteins are activated by exogenous molecules, e.g., prodrugs, which trigger apoptosis and / or cell death in the therapeutic cells when activated. Examples of safety switch proteins include, but are not limited to, suicide genes, e.g., caspase 9 (or caspase 3 or 7), thymidine kinase, cytosine deaminase, B-cell CD20, modified EGFR, and any combination thereof. In this strategy, a prodrug administered in the event of an adverse event is activated by the suicide-gene product and kills the transduced cells.

[0085] As used herein, the term "pharmaceuticalally active protein or peptide" refers to a protein or peptide capable of achieving biological and / or pharmaceutical effects on an organism. Pharmaceutically active proteins possess curative or palliative properties for curing diseases and may be administered to improve, alleviate, mitigate, reverse, or reduce the severity of the disease. Pharmaceutically active proteins also possess prophylactic properties and are used to prevent the onset of a disease or to reduce the severity of such disease or pathological condition when it occurs. Pharmaceutically active proteins include whole proteins or peptides or pharmaceutically active fragments thereof. They also include pharmaceutically active analogs of proteins or peptides or analogs of fragments of proteins or peptides. The term pharmaceutically active protein also refers to multiple proteins or peptides acting cooperatively or synergistically to provide therapeutic benefits. Examples of pharmaceutically active proteins or peptides include, but are not limited to, receptors, binding proteins, transcription and translation factors, tumor growth inhibitory proteins, antibodies or fragments thereof, growth factors and / or cytokines.

[0086] As used herein, the term “signaling molecule” refers to any molecule that regulates, participates in, inhibits, activates, reduces, or increases cellular signaling transduction. Signaling transduction refers to the transmission of molecular signals in the form of chemical modifications by the recruitment of protein complexes along pathways that ultimately trigger biochemical events in cells. Signaling transduction pathways are well known in the relevant art and include, but are not limited to, G protein-coupled receptor signaling, tyrosine kinase receptor signaling, integrin signaling, toll gate signaling, ligand-gated ion channel signaling, ERK / MAPK signaling pathway, Wnt signaling pathway, cAMP-dependent pathway, and IP3 / DAG signaling pathway.

[0087] As used herein, the term “targeting modality” refers to molecules, e.g., polypeptides, genetically introduced into cells to promote antigen and / or epitope specificity, including but not limited to i) antigen specificity associated with a unique chimeric antigen receptor (CAR) or T cell receptor (TCR), ii) engager specificity associated with a monoclonal antibody or bispecific engager, iii) targeting of transformed cells, iv) targeting of cancer stem cells, and v) other targeting strategies in the absence of specific antigens or surface molecules.

[0088] As used herein, the terms “specific” or “specificity” may be used to refer to the ability of a molecule, e.g., a receptor or an engager, to selectively bind to a target molecule in contrast to nonspecific or non-selective binding.

[0089] “HLA deficiency,” including HLA-class I deficiency, HLA-class II deficiency, or both, refers to a cell in which the surface expression of a complete MHC complex containing HLA class I protein heteromers and / or HLA class II heteromers is lacking, no longer maintained, or reduced, such that the reduced or decreased level is lower than that naturally detectable by other cells or by synthetic methods. HLA class I deficiency may be achieved by a functional deletion of any region of the HLA class I locus (chromosome 6p21), or by deleting or reducing the expression levels of HLA class-I associated genes, including but not limited to the beta-2 microglobulin (B2M) gene, TAP 1 gene, TAP 2 gene, and tafacin. HLA class II deficiency may be achieved by a functional deletion or reduction of HLA-II associated genes, including but not limited to RFXANK, CIITA, RFX5, and RFXAP. Previously, it was unclear whether HLA complex-deficient or altered iPSCs possessed the ability to generate developing, mature, and functionally differentiated cells while maintaining regulated activity. Additionally, it was previously unclear whether HLA complex-deficient differentiated cells could be reprogrammed into iPSCs to be maintained as pluripotent stem cells in an HLA complex-deficient state. Unexpected failures during cell reprogramming, pluripotency maintenance, and differentiation may be associated with aspects including, but not limited to, developmental stage-specific gene expression or its deficiency, requirements for HLA complex presentation, removal of proteins of introduced surface expression modes, the need for appropriate and efficient clonal reprogramming, and the need for reconfiguration of differentiation protocols.

[0090] "Modified HLA-deficient iPSC" refers to HLA-deficient iPSCs further modified by introducing genes expressing related proteins, such as non-classical HLA class I proteins (e.g., HLA-E and HLA-G), chimeric antigen receptors (CAR), T cell receptors (TCR), CD16 Fc receptors, BCL11b, NOTCH, RUNX1, IL15, 4-1BB, DAP10, DAP12, CD24, CD3z, 4-1BBL, CD47, CD113, and PDL1, which are used herein and possess enhanced differentiation potential, antigen targeting, antigen presentation, antibody recognition, persistence, immune evasion, resistance to suppression, proliferation, co-stimulation, cytokine stimulation, cytokine production (autocrine or paracrine), chemotaxis, and cytotoxicity. "Modified HLA-deficient" cells also include non-iPSC cells.

[0091] "Fc receptors," abbreviated as FcR, are classified based on the type of antibody they recognize. For example, the most common class of antibodies, those that bind to IgG, are designated as Fc-gamma receptors (FcγR); those that bind to IgA are designated as Fc-alpha receptors (FcαR); and those that bind to IgE are designated as Fc-epsilon receptors (FcεR). The classes of FcR are also distinguished by the cells that express them (macrophages, granulocytes, natural killer cells, T and B cells) and the signaling characteristics of each receptor. Fc-gamma receptors (FcγR) include several members, FcγRI (CD64), FcγRIIA (CD32), FcγRIIB (CD32), FcγRIIIA (CD16a), and FcγRIIIB (CD16b), which differ in their antibody affinities due to their different molecular structures.

[0092] CD16 has been identified as two isoforms: the Fc receptor FcγRIIIa (CD16a) and FcγRIIIb (CD16b). CD16a is a transmembrane protein expressed by NK cells that binds to monomeric IgG attached to target cells, thereby activating NK cells and enabling antibody-dependent cell-mediated cytotoxicity (ADCC). As used herein, “high-affinity CD16,” “non-cleavable CD16,” or “high-affinity non-cleavable CD16” refer to variants of CD16. Wild-type CD16 has low affinity and is subject to ectodomain shedding, a proteolytic cleavage process that regulates the cell surface density of various cell surface molecules on leukocytes upon NK cell activation. F176V and F158V are exemplary high-affinity CD16 variants; whereas the S197P variant is an example of a non-cleavable version of CD16.

[0093] The term “adoptive cell therapy” as used herein refers to a cell-based immunotherapy involving the infusion of autologous or allogeneic lymphocytes, such as CD34 cells, hematopoietic endothelial cells, hematopoietic stem or progenitor cells, hematopoietic pluripotent progenitor cells, T cell progenitors, NK cell progenitors, T cells, NKT cells, NK cells, B cells, or immunomodulatory cells (genetically modified or unmodified, expanded in vitro prior to transfusion).

[0094] As used herein, "therapeutic sufficient amount" refers, in its meaning, to a non-toxic but sufficient and / or effective amount of a specific therapeutic and / or pharmaceutical composition that provides the intended therapeutic effect. The exact amount required will vary depending on the subject, depending on factors such as the patient's general health condition, age, and the stage and severity of the condition. In certain embodiments, the therapeutic sufficient amount is sufficient and / or effective to improve, reduce, or enhance at least one symptom associated with the disease or condition of the subject being treated.

[0095] As used herein, the term "subject" refers to any animal, preferably a human patient, livestock, or other domestic animal.

[0096] As used herein, terms such as “treat,” “treatment,” etc., refer to obtaining desired pharmacological and / or physiological effects, including but not limited to achieving improvement or elimination of disease symptoms, when used in relation to subjects requiring treatment. Effects may be therapeutic in that they completely or partially prevent the disease or its symptoms, achieve improvement or elimination of symptoms, or provide partial or complete treatment for the disease and / or adverse effects resulting from the disease. The term “treatment” includes any treatment of a disease in mammals, particularly humans, and includes the following: (a) preventing the occurrence of the disease in subjects who may be susceptible to the disease but have not yet been diagnosed with it; (b) suppressing the disease or preventing its onset; (c) alleviating the disease, causing regression of the disease, or completely or partially eliminating the symptoms of the disease; and (d) restoring the individual to a pre-disease state, such as by reconstituting the hematopoietic system.

[0097] I. Composition for the production of induced pluripotent stem cells

[0098] Previously developed Fate Maintenance Mediums (FMMs) satisfied the long-term stability of iPSCs reprogrammed from various non-T cell somatic sources. Therefore, various modifications of FMMs were performed to improve long-term stability and preservation and to reduce the frequency of karyotype abnormalities in iPSCs reprogrammed from all cell sources, particularly T cells, which were found to be difficult cell types for generating pluripotent stem cells (TiPSCs) and differentiating them into lineage-specific and functional effector cells. Stress factors, including but not limited to single-cell dissociation, clonal expansion, freeze-thaw cycles, vector transfusion, electroporation, and genome editing, were observed to induce genomic instability in cells and impair the pluripotent potential, viability, and differentiation potential of pluripotent cells.

[0099] The compositions considered herein may comprise chemically defined stock base media and various combinations of small molecules, comprising small molecules and functional variants thereof, which support both efficient and effective reprogramming using minimal reprogramming factors in a feeder-free environment; and maintain a homogeneous and genomically stable pluripotent population for a long period (i.e., 25, 30, 35, or 50 or more passages) even when exposed to one or more stress factors, while enabling single-cell culture and expansion of pluripotent cells. Furthermore, regardless of the genetic background of non-pluripotent cells or the reprogramming process by which pluripotent cells are generated, the compositions provided herein are provided for culturing pluripotent cells, including TiPSCs, to a state of reduced spontaneous differentiation and ground-state pluripotency (also referred to as naive pluripotency).

[0100] The compositions considered herein are useful for producing industrial-grade or clinical-grade pluripotent cells having reduced spontaneous differentiation compared to cells produced or cultured in part without the composition. In one embodiment, non-pluripotent cells are induced to become pluripotent cells and cultured to maintain pluripotency for an extended period. In another embodiment, non-pluripotent cells are induced to become pluripotent cells and cultured to achieve and / or maintain reduced spontaneous differentiation compared to cells cultured in the absence of the composition. In another embodiment, non-pluripotent cells are induced to become pluripotent cells and cultured to achieve and / or maintain ground-state pluripotency.

[0101] In various embodiments, the composition provided herein reduces or prevents karyotype abnormalities including trisomy in iPSCs, particularly iPSCs obtained by reprogramming T cells, compared to iPSCs generated or maintained without contact with the composition. Accordingly, in various embodiments, the composition comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 60, 70, 80, 90, 100 or more passages (including any intermediate number of passages) of one or more pluripotent cells in a ground state It maintains pluripotency, normal karyotype, and genomic stability. In various embodiments, the composition provided herein is a reduced spontaneous growth in one or more pluripotent cells for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 60, 70, 80, 90, 100 or more passages (including any intermediate number of passages). Maintains differentiation.

[0102] In various embodiments, the chemically defined stock base medium for use in the culture medium of the present invention may be a defined base medium suitable for supporting the maintenance and / or growth of stem cells, such as a conventional human embryonic stem cell medium. Examples of defined base media that may be used according to embodiments of the present invention include, but are not limited to: Dulbecco’s modified Eagle medium (“DMEM”), Base Medium Eagle (BME), DMEM / F-12 (1:1 DMEM and F-12 volume:volume); Medium 199; F-12 (Ham) nutrient mixture; F-10 (Ham) nutrient mixture; Minimum Essential Medium (MEM), Williams’ Medium E; and RPMI 1640 (all of which are available from Gibco-BRL / Life Technologies, Inc., Gaithersburg, Maryland). Some versions of these many media, including but not limited to the following, may be used: DMEM 11966, DMEM 10314, MEM 11095, Williams’ Media E 12251, Ham F12 11059, MEM-Alpha 12561, and Media-199 11151 (Gibco-BRL / Life Technologies). The culture media may contain, for example, one or more of the following: amino acids, vitamins, organic salts, inorganic salts, trace elements, buffer salts, sugars, ATP, etc.

[0103] Small molecules and classes thereof for use in cell culture media according to embodiments of the present invention are described in more detail below. In one embodiment, the composition comprises a cell culture medium and a TGFβ family protein, a Rho kinase (ROCK) inhibitor (ROCKi), a MEK inhibitor (MEKi), and a WNT activator. In various embodiments, the composition does not include a TGFβ inhibitor (TGFβi). In various embodiments, one or more of the TGFβ family protein, ROCKi, MEKi, and WNT activator may be added at one or more specific stages during iPSC generation and maintenance for a predetermined period. These specific stages during iPSC maintenance include, but are not limited to: single-cell dissociation of iPSC colonies, single-cell sorting of dissociated iPSCs, iPSC single-cell clone expansion, cryopreservation of a cloned iPSC master cell bank (MCB), thawing of the iPSC MCB, and optionally additional cryopreservation-thaw cycles of the iPSC MCB. For example, in various embodiments, TGFβ family proteins may be optionally added to the composition at the single-cell dissociation of iPSC colonies, at the expansion of iPSC single-cell clones, or at any stage in between. In various embodiments, the concentration of MEK inhibitor and / or WNT activator during iPSC maintenance is reduced compared to the concentration of MEK inhibitor and / or WNT activator used to reprogram non-pluripotent cells into iPSCs. In some embodiments, the concentration of MEK inhibitor and / or WNT activator is an amount of about 30% to 60%, e.g., about 35% to 55%, preferably about 40% to 50% of the concentration of MEK inhibitor and / or WNT activator that can be used to reprogram non-pluripotent cells into iPSCs.

[0104] In one embodiment, the composition comprising a cell culture medium further comprises a TGFβ family protein, ROCKi, MEKi, and WNT activator, and optionally, LIF and / or bFGF, and the composition does not comprise a TGFβ inhibitor; optionally, adding any TGFβ family protein, ROCKi, MEKi, and WNT activator to the composition is stage-specific during iPSC maintenance.

[0105] In an additional embodiment, the cell culture medium included in the composition is substantially free of cytokines and / or growth factors and is optionally a feeder-free environment. In another embodiment, the cell culture medium contains supplements such as serum, extracts, growth factors, hormones, cytokines, etc.

[0106] In a further embodiment, the present invention provides a composition for producing induced pluripotent stem cells comprising a cell culture medium comprising ROCKi, MEKi, and WNT activators, a histone deacetylase (HDAC) inhibitor, and a TGFβ inhibitor, wherein optionally, the addition of any of ROCKi, MEKi, and WNT activators, the HDAC inhibitor, and the TGFβ inhibitor is stage-specific during the process of reprogramming non-pluripotent cells into iPSCs with increased reprogramming efficiency compared to reprogramming using the previous composition. During iPSC reprogramming, these specific stages include, but are not limited to, somatic cell transfection (day 0), exogenous gene expression, heterochromatin increase, loss of somatic identity, and iPSC colony formation. For example, in various embodiments, an HDAC inhibitor may be optionally added at the time of chromatin reconstruction or about 2 to 3 days (after transfection) and / or a TGFβ inhibitor may be optionally added at the stage of loss of somatic identity or about 6 to 8 days (after transfection). About 13 to 15 days after transfection, iPSC colonies are typically formed using the methods and compositions disclosed herein.

[0107] In one embodiment, a composition for producing induced pluripotent stem cells comprises a cell culture medium comprising ROCKi, MEKi, and WNT activators, an HDAC inhibitor, and a TGFβ inhibitor, and optionally, LIF and / or bFGF, wherein optionally, any addition of the HDAC inhibitor and the TGFβ inhibitor is stage-specific during iPSC reprogramming. In some embodiments, the HDAC inhibitor is valproic acid (VPA) or a functional variant or derivative thereof.

[0108] ROCK inhibitor

[0109] Rho-associated kinase (ROCK) is a serine / threonine kinase that acts as a downstream effector of Rho kinase (three isoforms, RhoA, RhoB, and RhoC, exist). ROCK inhibitors suitable for use in the compositions considered herein include, but are not limited to, polynucleotides, polypeptides, and small molecules. ROCK inhibitors considered herein may reduce ROCK expression and / or ROCK activity. Exemplary ROCK inhibitors include, but are not limited to, antibodies against ROCK, dominant-negative ROCK variants, and siRNA and antisense nucleic acids that inhibit the expression of ROCK. Other exemplary ROCK inhibitors include, but are not limited to: thiazovibine, Y27632, fasudyl, AR122-86, Y27632 H-1152, Y-30141, Wf-536, HA-1077, hydroxyl-HA-1077, GSK269962A, SB-772077-B, N-(4-pyridyl)-N'-(2,4,6-trichlorophenyl)urea, 3-(4-pyridyl)-1H-indole, and (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide.

[0110] Exemplary ROCK inhibitors for use in cell culture media according to embodiments of the present invention include thiazovibin, Y27632, pyrintegrin, blevistatin, and functional variants or derivatives thereof. In certain embodiments, the ROCK inhibitor is thiazovibin.

[0111] ERK / MEK inhibitors

[0112] Exemplary inhibitors of the ERK / MEK pathway include, but are not limited to: antibodies against MEK or ERK, dominant-negative MEK or ERK variants, and siRNAs and antisense nucleic acids that inhibit the expression of MEK and / or ERK. Other exemplary ERK / MEK inhibitors include, but are not limited to: PD0325901, PD98059, UO126, SL327, ARRY-162, PD184161, PD184352, sunitinib, sorafenib, vandetanib, pazopanib, axitinib, GSKl 120212, ARRY-438162, RO5126766, XL518, AZD8330, RDEAl 19, AZD6244, FR180204, PTK787, and functional variants or fragments thereof.

[0113] Further exemplary examples of MEK / ERK inhibitors include the following compounds: 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzimidazole-5-carboxylic acid (2,3-dihydroxy-propoxy)-amide; 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-(tetrahydro-pyran-2-ylmethyl)-3H-benzimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, 1-[6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzimidazole-5-yl]-2-hydroxy-ethanolone, 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzimidazole-5-carboxylic acid (2-hydroxy-1,1-dimethyl-ethoxy)-amide, 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-(tetrahydro-furan-2-ylmethyl)-3H-benzimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, 6-(4-bromo-2-fluoro-phenylamino)-7-fluoro-3-methyl-3H-benzimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, 6-(2,4-dichloro-phenylamino)-7-fluoro-3-methyl-3H-benzimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide (hereinafter referred to as MEK inhibitor 1); 2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (hereinafter referred to herein as MEK inhibitor 2); and 4-(4-bromo-2-fluorophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide or a pharmaceutically acceptable salt thereof.

[0114] In some embodiments, the MEK / ERK inhibitor is PD0325901.

[0115] Wnt activator

[0116] As used herein, the terms “Wnt signaling-promoter,” “Wnt pathway activator,” “Wnt activator,” or “Wnt pathway agonist” refer to agonists of the Wnt signaling pathway, including but not limited to one or more of Wntl, Wnt2, Wnt2b / 13, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt7c, Wnt8, Wnt8a, Wnt8b, Wnt8c, Wnt10a, Wntl0b, Wnt11, Wnt14, Wnt15, or Wnt16. Wnt pathway agonists additionally comprise, but are not limited to, one or more of the following polypeptides or fragments thereof: Dkk polypeptide, crescent polypeptide, kerberos polypeptide, axin polypeptide, Frzb polypeptide, T-cell factor polypeptide, or dominant-negative disrupted polypeptide.

[0117] Non-limiting examples of Wnt pathway agonists further include one or more of the following: a nucleic acid comprising a nucleotide sequence encoding a Wnt polypeptide; a polypeptide comprising an amino acid sequence of a Wnt polypeptide; a nucleic acid comprising a nucleotide sequence encoding an activated Wnt receptor; a polypeptide comprising an amino acid sequence of an activated Wnt receptor; a small organic molecule promoting Wnt / β-catenin signaling; a small organic molecule inhibiting the expression or activity of a Wnt antagonist; an antisense oligonucleotide inhibiting the expression of a Wnt antagonist; a ribozyme inhibiting the expression of a Wnt antagonist; an RNAi construct inhibiting the expression of a Wnt antagonist; siRNA or shRNA; an antibody binding to a Wnt antagonist and inhibiting its activity; a nucleic acid comprising a nucleotide sequence encoding a β-catenin polypeptide; a polypeptide comprising an amino acid sequence of a β-catenin polypeptide; a nucleic acid comprising a nucleotide sequence encoding a Lef-1 polypeptide; and a polypeptide comprising an amino acid sequence of a Lef-1 polypeptide. polypeptide, and functional variants or fragments thereof.

[0118] GSK-3β inhibitors

[0119] GSK-3β inhibitors are specific exemplary Wnt pathway agonists suitable for use in the compositions considered herein, and may include, but are not limited to, antibodies that bind to GSK-3β, dominant-negative GSK-3β variants, siRNAs and antisense nucleic acids that target GSK-3β. Other exemplary GSK-3β inhibitors include, but are not limited to: kenpolone, 1-azakenpolone, CHIR99021, CHIR98014, AR-A014418, CT 99021, CT 20026, SB216763, AR-A014418, lithium, SB 415286, TDZD-8, BIO, BIO-acetoxime, (5-methyl-1H-pyrazole-3-yl)-(2-phenylquinazolin-4-yl)amine, pyridocarbazole-cyclopentadiene-ilutenium complex, TDZD-8 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione, 2-thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole, OTDZT, alpha-4-dibromoacetophenone, AR-AO 144-18, 3-(1-(3-hydroxypropyl)-lH-pyrrolo[2,3-b]pyridin-3-yl]-4-pyrazine-2-yl-pyrrole-2,5-dione; TWSl 19 pyrrolopyrimidine compound, L803 H-KEAPPAPPQSpP-NH2 or its myristoylated form; 2-chloro-l-(4,5-dibromo-thiophene-2-yl)-ethanolone, SB216763, SB415286, and functional variants or fragments thereof. An exemplary GSK3 inhibitor for use in a cell culture medium according to an embodiment of the present invention is Includes CHIR99021, BIO, and Kenpaullone. In some embodiments, the GSK3 inhibitor is CHIR99021.

[0120] TGFβ receptor / ALK5 inhibitor

[0121] TGFβ receptor (e.g., ALK5) inhibitors may include an antibody against the TGFβ receptor (e.g., ALK5), a dominant negative variant of the said receptor, and an antibody against an antisense nucleic acid that inhibits the expression of the said receptor. Exemplary TGFβ receptor / ALK5 inhibitors include, but are not limited to: SB431542, A-83-01, 2-(3-(6-methylpyridine-2-yl)-1H-pyrazole-4-yl)-1,5-naftiridine, Wnt3a / BIO, BMP4, GW788388(-{4-[3-(pyridine-2-yl)-1H-pyrazole-4-yl]pyridine-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide), SM16, IN-1130(3-((5-(6-methylpyridine-2-yl)-4-(quinoxalin-6-yl)-1H-imidazole-2-yl)methyl)benzamide), GW6604 (2-phenyl-4-(3-pyridine-2-yl-1H-pyrazole-4-yl)pyridine), SB-505124 (2-(5-benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazole-4-yl)-6-methylpyridine hydrochloride) and pyrimidine derivatives. Additionally, "ALK5 inhibitors" are not intended to include non-specific kinase inhibitors, but should be understood to include inhibitors that inhibit ALK4 and / or ALK7 in addition to ALK5, such as SB-431542. Without intent to limit the scope of the invention, ALK5 inhibitors are believed to affect the process of transition / transition from mesenchymal to epithelial (MET). The TGFβ / activin pathway is the driver for transition from epithelial to mesenchymal (EMT). Therefore, inhibiting the TGFβ / activin pathway can promote the MET (i.e., reprogramming) process.

[0122] Inhibition of the TGFβ / activin pathway has been shown to have effects similar to those of ALK5 inhibition. Therefore, any inhibitor of the TGFβ / activin pathway (e.g., upstream or downstream) may be used in combination with or instead of ALK5 inhibitors as described in each paragraph of this Appendix. Exemplary TGFβ / activin pathway inhibitors include, but are not limited to, the following: TGFβ receptor inhibitors, inhibitors of SMAD 2 / 3 phosphorylation, inhibitors of the interaction between SMAD 2 / 3 and SMAD 4, and activators / agonists of SMAD 6 and SMAD 7. Furthermore, the classification described below is for organizational purposes only, and those skilled in the art will understand that a compound may affect one or more sites within the pathway and thus may function in more than one defined category.

[0123] Specific examples of TGFβ receptor inhibitors include, but are not limited to: SU5416; 2-(5-benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazole-4-yl)-6-methylpyridine hydrochloride (SB-505124); ledelimumab (CAT-152); metelimumab (CAT-192); GC-1008; ID11; AP-12009; AP-11014; LY550410; LY580276; LY364947; LY2109761; SB-505124; SB-431542; SD-208; SM16; NPC-30345; Ki26894; SB-203580; SD-093; Gleevec; 3,5,7,2',4'-pentahydroxyflavone (Morin); activin-M108A; P144; soluble TBR2-Fc; and antisense-transfused tumor cells targeting the TGFβ receptor.

[0124] Inhibitors of SMAD 2 / 3 phosphorylation may include antibodies against antisense nucleic acids targeting SMAD2 or SMAD3, dominant-negative variants, and antisense nucleic acids. Specific examples of inhibitors include PD169316; SB203580; SB-431542; LY364947; A77-01; and 3,5,7,2',4'-pentahydroxyflavone (Morin). Inhibitors of the interaction between SMAD 2 / 3 and SMAD4 may include antibodies against antisense nucleic acids targeting SMAD2, SMAD3, and / or SMAD4, dominant-negative variants, and antisense nucleic acids. Specific examples of inhibitors of the interaction between SMAD 2 / 3 and SMAD4 include, but are not limited to, Trx-SARA, Trx-xFoxH1b, and Trx-Lef1. Activators / agonists of SMAD 6 and SMAD 7 include, but are not limited to, antibodies against antisense nucleic acids targeting SMAD 6 or SMAD 7, dominant negative variants, and antisense nucleic acids.

[0125] HDAC inhibitors

[0126] Exemplary HDAC (histone deacetylase) inhibitors may include siRNA targeting HDAC, antibodies binding to antisense nucleic acids, and dominant-negative variants thereof. Histone acetylation is involved in the regulation of histone and DNA methylation. Generally, at a global level, pluripotent cells have more histone acetylation, while differentiated cells have less histone acetylation. HDAC inhibitors promote the activation of silenced pluripotent genes. HDAC inhibitors include, but are not limited to: TSA (tricostatin A), VPA (valproic acid), sodium butyrate (NaB), SAHA (suberoylanilide hydroxamic acid or vorinostat), sodium phenylbutyrate, depsipeptide (FR901228, FK228), trapoxin (TPX), 20 cyclic hydroxyamic acid-containing peptide 1 (CHAP I), MS-275, LBH589, and PXDIOI.

[0127] Cytokines and Growth Factors

[0128] In certain embodiments, the composition and / or cell culture medium of the present invention is substantially free of cytokines and / or growth factors. In certain embodiments, the cell culture medium contains one or more supplements, including but not limited to serum, extracts, growth factors, hormones, cytokines, etc., which may be added in a stage-specific manner to improve the quality and efficiency of the reprogramming and / or maintenance process.

[0129] Its uses in various growth factors and culture media are known, and include, for example, ECM proteins, laminin 1, fibronectin, collagen IV isotype, proteases, protease inhibitors, cell surface adhesion proteins, cell signaling proteins, cadherin, chloride intracellular channel 1, transmembrane receptor PTK7, insulin-like growth factor, inhibin beta A, inducers of the TGFβ / activin / nodal signaling pathway, and activin A. The cytokines used in the culture medium may include, for example, one or more of the following: growth factors, e.g., epidermal growth factor (EGF), acid fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), insulin-like growth factor 2 (IGF-2), keratinocyte growth factor (KGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), leukemia suppressor factor (LIF), vascular endothelial growth factor (VEGF); transferrin; various interleukins (e.g., IL-1 to IL-18); various colony-stimulating factors (e.g., granulocyte / macrophage colony-stimulating factor (GM-CSF)); various interferons (e.g., IFN-γ); and other factors affecting stem cells, such as stem cell factor (SCF) and erythropoietin (Epo). Cytokine.

[0130] In certain embodiments, the composition and / or culture medium may comprise a TGFβ family protein as a cytokine / growth factor component of the composition. Examples of TGFβ family proteins include, but are not limited to: activin A, TGFβ, nodal, and functional variants or fragments thereof. These cytokine / growth factors may be commercially available and may be natural or recombinant. In some embodiments, for the culture of a wide variety of mammalian cells, the base medium will contain FGF at concentrations of about 0.01 to 100 ng / ml, about 0.2 to 20 ng / ml, and in certain embodiments about 0.5 to 10 ng / ml. If used, other cytokines may be added at concentrations determined empirically or guided by established cytokine techniques.

[0131] II. Improved reprogramming and maintenance system and cells generated therefrom

[0132] Generally, the present disclosure provides an improved reprogramming process initiated by contacting non-pluripotent cells in the presence of at least one reprogramming factor and optionally a combination of a ROCK inhibitor, a MEK inhibitor, and a Wnt activator, and optionally a TGFβ inhibitor and / or an HDAC inhibitor, wherein one or both of the TGFβ inhibitor and the HDAC inhibitor are added at one or more selected stages of reprogramming (e.g., FRM2; Tables 1 and 2; see also FIG. 9). The present disclosure also provides an improved maintenance method for iPSCs exposed to one or more stressors, wherein the cells are optionally contacted with a combination of a ROCK inhibitor, a MEK inhibitor, and a WNT activator, and a TGFβ family protein at one or more selected stages, and the composition does not contain a TGFβ inhibitor (e.g., FMM2; Tables 1 and 2; see also FIG. 9).

[0133] [Table 1]

[0134]

[0135] [Table 2]

[0136]

[0137] Cell reprogramming

[0138] One method for obtaining footprint-free iPSCs (i.e., iPSCs that do not possess exogenous reprogramming factor polynucleotides) is to use a plasmid system that mediates transitional and transient transplant gene expression. One exemplary plasmid system for reprogramming comprises one or more first plasmids having polynucleotides encoding a replication origin and reprogramming factor(s) but not EBNA, and a second plasmid comprising an EBNA-coding polynucleotide but not a replication origin or reprogramming factor coding sequence (see, for example, the “STTR system” of U.S. Application Publication No. 20200270581, the relevant disclosure incorporated herein by reference).

[0139] The combination of plasmids enables the transient cytoplasmic expression of transplanted genes (EBNA and exogenous reprogramming factors) in cells upon transduction and generates an intermediate cell population, also known as reprogramming cells, which exhibits a transitional form or morphological change (e.g., mesenchymal-to-epithelial transition (MET)) but lacks pluripotent cell morphology or expression of endogenous pluripotent genes such as OCT4, yet can enter a stable, self-sustaining pluripotent state. The reprogramming cells described herein also differ from somatic cells prior to the introduction of reprogramming factors in that they can be reprogrammed into a pluripotent state if given sufficient time under culture conditions that support the continuation of the reprogramming process, both morphologically and functionally (e.g., conventional hES medium, FRM, or FRM2). In some embodiments, EBNA-free reprogramming cells are free of the transplant gene, and thus the generated iPSCs have no footprint without successive passages to remove EBNA and the transplant gene, as is often required in EBNA selection or episome reprogramming.

[0140] In addition to using the above plasmid system, exogenous reprogramming factors are also described in adenovirus transduction ([Zhou et al., Stem Cells (2009); 27:2667-2674]), Sendai virus vectors ([Fusaki et al., Proc Jpn Acad Ser B Phys Biol Sci. (2009); 85:348-362]; [Seki et al., Cell Stem Cell (2010); 7:11-14]; [Ban et al., PNAS (2011); 108:14234-14239]), minicircle DNA vectors ([Okita et al., Science (2008); 322:949-953]), and oriP / EBNA episome vectors ([Malik et al., Methods Mol Biol. It can be introduced by (2013); 997:23-33]).

[0141] All reprogramming factors known in the art for stem cell reprogramming may be used with the reprogramming system and method of the present invention. In one embodiment, the reprogramming factors include, but are not limited to, OCT4, YAP1, SOX2, and large T antigen (LTag). Additional reprogramming factors include, but are not limited to, NANOG, KLF, LIN28, MYC, ECAT1, UTF1, ESRRB, HESRG, CDH1, TDGF1, DPPA4, DNMT3B, ZIC3, and L1TD1. In another embodiment, the reprogramming factors include, but are not limited to: OCT4, YAP1, SOX2, large T antigen, MYC, LIN28, ESRRB, and ZIC3 for somatic cell reprogramming and for T cell reprogramming without using KLF. The polynucleotides encoding these reprogramming factors may be included in the same plasmid construct (i.e., the same first plasmid) that contains oriP but not EBNA. The polynucleotides encoding these reprogramming factors may be included in at least two plasmid constructs (i.e., multiple first plasmids) each that contain oriP but not EBNA. In various embodiments, the polynucleotides encoding these reprogramming factors are included in four plasmid constructs (i.e., four first plasmids) each that contain oriP but not EBNA.

[0142] The polynucleotides encoding these reprogramming factors may be contained in a polycistron construct (i.e., a multicoding sequence controlled by a single promoter) or a non-polycistron construct (a multicoding sequence in which some parts are controlled by a single promoter and others by different promoters). The promoter may be, for example, CMV, EF1α, PGK, CAG, UBC, and other suitable promoters that are constitutive, inducible, endogenous, or transient, tissue, or cell type specific. In one embodiment, the promoter is CAG. In another embodiment, the promoter is EF1α. In some embodiments, the polycistron construct may provide a single open read frame (e.g., the multicoding sequence is operably linked by a self-cleaving peptide coding sequence such as 2A) or multiple open read frames (e.g., a multicoding sequence linked by an internal ribosome entry site (IRES)).

[0143] In some embodiments of the plasmid system of the present invention, one or more plasmid constructs (first plasmids) collectively comprise polynucleotides encoding one or more reprogramming factors selected from the group consisting of OCT4, YAP1, SOX2, and large T antigen (LTag). In further embodiments, one or more plasmid constructs (first plasmids) collectively further comprise polynucleotides encoding one or both of SOX2 and KLF, or one or more of MYC, LIN28, ESRRB, and ZIC3. In some embodiments, only one first plasmid construct is in the system and provides all selected reprogramming factors. In some other embodiments, the system has two or more first plasmid constructs providing one or more reprogramming factors, each construct comprising the same or different reprogramming factors encoded by at least one polynucleotide copy. In some embodiments, one or more first plasmid constructs collectively comprise at least two polynucleotides encoding OCT4, and one or more polynucleotides encoding at least one of YAP1, SOX2, LTag, ECAT1, UTF1, ESRRB, HESRG, CDH1, TDGF1, DPPA4, DNMT3B, ZIC3, and L1TD1.

[0144] When the first plasmid construct comprises more than one polynucleotide encoding more than one reprogramming factor, adjacent polynucleotides are operably linked by a linker sequence encoding a self-cleaving peptide or an IRES. The self-cleaving peptide may be a 2A peptide. The 2A peptide may be derived from FMDV (foot-and-mouth disease virus), ERAV (equine rhinitis A virus), PTV-1 (swine Tesco virus-1), or TaV (tosea atigna virus), which are referred to as F2A, E2A, P2A, and T2A, respectively. Multiple 2A peptides of the first plasmid construct may be identical or different. In some embodiments, the two nearest adjacent 2A peptides are different, e.g.: RF-2A1-RF-2A2-RF-2A1, where 2A1 and 2A2 are different.

[0145] A library of first-stage plasmid constructs can be pre-constructed, and each construct contains one or more polynucleotides encoding combinations of various numbers, types, and / or reprogramming factors. Reprogramming is known as an inefficient and stochastic process with long latency. The timing and level of expression, and the stoichiometry of the reprogramming factors, drive reprogramming kinetics at different stages of reprogramming and intermediate states of cells undergoing reprogramming, and determine the completion of reprogramming. Reprogramming factor stoichiometry also influences reprogramming efficiency and generates iPSCs with various qualities, such as priming versus ground-state pluripotency, as well as related biological characteristics including iPSC clonality, self-renewal, homogeneity, and maintenance of pluripotency (as opposed to spontaneous differentiation). Stoichiometry is used to measure the quantitative relationships between reagents in a reaction process, determine the amount of reagent required for a given reaction, and sometimes determine the amount of product generated. Stoichiometry considers both the stoichiometric amount of a reagent and the stoichiometric ratio of a reagent that is the optimal amount or ratio of reagent(s) to complete the reaction. One aspect of the present application provides a system and method for evaluating or utilizing reprogramming factor stoichiometry by allowing one or more first plasmids to be conveniently selected from a library, mixed and matched, dosed, and co-transfected.

[0146] The second plasmid of the reprogramming system of the present invention provides an expression cassette comprising a promoter and an EBNA-coding polynucleotide, wherein the expression cassette and the second plasmid do not contain any polynucleotide-coding reprogramming factor. The promoter included in the second plasmid may be, for example, CMV, EF1α, PGK, CAG, UBC, and other suitable promoters that are constitutive, inducible, endogenous regulated, or transient, tissue or cell type specific. In one embodiment, the promoter is CAG. In another embodiment, the promoter is EF1α. By co-transfecting non-pluripotent cells with the aforementioned combination of at least one first plasmid and the second plasmid, standalone EBNA and oriP are introduced into the non-pluripotent cells along with at least one reprogramming factor to initiate reprogramming.

[0147] In some embodiments, reprogramming is initiated in the presence of a combination of small molecule compounds including a ROCK inhibitor, a MEK inhibitor, a WNT activator, an HDAC inhibitor, and a TGFβ inhibitor, and iPSCs are generated after a sufficient amount of time. In some embodiments, reprogramming is initiated in the presence of a combination of small molecule compounds including a ROCK inhibitor, a MEK inhibitor, and a WNT activator, optionally at the exogenous reprogramming factor expression stage or about 1 to 2 days after reprogramming factor transcription; then, an HDAC inhibitor is optionally added at the chromatin reorganization stage or about 2 to 3 days after reprogramming factor delivery; then, to establish pluripotency and genomic stability of the iPSCs, a TGFβ inhibitor is optionally added at the somatic identity loss stage or about 6 to 8 days after transfusion. In some embodiments, as disclosed herein, an optimized reprogramming composition and method comprising the use of first and second vectors, a combination of reprogramming factors, and / or small molecule processing during one or more selected stages during reprogramming generates reliably and reliably footprint-free iPSCs that are produced with higher efficiency and have established pluripotency (including naive pluripotency) and improved genomic stability compared to previous systems. Furthermore, iPSCs reprogrammed from T cells using the disclosed optimized reprogramming composition and method have a much lower tendency to have karyotype abnormalities, including trisomy.

[0148] In some embodiments, reprogramming is under feeder-free conditions. In certain embodiments, the feeder-free environment is essentially devoid of human feeder cells and is not pre-configured by feeder cells including, but not limited to, mouse embryonic fibroblasts, human fibroblasts, keratinocytes, and embryonic stem cells.

[0149] Maintenance of cells

[0150] Among the many key aspects of the manufacturing process for cell therapies, cell expansion and cryopreservation have been identified as areas of significant interest; cell viability and function are significantly affected during freeze-thaw cycles, and the in vivo cellular efficacy and persistence of effector cells derived from iPSC differentiation are complexly affected during the effector cell expansion stage after iPSC differentiation. Accordingly, another aspect of the present invention addresses the long-term preservation of induced pluripotent stem cells (iPSCs) under conditions particularly free of feeder cells when the cells undergo one or more stressors, including but not limited to single-cell dissociation, clonal expansion, freeze-thaw cycles, vector transfusion, electroporation, and genome editing. In some embodiments, the genome editing of the iPSCs is multiple editing.

[0151] Accordingly, in some embodiments, cells are induced for about 7 to 35 days, about 10 to 32 days, about 15 to 31 days, about 17 to 29 days, about 19 to 27 days, or about 21 to 25 days, after which the cells are selectively dissociated by enzymatic or mechanical means to dissociate into a single-cell suspension. The dissociated cells may be resuspended in any suitable solution or medium to maintain the cells or to perform cell sorting. In some embodiments, the single-cell dissociated suspension comprises a TGFβ family protein, a ROCK inhibitor and a MEK inhibitor, and a WNT activator. In some embodiments, the TGFβ family protein is selectively added at the single-cell dissociation of the iPSC colony, at the iPSC single-cell expansion, or at any stage in between. In certain embodiments, the WNT activator comprises and / or comprises a GSK3 inhibitor, or the TGFβ family protein comprises at least one of activin A, TGFβ, nodal, and functional variants or fragments thereof. In certain embodiments, the GSK3 inhibitor is CHIR99021, the MEK inhibitor is PD0325901 and / or the Rock inhibitor is thiazobibin.

[0152] In some embodiments, a single dissociated cell suspension may be further sorted. In various embodiments, enrichment provides a method for inducing clonal iPSC colonies in a relatively short time, thereby improving iPSC generation efficiency. Enrichment may include sorting the cell population by identifying and obtaining cells expressing a pluripotency marker to obtain an enriched pluripotency cell population. Further enrichment methodologies include depletion of cells expressing a differentiation marker, cells not reprogrammed, or non-pluripotency cells. In some embodiments, the cells for sorting are pluripotency cells. In some embodiments, the cells for sorting are reprogramming cells. In some embodiments, the cells for sorting were induced to reprogram for at least 1, 2, 3, 4, 5, 6, 7, 8 days, but 25, 26, 28, 30, 32, 35, 40 days or less, or for a number of days in between. In some embodiments, cells for classification were induced to reprogram for about 21 to 25 days, about 19 to 23 days, about 17 to 21 days, about 15 to about 19 days, or about 16 to about 18 days.

[0153] Cells may be classified by any suitable cell sorting method, such as magnetic bead or flow cytometry (FACS) sorting. Cells may be classified based on one or more pluripotency markers, including, but not limited to, the expression of SSEA3 / 4, TRA1-60 / 81, TRA1-85, TRA2-54, GCTM-2, TG343, TG30, CD9, CD29, CD133 / prominin, CD140a, CD56, CD73, CD105, OCT4, NANOG, SOX2, KLF4, SSEA1 (mouse), CD30, SSEA5, CD90 and / or CD50. In various embodiments, cells are classified based on at least two, at least three, or at least four pluripotency markers. In certain embodiments, cells are classified based on the expression of SSEA4, and in certain specific embodiments, based on the expression of SSEA4 in combination with TRA1-81 and / or TRA1-60. In certain embodiments, cells are classified based on the expression of SSEA4, TRA1-81, or TRA1-60, and / or CD30. In one embodiment, cells are classified based on SSEA4, TRA1-81, and CD30. In another embodiment, cells are classified based on SSEA4, TRA1-60, and CD30. In certain embodiments, cells were initially depleted for non-reprogrammed cells using one or more surface markers of differentiated cells, including but not limited to CD13, CD26, CD34, CD45, CD31, CD46, and CD7, and then enriched for pluripotency markers, such as SSEA4, TRA1-81, and / or CD30.

[0154] After reprogramming, iPSCs are maintained, passaged, expanded, and / or cryopreserved. In some embodiments, iPSCs are cultured as single cells for an extended period in a maintenance medium, e.g., FMM2, as shown in Table 2, i.e., maintained, passaged, expanded, and cryopreserved. iPSCs cultured in FMM2 have been shown to maintain undifferentiated and bottom or naive profiles; genomic stability requiring no culture washing or selection; in vitro differentiation through three somatic lineages, embryos, or monolayers (without embryo formation); and readily induce in vivo differentiation by teratogenesis. For example, reference is made to International Publication WO 2015 / 134652 and U.S. Application Publication No. 20170073643, the disclosures of which are incorporated herein by reference. In various embodiments, iPSCs cultured in FMM2 demonstrated increased expression of one or more naive-specific markers, including but not limited to the following, compared to expression in the previous system: TBX3 (T-box transcription factor; UniProt Accession No. O15119), TFCP2L1 (transcription factor CP2-like protein 1; UniProt Accession No. Q9NZI6), UTF1 (undifferentiated embryonic cell transcription factor 1; UniProt Accession No. Q5T230), FGF4 (fibroblast growth factor receptor 4; UniProt Accession No. P22455), TFCP2L1 (transcription factor CP2-like protein 1; UniProt Accession No. Q9NZI6), PRDM14 (PR domain zinc finger protein 14; UniProt Accession No. Q9GZV8), DPPA5 (pluripotency-associated 5 protein; UniProt Accession No. A6NC42), DNMT3L(DNA (cytosine-5)-methyltransferase 3-like; UniProt Accession No. Q9UJW3), KLF4(Krueppel-like factor 4; UniProt Accession No.O43474), and MAEL (protein Maelstrom homolog; UniProt Accession No. Q96JY0). Cells suitable for reprogramming using the reprogramming system and method generally comprise any non-pluripotent cells. Non-pluripotent cells comprise, but are not limited to, terminally differentiated cells; or pluripotent or progenitor cells that cannot give rise to all three types of germ layer lineage cells. In some embodiments, the non-pluripotent cells for reprogramming are primary cells, i.e., cells isolated directly from human or animal tissue. In some embodiments, the non-pluripotent cells for reprogramming are source-specific cells, e.g., donor-, disease-, or treatment-response-specific. In some embodiments, the non-pluripotent cells for reprogramming are primary immune cells. In some embodiments, the non-pluripotent cells for reprogramming are derived from pluripotent cells, including embryonic stem cells and induced pluripotent stem cells. In some embodiments, the non-pluripotent cells for reprogramming are induced immune effector cells, e.g., iPSC-derived non-natural T- or NK-like cells.

[0155] In some other embodiments, the non-pluripotent cells for reprogramming are genomically modified primary or derived cells. The genetic modifications contained in the non-pluripotent cells include insertions, deletions, or substitutions in the genome that induce a knock-in, knock-out, or knock-down of gene expression. The modified expression in the non-pluripotent cells for reprogramming may be constitutive or inductive (e.g., developmental stage-, tissue-, cell-, or inducer-specific). In some embodiments, the insertions or substitutions are locus-specific targeted integrations. In some embodiments, the locus selected for integration is a safe harbor locus or an endogenous gene of interest locus. Safe harbor loci may include AAVS1, CCR5, ROSA26, collagen, HTRP, H11, beta-2 microglobulin, GAPDH, TCR, or RUNX1, and other loci that meet the criteria for a genomic safe harbor. For an integration site to become a potential safe harbor locus, it must ideally meet criteria including, but not limited to: the absence of disruption of regulatory elements or genes as judged by sequence annotation; a convergent location between two genes transcribed in opposite directions or in intergene regions of gene-dense areas; maintenance of distance to minimize the possibility of long-range interactions between the transcription activator encoded by the vector and adjacent genes, particularly promoters of cancer-associated and microRNA genes; and the possession of apparent ubiquitous transcriptional activity as reflected by extensive spatial and temporal expression sequence tag (EST) expression patterns (indicating ubiquitous transcriptional activity). This latter feature is particularly important in relation to pluripotent cells, where chromatin remodeling during differentiation typically leads to the silencing of some loci and the potential activation of others. Within a region suitable for exogenous insertion, the precise locus selected for insertion is free of repetitive elements and conserved sequences, and primers for the amplification of homologous arms can be easily designed.In one example, a non-pluripotent cell to be reprogrammed using the system and method of the present invention is a T cell containing a CAR at an endogenous TCR locus, and TCR expression is destroyed as a result of CAR integration.

[0156] In one embodiment, reprogramming of genetically modified non-pluripotent cells is to obtain genome-engineered iPSCs containing the same genetic modification(s). As such, in some other embodiments, one or more of these genome edits may be introduced into the iPSCs after reprogramming to obtain genome-engineered iPSCs. In one embodiment, the iPSCs for genome editing are a clonal lineage or a clonal iPS cell population.

[0157] In some embodiments, genome-engineered iPSCs containing one or more targeted gene edits are maintained, passaged, expanded, and / or cryopreserved in a medium containing a TGFβ family protein, ROCKi, MEKi, and a WNT activator, and are free of or essentially free of TGFβ receptor / ALK5 inhibitors, and the iPSCs maintain intact and functional targeted edits at selected sites. In some embodiments, the TGFβ family protein, ROCKi, and / or MEKi and WNT activator are added at specific stages during iPSC maintenance. In some embodiments, iPSC maintenance comprises one or more sequential stages, including but not limited to: single-cell dissociation of an iPSC colony, single-cell sorting of the dissociated iPSC, iPSC single-cell clone expansion, cryopreservation of a cloned iPSC master cell bank (MCB), thawing of the iPSC MCB, and optionally additional cryopreservation-thaw cycles of the iPSC MCB. In some embodiments, the addition of TGFβ family proteins occurs optionally at the single-cell dissociation of iPSC colonies, at the expansion of iPSC single-cell clones, or at any stage in between. In some embodiments, MEKi and / or WNT activators are present in an amount of about 30 to 60% used to reprogram non-pluripotent cells.

[0158] In some embodiments, gene editing introduces one or more of the following: a safety switch protein, a targeting modulus, a receptor, a signaling molecule, a transcription factor, a pharmaceutically active protein or peptide, a drug target candidate, and a protein that promotes the engraftment, trafficking, homing, tumor invasion, viability, self-renewal, persistence, and / or survival of pluripotent cells and / or derivatives thereof. In one embodiment, the genome-engineered iPSC comprises one or more suicide gene-mediated safety switches, including but not limited to caspase 9 (or caspase 3 or 7), thymidine kinase, cytosine deaminase, B-cell CD20, modified EGFR, and any combination thereof. In some embodiments, the genome-engineered iPSC has at least one genome modification comprising: the introduction or increased expression of a chimeric receptor, a homing receptor, an anti-inflammatory molecule, an immune checkpoint protein, a cytokine / chemokine attractant receptor, a growth factor, a modified pro-inflammatory cytokine receptor, a CAR, or a surface-triggered receptor for coupling with a bispecific, multispecific, or universal engager; or the reduced or silencing of a co-stimulatory gene. In some embodiments, the genome-engineered iPSC comprises a high-affinity and / or non-cleavage CD16 as a targeting mode. In some other embodiments, the targeting mode included in the genome-engineered iPSC is a chimeric antigen receptor (CAR) that is T cell-specific, NK cell-specific, or suitable for both T and NK cells.

[0159] In some embodiments, the genome-engineered iPSC contains in / del in one or more exogenous polynucleotides or in one or more endogenous genes. In some embodiments, the in / del contained in the endogenous gene causes disruption of gene expression. In some embodiments, the in / del contained in the endogenous gene causes knockout of the edited gene. In some embodiments, the in / del contained in the endogenous gene causes knockdown of the edited gene. In some embodiments, the genome-engineered iPSC containing one or more exogenous polynucleotides at selected site(s) may further contain one or more targeted edits containing in / del at selected site(s). In some embodiments, the in / del is contained in one or more endogenous genes involved in the regulation and mediation of immune responses. In some embodiments, the in / del is contained within one or more endogenous checkpoint genes. In some embodiments, the in / del is contained within one or more endogenous T cell receptor genes. In some embodiments, in / del is contained within one or more endogenous MHC class I repressor genes. In some embodiments, in / del is contained within one or more endogenous genes associated with major histocompatibility complexes. In one embodiment, the modified iPSC cells comprise deletion, disruption, or reduced expression of at least one of the B2M, TAP1, TAP2, Tafacin, NLRC5, RFXANK, CIITA, RFX5, RFXAP, and HLA genes in the chromosome 6p21 region. In another embodiment, the modified iPS cells comprise the introduction of HLA-E or HLA-G. In yet another embodiment, the genome-manipulated iPS cells comprise a disconnected TCR locus.

[0160] Various target gene editing methods for iPSCs, particularly methods for effectively manipulating iPSCs at the single-cell level with a multi-locus targeting strategy, include, for example, those described in International Publication WO 2017 / 079673 (the contents of which are incorporated herein by reference).

[0161] III. iPSC derivative cells obtained in vitro

[0162] In some embodiments, the present invention further provides non-pluripotent cells derived from iPSCs obtained using systems and methods as disclosed herein. In some embodiments, the iPSCs for generating derivative non-pluripotent cells are genome-manipulated through targeted editing of the iPSCs, or through reprogramming genome-manipulated non-pluripotent cells having site-specific integration or in / del. In some embodiments, the iPSC-derived non-pluripotent cells are progenitor cells or fully differentiated cells. In some embodiments, the iPSC-derived non-pluripotent cells are immune effector cells. In some embodiments, the iPSC-derived cells possessing the same targeted editing contained in the genome-manipulated iPSCs are non-natural mesenchymal cells, CD34 cells, hematopoietic endothelial cells, hematopoietic stem or progenitor cells, hematopoietic pluripotent progenitor cells, T cell progenitors, NK cell progenitors, T cells, NKT cells, NK cells, B cells, immunomodulatory cells, or any desired cell of any germ layer lineage. In some embodiments, iPSC-derived non-natural immune regulatory cells include myeloid-derived suppressor cells (MDSC), regulatory macrophages, regulatory dendritic cells, or mesenchymal stromal cells, which are potent immunomodulators of NK, B, and T cells.

[0163] Not only does it produce an unlimited number of specific or subtypes of cells that are difficult to obtain through isolation from donor sources, but human iPSC-derived lines have been shown to exhibit fetal cell characteristics, and the reprogramming process resets cell patency (from designation / differentiation to pluripotency) as well as the chronological age characteristics of the donor cell population, regardless of the age of the initial somatic cell donor. In addition to fetal-like characteristics observed in iPSC-derived lines including neuronal, cardiac, or pancreatic cells, cellular characteristics of aging showed measurable changes demonstrating the rejuvenation of cells redifferentiated from iPSCs following the reprogramming process. Age-related parameters expressed in aged donor fibroblast populations were reset after iPSC induction and differentiation into iPSC-derived fibroblast-like cells (Miller et al., 2013). iPSC-derived antigen-specific T cells differentiated from iPSCs reprogrammed from T cell clones demonstrate rejuvenation through telomeres that are longer than those found in the original T cell clones. Additional changes in fully differentiated cells indicative of the rejuvenation process include, but are not limited to: an overall increase in heterochromatin, improved mitochondrial function (decreased ROS, reduced mtDNA mutations, presence of superstructure), increased DNA damage response, telomere elongation and a decrease in the percentage of short telomeres, and a decrease in the proportion of senescent cells (Reference [Nishimura et al., 2013]). Positive resetting of these various age-related modalities leads to non-natural cells with higher potential for functions such as proliferation, survival, persistence, and memory. Thus, reprogramming and redifferentiation-mediated rejuvenation confer many molecular, phenotypic, and functional characteristics upon fully differentiated iPSC-derived cells, and these non-natural characteristics distinguish them from their primary cell counterparts despite cell lineage similarities.

[0164] Applicable differentiation methods and compositions for obtaining iPSC-derived hematopoietic cell lines include, for example, those described in International Patent Application Publication WO 2017 / 078807, the disclosure thereof is incorporated herein by reference. As provided herein, methods and compositions for generating hematopoietic cell lines are derived from definitive hematopoietic endothelial (HE) derived from pluripotent stem cells, including iPSCs in an amplifiable monolayer cultured on a platform, under serum-free, feeder-free, and / or substrate-free conditions where EB formation is not required. Cells that can be differentiated according to the provided methods range from pluripotent stem cells to particularly terminally differentiated cells and transdifferentiated cells, and to progenitor cells committed to various lineages of cells that are directly transferred to hematopoietic cells without passing through pluripotent intermediates. Similarly, cells produced by the differentiation of stem cells range from pluripotent stem or progenitor cells to terminally differentiated stem cells and all intermediate hematopoietic cell lines.

[0165] A method for differentiating and expanding hematopoietic lineage cells from pluripotent stem cells in monolayer culture comprises contacting pluripotent stem cells with a BMP pathway activator and, optionally, bFGF. As provided, pluripotent stem cell-derived mesenchymal cells are obtained and expanded from pluripotent stem cells without forming a zygote. The mesenchymal cells are then contacted with a BMP pathway activator, bFGF, and a WNT pathway activator to obtain expanded mesenchymal cells with terminal hematopoietic endothelial (HE) potential without forming a zygote from pluripotent stem cells. Subsequent contact with bFGF and, optionally, a ROCK inhibitor and / or a WNT pathway activator causes the mesenchymal cells with terminal HE potential to differentiate into terminal HE cells, which are also expanded during differentiation.

[0166] The method provided herein for obtaining hematopoietic lineage cells is superior to EB-mediated pluripotent stem cell differentiation because EB formation usually leads to minimal cell expansion, does not allow for a monolayer culture which is important for many applications requiring homogeneous expansion and homogeneous differentiation of cells in a population, and is difficult and low-efficiency.

[0167] The provided monolayer differentiation platform enables differentiation into definitive hematopoietic endothelial cells that induce hematopoietic stem cells and differentiated progeny, such as T, B, NKT, NK-like cells, and regulatory cells. The monolayer differentiation strategy combines enhanced differentiation efficiency with large-scale expansion that enables the delivery of therapeutically relevant numbers of pluripotent stem cell-derived hematopoietic effector cells for various therapeutic applications. Additionally, monolayer culture using the method provided herein leads to functional hematopoietic lineage cells that enable a full range of in vitro differentiation, in vitro conditioning, and long-term in vivo hematopoietic self-renewal, reconstitution, and engraftment. As provided, iPSC-derived hematopoietic lineage cells include, but are not limited to: terminal hematopoietic endothelial cells, hematopoietic pluripotent progenitor cells, hematopoietic stem and progenitor cells, T cell progenitors, NK cell progenitors, and immune effector cells having T cell function, NK cells, NKT cells, B cells, macrophages, neutrophils, myeloid-derived suppressor cells (MDSC), regulatory macrophages, regulatory dendritic cells, mesenchymal stromal cells, or combinations thereof.

[0168] A method for differentiating pluripotent stem cells into cells of a final hematopoietic lineage comprises: (i) contacting pluripotent stem cells with a composition comprising a BMP activator and optionally bFGF to initiate differentiation and expansion of mesenchymal cells from pluripotent stem cells; (ii) contacting mesenchymal cells with a composition comprising a BMP activator, bFGF, and a GSK3 inhibitor to initiate differentiation and expansion of mesenchymal cells having final HE potential from mesenchymal cells, wherein the composition optionally does not contain a TGFβ receptor / ALK inhibitor; (iii) contacting mesenchymal cells having final HE potential with a ROCK inhibitor; one or more growth factors and cytokines selected from the group consisting of bFGF, VEGF, SCF, IGF, EPO, IL6, and IL11; and optionally, a step of initiating differentiation and expansion of the final hematopoietic endothelial from pluripotent stem cell-derived mesenchymal cells having final hematopoietic endothelial potential by contacting with a composition containing a Wnt pathway activator, wherein the composition optionally does not contain a TGFβ receptor / ALK inhibitor.

[0169] In some embodiments, the method further comprises the step of contacting pluripotent stem cells with a composition comprising a ROCK inhibitor, a MEK inhibitor, a WNT activator, and optionally a TGFβ family protein, wherein the composition seedes and expands pluripotent stem cells that are free of TGFβ receptor / ALK inhibitors and have a lower tendency toward genomic abnormalities compared to pluripotent stem cells not in contact with the composition. In some embodiments, the pluripotent stem cells are iPSCs, or naive iPSCs, or iPSCs containing one or more genetic imprints; and one or more genetic imprints contained within the iPSCs are retained in hematopoietic cells differentiated therefrom. In some embodiments of the method for inducing pluripotent stem cells into hematopoietic lineage cells, the differentiation of pluripotent stem cells into hematopoietic lineage cells is in a monolayer culture form without the generation of embryos.

[0170] In some embodiments of the above method, the obtained pluripotent stem cell-derived final hematopoietic endothelial cells are CD34 + is. In some embodiments, the obtained final hematopoietic endothelial cells are CD34 + CD43 - is. In some embodiments, the final hematopoietic endothelial cells are CD34 + CD43 - CXCR4 - CD73 - is. In some embodiments, the final hematopoietic endothelial cells are CD34 + CXCR4 - CD73 - is. In some embodiments, the final hematopoietic endothelial cells are CD34 + CD43 - CD93 - is. In some embodiments, the final hematopoietic endothelial cells are CD34 + CD93 - is. In some embodiments, the final hematopoietic endothelial cells are CD34 + CD93 - CD73 - am.

[0171] In some embodiments of the above method, the method further comprises the following steps: (i) contacting a pluripotent stem cell-derived definitive hematopoietic endothelium with a composition comprising a ROCK inhibitor; one or more growth factors and cytokines selected from the group consisting of VEGF, bFGF, SCF, Flt3L, TPO, and IL7; and optionally a BMP activator; thereby initiating differentiation of the definitive hematopoietic endothelium into a pre-T cell precursor; and optionally, (ii) contacting the pre-T cell precursor with a composition comprising one or more growth factors and cytokines selected from the group consisting of SCF, Flt3L, and IL7, but lacking one or more of VEGF, bFGF, TPO, BMP activator, and ROCK inhibitor; thereby initiating differentiation of the pre-T cell precursor into a T cell precursor or a T cell. In some embodiments of the above method, the pluripotent stem cell-derived T cell precursor is CD34 + CD45 + CD7 + is. In some embodiments of the above method, the pluripotent stem cell-derived T cell precursor is CD45 + CD7 + is. In some embodiments, pluripotent stem cell-derived T cells contain a fraction of γδT cells much higher than that of primary T cells isolated from a donor source.

[0172] In some additional embodiments of the above method for inducing differentiation of pluripotent stem cells into hematopoietic lineage cells having improved genomic stability, the method further comprises the following step: (i) a ROCK inhibitor for pluripotent stem cell-derived definitive hematopoietic endothelial; one or more growth factors and cytokines selected from the group consisting of VEGF, bFGF, SCF, Flt3L, TPO, IL3, IL7, and IL15; and optionally, a step of initiating differentiation of definitive hematopoietic endothelial pre-NK cell precursors by contacting with a composition comprising a BMP activator; (ii) a step of initiating differentiation of the pre-NK cell precursors into NK cell precursors or NK cells by contacting the pluripotent stem cell-derived pre-NK cell precursors with a composition comprising one or more growth factors and cytokines selected from the group consisting of SCF, Flt3L, IL3, IL7, and IL15 (wherein the medium is free of one or more of VEGF, bFGF, TPO, BMP activator, and ROCK inhibitor). In some embodiments, the pluripotent stem cell-derived NK precursors are CD3 - CD45 + CD56 + CD7 + is. In some embodiments, pluripotent stem cell-derived NK cells are CD3 - CD45 + CD56 + is. In some embodiments, pluripotent stem cell-derived NK cells are optionally further defined by one or more of NKp46 (CD335), NKp30 (CD337), DNAM-1 (CD226), 2B4 (CD244), CD57 and CD16.

[0173] In another embodiment of the method, the method enables the production of immunomodulatory cells by contacting a fully formed HE derived from pluripotent stem cells with a medium comprising: a ROCK inhibitor, MCSF, GMCSF, and one or more growth factors and cytokines selected from the group consisting of IL1b, IL3, IL6, IL4, IL10, IL13, TGFβ, bFGF, VEGF, SCF, and FLT3L, and optionally, one or both of an AhR antagonist and a prostaglandin pathway agonist.

[0174] In some embodiments, the derived immunomodulatory cells include myeloid-derived suppressor cells (MDSCs). In one embodiment, the population of derived immunomodulatory cells is CD45 + CD33 + It includes cells. In some embodiments, the population of derived immunomodulatory cells includes monocytes. In some embodiments, the monocytes are CD45 + CD33 + CD14 + It includes cells. In another embodiment, the population of derived immunomodulatory cells is CD45 + CD33 + PDL1 + It includes cells. One aspect of the present invention is CD45 + CD33 + , CD45 + CD33 + CD14 + , or CD45 + CD33 + PDL1 + Provides a cell population or subpopulation rich in iPSC-derived immunomodulatory cells containing cells. In some other embodiments, the population of derived immunomodulatory cells is CD33 + CD15 + CD14 - CD11b -The population of induced immunomodulatory cells comprising iMDSCs comprises about 50%, about 40%, about 30%, about 20%, about 10%, about 5%, about 2%, about 1%, and less than about 0.1% of red blood cells, lymphocytes, granulocytes, and CD45 cells. - CD235 + Cell, CD45 + CD7 + cell, or CD45 + CD33 + CD66b + It includes cells. In some embodiments, the population of induced immunomodulatory cells is essentially red blood cells, lymphocytes, granulocytes, CD45 - CD235 + Cell, CD45 + CD7 + cell, or CD45 + CD33 + CD66b + There are no cells.

[0175] III. Therapeutic Uses of iPSCs and Immune Cells Derived Therefrom

[0176] The present invention provides a composition comprising an isolated population or subpopulation of iPSCs and / or immune cells derived from said iPSCs using a method and composition as disclosed in some embodiments. In some embodiments, the iPSCs comprise one or more targeted gene edits that can be maintained in iPSC-derived immune effector cells, and the genetically engineered iPSCs and their derivative cells are suitable for cell-based adoptive therapy. In one embodiment, the isolated population or subpopulation of genetically engineered immune cells comprises iPSC-derived HSC cells. In one embodiment, the isolated population or subpopulation of genetically engineered immune cells comprises iPSC-derived HSC cells. In one embodiment, the isolated population or subpopulation of genetically engineered immune cells comprises iPSC-derived proT or T-like cells. In one embodiment, the isolated population or subpopulation of genetically engineered immune cells comprises iPSC-derived proNK or NK-like cells. In one embodiment, the isolated population or subpopulation of genetically engineered immune cells comprises iPSC-derived immunomodulatory cells or bone marrow-derived suppressor cells (MDSCs). In some embodiments, the iPSC-derived genetically engineered immune cells are further modified in vitro for enhanced therapeutic potential. In one embodiment, the isolated population or subpopulation of genetically engineered immune cells derived from iPSCs comprises an increased number or proportion of naive T cells, stem cell memory T cells, and / or central memory T cells. In one embodiment, the isolated population or subpopulation of genetically engineered immune cells derived from iPSCs comprises an increased number or proportion of type I NKT cells. In another embodiment, the isolated population or subpopulation of genetically engineered immune cells derived from iPSCs comprises an increased number or proportion of adaptive NK cells.In some embodiments, an isolated population or subpopulation of myeloid-derived suppressor cells derived from genetically engineered CD34 cells, HSC cells, T cells, NK cells, or iPSCs is homologous. In some other embodiments, an isolated population or subpopulation of MDSCs derived from genetically engineered CD34 cells, HSC cells, T cells, NK cells, or iPSCs is autogenetic.

[0177] In some embodiments, the iPSC for differentiation comprises a genetic imprint that delivers desirable therapeutic properties to effector cells, and this genetic imprint is maintained and functions in differentiated hematopoietic cells derived from said iPSC.

[0178] In some embodiments, the genetic imprint of the pluripotent stem cell comprises (i) one or more genetically modified modes obtained through genomic insertions, deletions, or substitutions in the genome of the pluripotent cell during or after reprogramming the non-pluripotent cell into an iPSC; or (ii) one or more sustainable therapeutic properties of a source-specific immune cell that is donor-, disease-, or treatment-response-specific, and the iPSC retains the source-specific therapeutic properties, which are also included in the iPSC-derived hematopoietic lineage cells.

[0179] In some embodiments, the genetically modified mode comprises one or more of the following: a safety switch protein, a targeting mode, a receptor, a signaling molecule, a transcription factor, a pharmaceutically active protein and peptide, a drug target candidate; or a protein that promotes the engraftment, trafficking, homing, viability, self-renewal, persistence, regulation and coordination of immune response, and / or survival of iPSC or derivative cells. In some other embodiments, the genetically modified mode comprises one or more of the following: (i) deletion, disruption, or reduced expression of B2M, TAP1, TAP2, Tapasin, NLRC5, PD1, LAG3, TIM3, RFXANK, CIITA, RFX5, or RFXAP, and any gene in the chromosome 6p21 region; (ii) HLA-E, HLA-G, CD16, 4-1BBL, CD3, CD4, CD8, CD47, CD113, CD131, CD137, CD80, PDL1, A 2A Introduction of a surface-triggered receptor for coupling with R, CAR, TCR, Fc receptors or surface-triggered receptors, dual or multispecific or universal engagers.

[0180] In another embodiment, hematopoietic lineage cells include therapeutic properties of source-specific immune cells associated with one or more of the following: (i) expression of antigen-targeting receptors; (ii) HLA display or lack thereof; (iii) resistance to the tumor microenvironment; (iv) induction and immunomodulation of bystander immune cells; (v) improved target specificity with reduced off-tumor effects; (vi) resistance to treatments such as chemotherapy; and (vii) improved homing, persistence, and cytotoxicity.

[0181] In some embodiments, iPSCs and their derivative hematopoietic cells are B2M null or low, HLA-E / G, PDL1, A 2AThey include one or more of R, CD47, LAG3 null or low, TIM3 null or low, TAP1 null or low, TAP2 null or low, Tapacin null or low, NLRC5 null or low, PD1 null or low, RFKANK null or low, CIITA null or low, RFX5 null or low, and RFXAP null or low. These cells with modified HLA classes I and / or II exhibit increased resistance to immunodetection, resulting in improved in vivo persistence. Additionally, since these cells can avoid the need for HLA matching in adoptive cell therapy, they can provide a source for universal off-the-shelf therapeutic regimens.

[0182] In some embodiments, iPSCs and their derivative hematopoietic cells are hnCD16 (high-affinity intractable CD16), HLA-E, HLA-G, 4-1BBL, CD3, CD4, CD8, CD47, CD113, CD131, CD137, CD80, PDL1, A 2A It includes one or more of CD16 or variants thereof containing R, CAR, TCR, engager, or surface-induced receptors for engagers. These cells have enhanced immune effector capabilities.

[0183] In some embodiments, iPSCs and their derivative hematopoietic cells are antigen-specific.

[0184] Various diseases can be improved by introducing immune cells according to an embodiment of the present invention into a subject suitable for adoptive cell therapy. Examples of diseases including various autoimmune disorders include, but are not limited to, the following: alopecia areata, autoimmune hemolytic anemia, autoimmune hepatitis, dermatomyositis, diabetes mellitus (type 1), some forms of juvenile idiopathic arthritis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, idiopathic thrombocytopenic purpura, myasthenia gravis, some forms of myocarditis, multiple sclerosis, pemphigus / pemphigoid-like disease, pernicious anemia, polyarteritis nodosum, polymyositis, primary biliary cirrhosis, psoriasis, rheumatoid arthritis, scleroderma / systemic sclerosis, Sjogren's syndrome, systemic lupus erythematosus, some forms of thyroiditis, some forms of uveitis, vitiligo, polyangiitis granulomatosis (Wegener's granulomatosis); Hematological malignancies including but not limited to acute and chronic leukemia, lymphoma, multiple myeloma, and myelodysplastic syndrome; solid tumors including but not limited to tumors of the brain, prostate, breast, lung, colon, uterus, skin, liver, bone, pancreas, ovary, testis, bladder, kidney, head, neck, stomach, cervical, rectum, larynx, or esophagus; and infections including but not limited to HIV- (human immunodeficiency virus), RSV- (respiratory syncytial virus), EBV- (Epstein-Barr virus), CMV- (cytomegalovirus), adenovirus- and BK polyomavirus-related disorders.

[0185] In some embodiments, the present invention provides a therapeutic composition comprising pluripotent cell-derived hematopoietic lineage cells produced by the methods and compositions further disclosed herein, and the pharmaceutical composition further comprises a pharmaceutically acceptable medium. In one embodiment, the therapeutic composition comprises pluripotent cell-derived T cells produced by the methods and compositions disclosed herein. In one embodiment, the therapeutic composition comprises pluripotent cell-derived NK cells produced by the methods and compositions disclosed herein. In one embodiment, the therapeutic composition comprises pluripotent cell-derived CD34 cells produced by the methods and compositions disclosed herein. + It includes HE cells. In one embodiment, the therapeutic composition includes pluripotent cell-derived HSCs prepared by the method and composition disclosed herein. In one embodiment, the therapeutic composition includes pluripotent cell-derived MDSCs prepared by the method and composition disclosed herein.

[0186] Additionally, the present invention provides a therapeutic use of said therapeutic composition by introducing the composition to a subject suitable for adoptive cell therapy in some embodiments, wherein the subject has an autoimmune disorder; a hematological malignancy; a solid tumor; or an infection associated with HIV, RSV, EBV, CMV, adenovirus, or BK polyomavirus.

[0187] Hematopoietic lineage cells derived from isolated pluripotent stem cells comprise at least approximately 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% T cells, NK cells, NKT cells, proT cells, proNK cells, and CD34 +HE cells, HSCs, B cells, myeloid-derived suppressor cells (MDSCs), regulatory macrophages, regulatory dendritic cells, or mesenchymal stromal cells may be present. In some embodiments, the isolated pluripotent stem cell-derived hematopoietic lineage cells consist of about 95% to about 100% T cells, NK cells, NKT cells, proT cells, proNK cells, CD34 cells. + It has HE cells, HSCs, B cells, myeloid-derived suppressor cells (MDSCs), regulatory macrophages, regulatory dendritic cells, or mesenchymal stromal cells. In some embodiments, the present invention has purified T cells, NK cells, NKT cells, CD34 cells for treating subjects requiring cell therapy. + A therapeutic composition having HE cells, proT cells, proNK cells, HSCs, B cells, myeloid-derived suppressor cells (MDSCs), regulatory macrophages, regulatory dendritic cells, or mesenchymal stromal cells, e.g., about 95% T cells, NK cells, NKT cells, proT cells, proNK cells, CD34 + The present invention provides a composition having an isolated population of HE cells, HSCs, B cells, myeloid-derived suppressor cells (MDSCs), regulatory macrophages, regulatory dendritic cells, or mesenchymal stromal cells.

[0188] Treatment using hematopoietic line cells derived from the embodiments disclosed herein may be performed according to symptoms or to prevent recurrence. The therapeutic agent or composition may be administered before, during, or after the onset of the disease or injury. Treatment of an ongoing disease in which the treatment stabilizes or reduces undesirable clinical symptoms in the patient is also of particular importance. In certain embodiments, the subject requiring treatment has a disease, pathology, and / or injury that can be treated, improved, and / or enhanced in at least one associated symptom by cell therapy. Certain embodiments consider that the subject requiring cell therapy includes, but is not limited to: a candidate for bone marrow or stem cell transplantation; a subject who has received chemotherapy or radiation therapy; a subject who has or is at risk of having a hyperproliferative disorder or cancer, e.g., a hyperproliferative disorder or hematopoietic cancer; a subject who has or is at risk of developing a tumor, e.g., a solid tumor; or a subject who has or is at risk of having a viral infection or a disease associated with a viral infection.

[0189] A therapeutic composition comprising hematopoietic lineage cells derived as disclosed may be administered to a subject before, during, and / or after other treatments. As such, the method of combination therapy may include the administration or preparation of iPSC-derived immune cells before, during, and / or after the use of additional therapeutic agents. As provided above, one or more additional therapeutic agents comprise peptides, cytokines, mitogens, growth factors, small RNAs, dsRNA (double-stranded RNA), mononuclear blood cells, feeder cells, feeder cell components or alternative factors thereof, vectors containing one or more polynucleic acids of interest, antibodies, chemotherapy agents or radioactive moietyes, or immunomodulatory drugs (IMiDs). The administration of iPSC-derived immune cells may be temporally separated from the administration of additional therapeutic agents by hours, days, or even weeks. Additionally or alternatively, administration may be combined with other biological agents or methods, such as antineoplastic agents, non-drug therapies such as surgery, but not limited thereto.

[0190] In some embodiments, the additional therapeutic agent comprises an antibody or antibody fragment. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody may be a humanized antibody, a humanized monoclonal antibody, or a chimeric antibody. In some embodiments, the antibody or antibody fragment specifically binds to a viral antigen. In other embodiments, the antibody or antibody fragment specifically binds to a tumor antigen. In some embodiments, the tumor or virus-specific antigen activates administered iPSC-derived hematopoietic lineage cells to enhance their ability to kill. In some embodiments, antibodies suitable for combination therapy as additional therapeutic agents for administered iPSC-derived hematopoietic lineage cells include, but are not limited to: anti-CD20 (letuximab, veltuzumab, ofatumumab, ublituximab, ocaratuzumab, obinutuzumab), anti-Her2 (trastuzumab), anti-CD52 (alemtuzumab), anti-EGFR (cetuximab), and anti-CD38 (daratumumab, isatuximab, MOR202), and their humanized and Fc modified variants.

[0191] In some embodiments, additional therapeutic agents comprise one or more chemotherapy agents or radioactive moiety. The term chemotherapy agent refers to a cytotoxic antineotherapy agent, that is, a chemical agent used therapeutically to primarily kill new cells, disrupt the cell cycle of rapidly proliferating cells, combat cancer stem cells, or prevent or reduce the growth of new cells. Chemotherapy agents are sometimes referred to as antineotherapy agents or cytotoxic drugs or preparations, which are well known in the art.

[0192] In some embodiments, the chemotherapy agent comprises anthracyclines, alkylating agents, alkyl sulfonates, aziridines, ethyleneimines, methylmelamine, nitrogen mustard, nitrosourea, antibiotics, antimetabolites, folic acid analogs, purine analogs, pyrimidine analogs, enzymes, podophyllotoxin, platinum-containing agents, interferons, and interleukins. Exemplary chemotherapeutic agents include, but are not limited to, the following: alkylating agents (cyclophosphamide, mechlorethamine, mephaline, chlorambucil, heamethylmelamine, thiotepa, busulfan, carmustine, lomustine, semustine), anmetatars (methotrexate, fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, thioguanine, pentostatin), vinca alkaloids (vincristine, vinblastine, vindesin), epipodophillotoxins (etoposide, etoposide orthoquinone, and tenifoside), antibiotics (daunorubicin, doxorubicin, mitoxantrone, virsanthren, actinomycin D, plicamycin, puromycin, and gramicidin D), paclitaxel, colchicine, cytocalcin B, emetine, meitansine, and Amsacrin.Additional agents include amineglutechimide, cisplatin, carboplatin, mitomycin, altretamine, cyclophosphamide, lomustine (CCNU), carmustine (BCNU), irinotecan (CPT-11), alemtuzamab, altretamine, anastrozole, L-asparaginase, azacitidine, bevacizumab, bexarotene, bleomycin, bortezomib, busulfan, calosterone, capecitabine, celecoxib, cetuximab, cladribine, clofurabine, cytarabine, dacarbazine, denyleukin diptitox, diethylstilbestrol, docetaxel, dromostanolone, epirubicin, erlotinib, estramustine, etoposide, ethinyl estradiol, exemestane, floroxuridine, 5-Florouracil, Fludarabine, Flutamide, Fulvestrant, Gefitinib, Gemcitabine, Goserelin, Hydroxyurea, Ibritumomab, Idarubicin, Ifosfamide, Imatinib, Interferon Alpha (2a, 2b), Irinotecan, Letrozole, Leucovorin, Leuprolide, Levamisole, Mechloretamine, Megestrol, Melphaline, Mercaptopurine, Methotrexate, Methoxalenn, Mitomycin C, Mitotan, Mitoxantrone, Nandrolone, Nofetumomab, Oxaliplatin, Paclitaxel, Famidronate, Pemetrexid, Pegademase, Pegasparagase, Pentostatin, Pifobroman, Plicamycin, Polypeproic Acid, Porfimer, Procarbazine, Quinacrine, This includes rituximab, sargramostim, streptozosin, tamoxifen, temozolomide, tenifoside, testolactone, thioguanine, thiotepa, topetecan, toremifene, tocitumomab, trastuzumab, tretinoin, uracil mustard, valubicin, vinorelbine, and zoledronate. Other suitable agents are those approved for human use, including those approved as chemotherapy or radiotherapy agents and known in the art. These agents are referenced in numerous standard physician and oncologist literature (e.g., Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill, NY).It may be mentioned on the National Cancer Institute website (fda.gov / cder / cancer / druglistfrarne.htm) (both updated from time to time).

[0193] Immunomodulatory drugs (IMiDs), e.g., thalidomide, lenalidomide, and pomalidomide, stimulate both NK cells and T cells. As provided herein, IMiDs can be used with iPSC-derived therapeutic immune cells for cancer treatment.

[0194] Those skilled in the art will understand that both autologous and allogeneic hematopoietic lineage cells derived from iPSCs based on the methods and compositions of the present invention can be used in cell therapies as described above. For autologous transplantation, the isolated population of derived hematopoietic lineage cells is fully or partially HLA-matched with the patient. In other embodiments, the induced hematopoietic lineage cells are not HLA-matched with the subject.

[0195] In some embodiments, the number of hematopoietic lineage cells derived from the therapeutic composition is at least 0.1 x 10 per dose. 5 Cells, at least 1 x 10⁶ 5 Cells, at least 5 x 10 5 Cells, at least 1 x 10⁶ 6 Cells, at least 5 x 10 6 Cells, at least 1 x 10⁶ 7 Cells, at least 5 x 10 7 Cells, at least 1 x 10⁶ 8 Cells, at least 5 x 10 8 Cells, at least 1 x 10⁶ 9 Cells, or at least 5 x 10 9 It is a cell. In some embodiments, the number of hematopoietic lineage cells derived in the therapeutic composition is about 0.1 x 10 per dose. 5 Cells to about 1 x 10⁶ 6 Cells; approx. 0.5 x 10⁶ per dose 6 Cells to about 1 x 10⁻⁶7 Cells; approx. 0.5 x 10⁶ per dose 7 Cells to about 1 x 10⁶ 8 Cells; approx. 0.5 x 10⁶ per dose 8 Cells to about 1 x 10⁶ 9 Cells; approximately 1 x 10⁶ per dose 9 Cells up to about 5 x 10 9 Cells; approx. 0.5 x 10⁶ per dose 9 Cells up to about 8 x 10 9 Cells; approximately 3 x 10 per dose 9 Cells to about 3 x 10 10 It is the range of cells, or between them. Generally, 1 x 10⁻⁶ 8 The cell / dose ratio is 1.67 x 10 for a 60 kg patient. 6 It is converted to cells / kg.

[0196] In one embodiment, the number of hematopoietic lineage cells derived in the therapeutic composition is the number of immune cells in a partial or single umbilical cord blood, or at least 0.1 x 10⁻⁶ 5 Cells / body weight kg, at least 0.5 x 10⁻⁶ 5 Cells / body weight kg, at least 1 x 10⁻⁶ 5 Cells / body weight kg, at least 5 x 10 5 Cells / body weight kg, at least 10 x 10 5 Cells / body weight kg, at least 0.75 x 10⁻⁶ 6 Cells / body weight kg, at least 1.25 x 10⁻⁶ 6 Cells / body weight kg, at least 1.5 x 10⁻⁶ 6 Cells / body weight kg, at least 1.75 x 10⁻⁶ 6 Cells / body weight kg, at least 2 x 10⁻⁶ 6 Cells / body weight kg, at least 2.5 x 10⁻⁶ 6 Cells / body weight kg, at least 3 x 10⁻⁶ 6 Cells / body weight kg, at least 4 x 10 6 Cells / body weight kg, at least 5 x 10 6 Cells / body weight kg, at least 10 x 10 6 Cells / body weight kg, at least 15 x 106 Cells / body weight kg, at least 20 x 10 6 Cells / body weight kg, at least 25 x 10⁻⁶ 6 Cells / body weight kg, at least 30 x 10 6 Cells / body weight kg, 1 x 10⁻⁶ 8 Cells / body weight kg, 5 x 10 8 Cells / kg body weight, or 1 x 10⁻⁶ 9 It is cell / body weight kg.

[0197] In one embodiment, a dose of derived hematopoietic lineage cells is delivered to the subject. In one exemplary embodiment, the effective amount of cells provided to the subject is at least 2 x 10 6 Cells / kg, at least 3 x 10 6 Cells / kg, at least 4 x 10 6 Cells / kg, at least 5 x 10 6 Cells / kg, at least 6 x 10 6 Cells / kg, at least 7 x 10 6 Cells / kg, at least 8 x 10 6 Cells / kg, at least 9 x 10 6 Cells / kg, or at least 10 x 10⁻⁶ 6 It is cells / kg, or more cells / kg (including all intermediate doses of cells).

[0198] In another exemplary embodiment, the effective amount of cells provided to the subject is about 2 x 10 6 Cells / kg, approx. 3 x 10⁻⁶ 6 Cells / kg, approx. 4 x 10 6 Cells / kg, approx. 5 x 10 6 Cells / kg, approx. 6 x 10 6 Cells / kg, approx. 7 x 10 6 Cells / kg, approx. 8 x 10 6 Cells / kg, approx. 9 x 10 6 Cells / kg, or about 10 x 10⁻⁶ 6 It is cells / kg, or more cells / kg (including all intermediate doses of cells).

[0199] In another exemplary embodiment, the effective amount of cells provided to the subject is about 2 x 10 6 cells / kg to about 10 x 10⁶ 6 Cells / kg, approx. 3 x 10⁻⁶ 6 cells / kg to about 10 x 10⁶ 6 Cells / kg, approx. 4 x 10 6 cells / kg to about 10 x 10⁶ 6 Cells / kg, approx. 5 x 10 6 cells / kg to about 10 x 10⁶ 6 Cells / kg, 2 x 10⁻⁶ 6 cells / kg to about 6 x 10⁶ 6 Cells / kg, 2 x 10⁻⁶ 6 cells / kg to about 7 x 10⁶ 6 Cells / kg, 2 x 10⁻⁶ 6 cells / kg to about 8 x 10⁶ 6 Cells / kg, 3 x 10⁻⁶ 6 cells / kg to about 6 x 10⁶ 6 Cells / kg, 3 x 10⁻⁶ 6 cells / kg to about 7 x 10⁶ 6 Cells / kg, 3 x 10⁻⁶ 6 cells / kg to about 8 x 10⁶ 6 Cells / kg, 4 x 10 6 cells / kg to about 6 x 10⁶ 6 Cells / kg, 4 x 10 6 cells / kg to about 7 x 10⁶ 6 Cells / kg, 4 x 10 6 cells / kg to about 8 x 10⁶ 6 Cells / kg, 5 x 10 6 cells / kg to about 6 x 10⁶ 6 Cells / kg, 5 x 10 6 cells / kg to about 7 x 10⁶ 6 Cells / kg, 5 x 10 6 cells / kg to about 8 x 10⁶ 6 cells / kg, or 6 x 10⁶ 6 cells / kg to about 8 x 10⁶ 6 It is cells / kg (including all intermediate volume cells).

[0200] Slight variations in dosage will inevitably occur depending on the condition of the subject being treated. The person in charge of administration determines the appropriate dosage for each individual subject in all cases.

[0201] In some embodiments, the therapeutic use of the derived hematopoietic line cell is a single-dose treatment. In some embodiments, the therapeutic use of the derived hematopoietic line cell is a multiple-dose treatment. In some embodiments, the multiple-dose treatment is a single dose every day, every 3 days, every 7 days, every 10 days, every 15 days, every 20 days, every 25 days, every 30 days, every 35 days, every 40 days, every 45 days, every 50 days, or any number of days in between.

[0202] A composition comprising a population of derived hematopoietic lineage cells according to an embodiment of the present invention may be sterile and may be suitable and ready for administration to a human patient (i.e., may be administered without further processing). A cell-based composition ready for administration means that the composition does not require any additional treatment or manipulation before being implanted or administered to a subject. In another embodiment, the present invention provides an isolated population of derived hematopoietic lineage cells that are expanded and / or regulated before administration with one or more agents. In the case of derived hematopoietic lineage cells genetically engineered to express a recombinant TCR or CAR, the cells may be activated and expanded, for example, using the method described in U.S. Patent No. 6,352,694, the disclosure of which is incorporated herein by reference.

[0203] In certain embodiments, the primary stimulation signal and the co-stimulation signal to the derived hematopoietic lineage cells may be provided by different protocols. For example, the agent providing each signal may be in solution or coupled to a surface. When coupled to a surface, the agent may bind to the same surface (i.e., a "cis" formation) or a separate surface (i.e., a "trans" formation). Alternatively, one agent may be coupled to a surface and the other agent may be in solution. In one embodiment, the agent providing the co-stimulation signal may be coupled to a cell surface, and the agent providing the primary activation signal may be in solution or coupled to a surface. In certain embodiments, both agents may be in solution. In another embodiment, the formulation may be in a soluble form and may then be bound to a surface, such as a cell-expressed Fc receptor or antibody, or to another binder to the formulation, such as that disclosed in U.S. Applications No. 2004 / 0101519 and No. 2006 / 0034810, the disclosures thereof of which are incorporated herein by reference.

[0204] A therapeutic composition suitable for administration to a patient may comprise one or more pharmaceutically acceptable carriers (additives) and / or diluents (e.g., pharmaceutically acceptable media, e.g., cell culture media), or other pharmaceutically acceptable components. The pharmaceutically acceptable carriers and / or diluents are determined by the specific composition to be partially administered as well as by the specific method used to administer the therapeutic composition. Accordingly, a wide variety of suitable formulations of the therapeutic composition according to embodiments of the present invention exist (e.g., the literature whose entire disclosure is incorporated herein by reference [Remington's Pharmaceutical Sciences, 17 th [See ed. 1985]).

[0205] In certain embodiments, a therapeutic cell composition having an isolated population of iPSC-derived hematopoietic lineage cells also has a pharmaceutically acceptable cell culture medium, or a pharmaceutically acceptable carrier and / or diluent. A therapeutic composition comprising an iPSC-derived hematopoietic lineage cell population as disclosed herein may be administered individually or in combination with other suitable compounds to achieve a desired therapeutic goal by intravenous, intraperitoneal, enteral, or tracheal administration methods.

[0206] Such pharmaceutically acceptable carriers and / or diluents may be present in an amount sufficient to maintain the pH of the therapeutic composition at about 3 to about 10. As such, the buffer may be about 5% by weight of the total composition. Electrolytes (but not limited to) such as sodium chloride and potassium chloride may also be included in the therapeutic composition. In one embodiment, the pH of the therapeutic composition is in the range of about 4 to about 10. Alternatively, the pH of the therapeutic composition is in the range of about 5 to about 9, about 6 to about 9, or about 6.5 to about 8. In another embodiment, the therapeutic composition comprises a buffer having a pH of one of the above pH ranges. In another embodiment, the therapeutic composition has a pH of about 7. Alternatively, the therapeutic composition has a pH in the range of about 6.8 to about 7.4. In yet another embodiment, the therapeutic composition has a pH of about 7.

[0207] The present invention also provides for the use of pharmaceutically acceptable cell culture media in certain compositions and / or cultures according in part to embodiments of the present invention. Such compositions are suitable for administration to human subjects. Generally speaking, any medium that supports the maintenance, growth, and / or health of iPSC-derived immune cells according to embodiments of the present invention is suitable for use as a pharmaceutical cell culture medium. In certain embodiments, the pharmaceutically acceptable cell culture medium is a serum-free and / or feeder-free medium. In various embodiments, the serum-free medium may be animal-free and optionally protein-free. Optionally, the medium may contain a biopharmaceutical-acceptable recombinant protein. An animal-free medium refers to a medium in which the components are derived from non-animal sources. Recombinant proteins replace natural animal proteins in the animal-free medium, and nutrients are obtained from synthetic, plant, or microbial sources. In contrast, a protein-free medium is defined as substantially protein-free. Those skilled in the art will understand that the above examples of culture media are exemplary and do not in any way limit the formulations of culture media suitable for use in embodiments of the present invention.

[0208] Examples

[0209] The following examples are provided by the method of example and not by the method of limitation.

[0210] Example 1 - Materials and Method

[0211] Single-cell dissociation All reprogramming cultures were switched to FMM or FMM2 approximately 14 days after transfection. Once all reprogramming cultures were maintained in FMM / FMM2, they were dissociated using Accutase. Then, single cells were passaged on a Matrigel or Vitronectin-coated surface. The dissociated single cells were expanded in FMM or FMM2 and maintained until flow cytometry sorting.

[0212] Flow cytometry analysis and classification The single-cell dissociated reprogramming pool was resuspended in cooled staining buffer. Conjugated primary antibodies, including SSEA4-FITC, TRA181-Alexa Fluor-647, and CD30-PE (BD Biosciences), were added to the cell solution and incubated on ice for 15 minutes. All antibodies were used at 7 to 10 μL per million cells in 100 μL staining buffer. The dissociated single cells resuspended in staining buffer were spun, resuspended in staining buffer containing ROCK inhibitors, and kept on ice for flow cytometry sorting. Flow cytometry sorting was performed on a FACS Aria II (BD Biosciences). The sorted cells were directly drained into 96-well plates at concentrations of 3 and 9 events per well. Each well was pre-filled with FMM2. Once sorting was complete, the 96-well plates were incubated for colony formation and expansion. Seven to ten days after sorting, the cells were passaged. Subsequent passages of FMM2 were typically performed at 75 to 90% confluence. Flow cytometry was performed on a Guava EasyCyte 8 HT (Millipore) and analyzed using FCS Express 4 (De Novo Software).

[0213] Test for the presence of transplant genesGenomic DNA was isolated using the QIAamp® DNA Mini Kit and Proteinase K digestion (Qiagen). 100 ng of genomic DNA was amplified using the Taq PCR Master Mix Kit (Qiagen) with a primer set specific to the transplant gene, including reprogramming factor and EBNA1. The PCR reaction was performed for 35 cycles as follows: 30 seconds at 94°C (denaturation), 30 seconds at 60 to 64°C (annealing), and 1 minute at 72°C (extension). Genomic DNA from fibroblasts, T cells, and hiPSCs generated by the lentiviral method was used as a negative control. DNA from episomal constructs was used as a positive control.

[0214] Karyotype analysis Cytogenetic analysis was performed on G-band metaphase cells by the WiCell Research Institute (Madison, WI). Each karyotype analysis includes a minimum count of 20 spreads, with an analysis expanded to a 40-spread count where nonclonal aberrations are identified in the first 20.

[0215] Statistical analysis At least three independent experiments were performed. Values ​​are reported as mean + SEM. Statistical analysis was performed using ANOVA with a p < 0.05 value considered significant.

[0216] culture mediumConventional hESC cultures contain DMEM / F12 culture medium supplemented with 20% knockout serum replacement, 0.1 mM (or 1% v / v) non-essential amino acids, 1 to 2 mM L-glutamine, 0.1 mM β-mercaptoethanol, and 10 to 100 ng / ml bFGF. In contrast, multistage culture media additionally contain one or more of HDAC inhibitors, ROCK inhibitors, GSK3 inhibitors / WNT activators, MEK inhibitors, and TGFβ inhibitors. This stage-specific culture platform also supports feeder-free reprogramming and maintenance.

[0217] In certain applications, the reprogramming medium (e.g., FRM) contains SMC4, a combination of a ROCK inhibitor, a GSK3 inhibitor / WNT activator, a MEK inhibitor, and a TGFβ inhibitor, in addition to the components for conventional culture. In the case of the STTR2 reprogramming system, the enhanced reprogramming medium (e.g., FRM2) does not contain a TGFβ inhibitor until the cells lose somatic identity (e.g., loss of cell type-specific gene expression) in about 6 to 8 days, and contains an HDAC inhibitor selectively added later than ROCKi, MEKi, and GSK3i. In certain applications, the maintenance medium (FMM) contains SMC3, a combination of a ROCK inhibitor, a GSK3 inhibitor, and a MEK inhibitor. In the case of STTR2 reprogramming, the enhanced maintenance medium (FMM2) contains members of the transforming growth factor beta superfamily (examples include, but are not limited to, activin A, TGFβ, and nodal), and optionally, the concentrations of one or both of the GSK3 inhibitor and MEK inhibitor were reduced by 30% to 60% compared to the concentrations in FRM2. Nodal is a secreted protein belonging to the TGFb superfamily and is encoded by the NODAL gene located on human chromosome 10q22.1. TGFβ is a polyfunctional cytokine belonging to the TGFb superfamily. Activin A is a TGFβ superfamily cytokine closely related to TGFβ.

[0218] Example 2 - Improvement of long-term stability and preservation using FMM2

[0219] The long-term preservation of induced pluripotent stem cells (iPSCs), particularly under conditions without feeder cells, is subjected to various stressors during cell manipulation processes including but not limited to single-cell dissociation and sorting, clonal expansion, freeze-thaw cycles, vector transfusion, electroporation, and genome editing. This results in genomic instability of the cells, including various karyotype abnormalities that can be detected by G-band karyotyping and droplet digital PCR. Among chromosomal deletions, duplications, translocations, or inversions, trisomy of specific chromosomes was observed more frequently in iPSCs reprogrammed from T cells (TiPSCs) than in other somatic cell types such as fibroblasts. Furthermore, these stressors impair the pluripotency, viability, and differentiation potential of the obtained pluripotent cells, which are often cryopreserved over long periods.

[0220] The previously developed FMM (Fate Maintenance Medium) satisfied the long-term stability of iPSCs reprogrammed from various somatic cells other than T cells. In addition to some basic components, FMM consists of small molecules such as ROCK inhibitors, WNT activators, and MEK inhibitors. To improve the long-term stability and preservation of iPSCs reprogrammed from all cell sources, particularly T cells, and to reduce the frequency of karyotype abnormalities, various modifications of FMM have been performed as disclosed and illustrated in FIG. 1a of this application, and the modified and improved iPSC maintenance medium is sometimes referred to as FMM2 in this application. T cell reprogramming was initiated using a non-integrated STTR plasmid and a modified and enhanced FRM known as Fate Reprogramming Medium (FRM) or FRM2. The generated cells were either transfected with a CRISPR ribonucleoprotein (RNP) complex (manipulated) mediating locus-specific target insertion or deletion, or proceeded directly to single-cell sorting (unmanipulated) to produce single-cell sorted, manipulated, and non-manipulated iPSC clones. To test the effects of FMM2 on long-term iPSC preservation, particularly on iPSC banks undergoing freeze-thaw cycles, single-cell sorted iPSC clones were expanded in FMM and then cryopreserved in FMM (Bank 1). A second bank (Bank 2) was created by thawing the iPSC clones from Bank 1, expanding them in FMM or FMM2, and cryopreserving them in FMM or FMM2, respectively. FMM variants are primarily small molecule compositions of FMM, and variants tested in combination with reducing or not reducing the concentration of MEK inhibitors (MEKi) and / or GSK3 inhibitors (GSKi) by about 40 to 60% compared to FMM include supplementation of at least one of activin A (Act A), TGFβ, and Forskolin. Here, for example, a 50% reduction in concentration of MEKi or GSK3i was used.

[0221] To test the long-term stability of iPSC clones under different media treatments, tests were performed after thawing the secondary bank. Genome stability was examined by two independent methods: determination of chromosome 12 copy number by ddPCR and whole-genome stability determined by G-band karyotyping analysis at indicated passages. The G-band karyotyping revealed microscopic genomic abnormalities (>5 Mb), including inversions, duplications / deletions, balanced and unbalanced translocations, and aneuploidy with a susceptibility of >10% mosaicism.

[0222] As shown in Fig. 1b, one iPSC clone derived from T cell donor 1 and two iPSC clones from T cell donor 2 were tested as described above. The karyotype results were labeled as "normal karyotype" (i.e., 46,XY or 46,XX) and "abnormal karyotype". The clones with abnormal karyotypes were further analyzed using ddPCR to determine the presence of trisomy 12. The ddPCR results were labeled as "normal 12" (i.e., copy number < 2.3) and "trisomy 12" (i.e., copy number > 2.3). Regardless of the differences in benefits from various FMM modifications, and considering the gap between donor and clone, it was found that supplementing FMM with a member of the TGFβ family (e.g., activin A, TGFβ, or nodal) with or without the combination of GSK3 inhibitors and a reduction in MEK concentration in FMM improved and enhanced the long-term stability of iPSCs, including TiPSCs, compared to TiPSCs cultured in FMM without the benefit of exposure to the modifications described above, as indicated by the reduction of chromosome 12 trisomy and the maintenance of a normal karyotype during extended passages and multiple freeze-thaw cycles (and possibly including expansion, genome manipulation and sorting and thawing and freezing in between).

[0223] E8 is a commercial medium for maintaining and preserving iPSCs and is known to promote primed pluripotency in iPSCs. As described, TiPSCs generated using the reprogramming platform were maintained for more than 10 passages in E8, FMM, or FMM2, respectively, and harvested for gene expression profiling and principal component analysis (PCA). As shown in Figure 2, the TiPSC clones maintained in E8, FMM, or FMM2 each formed three distinct clusters corresponding to the medium to which the cells were exposed.

[0224] TiPSC clones cultured on E8, FMM, or FMM2 were further prepared for RNA-seq analysis of pluripotency markers. Common pluripotency markers, including DPPA3, TDGF1, SALL4, NANOG, OCT4, MYC, LIN28, and SOX2, were expressed under all culture conditions tested without clustering. In particular, primed pluripotency-specific genes such as THY1, OTX2, DUSP6, and ZIC2 were upregulated in TiPSCs under E8 conditions. The clones exhibited low-level expression of primed-specific markers and intermediate-level expression of naive-specific markers, e.g., TBX3, TFCP2L1, UTF1, FGF4, PRDM14, DPPA5, DNMT3L, KLF4, and MAEL. The expression of all these naive-specific markers was further upregulated in TiPSC clones cultured on FMM2, in which case activin A was added. In addition, FMM2 cultured iPSCs also most distinctly express additional naive pluripotency-specific gene families that are mostly silenced in iPSCs maintained under very high levels of PRDM14, DPPA5, DNMT3L, KLF4, and MAEL, E8, or FMM conditions (see Figures 3a and 3b), demonstrating FMM2’s ability to deepen the pluripotency level of iPSCs in the spectrum or continuum of pluripotency (e.g., from priming to naive, from low naive to high naive) and adapt to iPSCs at lower pluripotency levels, regardless of the reprogramming process used.

[0225] Example 3 - FMM2 prevents stress-induced genomic abnormalities in iPSCs

[0226] As illustrated in Fig. 4A, to test whether the addition of a TGF beta superfamily member to FMM improves stress-induced genetic engineering and genomic stability after cryopreservation of previously stored iPSCs, clonal iPSC samples from the first bank described above were thawed, manipulated, sorted, and expanded, and a second bank was created by separately cryopreserving them in FMM or FMM supplemented with about 10 to 30 ng / mL of activin A. The manipulation was performed by electroporating the iPSCs with a CRISPR RNP complex that mediates the targeted insertion of a desired transplant gene into a specific genomic locus as described above.

[0227] For karyotype analysis, samples from the transfused population (the engineered iPSC pool and iPSCs were taken from the first cryopreservation bank) were harvested, while the remaining cells were used for single-cell sorting to generate clonal engineered iPSCs. Karyotype analysis was performed after transfection of the engineered iPSC pool and the sorted and expanded clonal iPSC populations cultured in FMM or FMM+Activin A. As shown in Figure 4B, for the genetically engineered cell populations, only 80% of the engineered cell population cultured in FMM exhibited a normal karyotype (46+XY), whereas 100% of the engineered cells cultured in FMM2 exhibited a normal karyotype.

[0228] Additionally, individual clones were screened from the single-cell classified transfected populations for defined attributes, including successful and precise engineering. The accepted clones were expanded and cryopreserved as individual clone populations (Fig. 4A) to create a secondary (second) iPSC cryopreservation bank. Then, iPSCs were retrieved from the second bank, thawed, and maintained in FMM or FMM2 medium. The results of karyotype analysis and copy number variation analysis by SNP microarray assays performed on the iPSC clone populations of the second cryopreservation bank after cryopreservation and thawing are shown in Fig. 4C: only 1 out of 3 clones (33%) generated in FMM exhibited a normal karyotype (46+XY), whereas 100% of the clones generated in FMM2 exhibited a normal karyotype (46+XY). All clones generated from FMM2 were found to have no reportable copy number changes via SNP microarray analysis and no reportable loss or absence of heterozygous regions, despite multiple rounds of freeze-thaw cycles. As such, the various stress factors of the iPSC manufacturing process, including engineering, single-cell sorting, screening, expansion, and multiple freeze-thaw cycles, have a cumulative negative impact on iPSC genomic stability that can be reduced or prevented by FMM2, which includes the addition of TGFb superfamily members, including activin A, TGFb, and nodals.

[0229] Example 4 - FMM2 improves genomic stability of reprogrammed iPSCs in T cells

[0230] To generate reprogrammed iPSCs (TiPSCs) from T cells, primary T cells were transfected with a reprogramming plasmid to create an essentially heterogeneous iPSC pool. Single-cell sorting was performed to establish iPSC clones. As shown in Fig. 5a, after sorting, TiPSC clones expanded in FMM or various forms of FMM2: FMM + ActA; FMM + ActA with a 50% reduction in GSK3 inhibitor concentration compared to that used in FMM (FMM + ActA - 50% CHIR); FMM + ActA with a 50% reduction in MEK inhibitor concentration (FMM + ActA - 50% PD); or FMM + ActA with a 50% reduction in both GSK3 inhibitor and MEK inhibitor concentrations (FMM + ActA - 50% CHIR / PD).

[0231] Screening criteria for fully reprogrammed TiPSC clones included morphological and pluripotency marker expression. Accepted clones were expanded and cryopreserved in each medium shown above. Genomic stability was first examined by determining the chromosome 12 copy number by droplet digital PCR (ddPCR) pre-cryo, and then the selected clones were tested for whole-genomic stability by G-band karyotyping analysis after cryopreservation. As shown in Figure 5b, copy number determination by ddPCR and karyotyping analysis indicated a significant reduction in genomic aberration using various FMM2 formulations compared to FMM in the context of T cell reprogramming. Even without manipulation or multiple freeze-thaw cycles, the genomic aberration rate of TiPSCs under FMM conditions was approximately 75%, which is close to that observed in FiPSCs that underwent multiple freeze-thaw cycles and additional stress cell manipulation, reflecting the difficulties of T cell reprogramming. In contrast, the genomic aberration rates of TiPSCs under FMM2 conditions are significantly lower: 0%–50% PD in FMM + ActA, and approximately 8%, 15%, and 20%–50% CHIR / PD in FMM + ActA, and 50% CHIR in FMM + ActA, respectively.

[0232] Example 5 - Reprogramming using an enhanced transient and temporary reprogramming system in addition to FMM2 iPSC retention

[0233] The vector required for the Transitional and Transient Reprogramming System (STTR) is illustrated in Fig. 6. Vector 1 is a plasmid vector containing oriP, a promoter that induces the expression of one or more operantly linked selected reprogramming factor(s) (RF). Vector 1 is also referred to as the oriP / RF plasmid. If there are two or more RFs in a single Vector 1 plasmid, adjacent RFs are separated by a 2A peptide or IRES. Vector 1 does not contain an EBNA coding sequence, and consequently, the residence time in host cells is shortened. Multiple Vector 1 plasmids containing all selected RFs collectively can be used in various combinations as desired, depending on the total number of RFs used for reprogramming. Additionally, it is desirable to use multiple Vector 1 plasmids for co-transfection when the stoichiometry of the reprogramming factors is improved by controlling the relative copy number of each reprogramming factor in the combination of multiple Vector 1 plasmids. Vector 2 is a plasmid containing a promoter and EBNA coding sequence, and expression is driven by the promoter. More importantly, because Vector 2 lacks oriP, the retention time of Vector 2 in the transfected host cell population is significantly reduced. The separation of EBNA and oriP sequences into separate constructs ensures transient expression of the transplanted gene as cells divide and faster, earlier spontaneous loss of the reprogramming vector, thereby generating footprint-free iPSCs. Vector 2 can also be replaced with EBNA mRNA or protein / peptide.

[0234] For example, a series of Vector 1 and Vector 2 constructs were prepared as described in Table 3 and Figure 6. The reprogramming factors used in this exemplary system comprise four Vector 1 plasmids, each containing OCT4 and YAP1, SOX2 and MYC, LIN28 and large T antigen (LTag), and ESRRB and ZIC3, respectively. However, it should be understood that any number of Vector 1 plasmids may be used and the order of RFs in a single Vector 1 plasmid may also vary, provided that multiple Vector 1 plasmids collectively contain polynucleotides encoding at least OCT4, YAP1, SOX2, and LTag.

[0235] [Table 3]

[0236]

[0237] On day 0, human T cells from three different donors were transfected with the reprogramming plasmid. To determine whether the HDAC inhibitor improves reprogramming efficiency, specifically T cell reprogramming efficiency compared to reprogramming cultures without the same treatment, approximately 2 to 3 days after transfection, the reprogramming cultures were treated with valproic acid (VPA) until a xenogeneic iPSC population was generated. The expression of iPSC surface markers (SSEA4, TRA-1-81, and CD30) was analyzed by flow cytometry. As shown in Figures 7a and 7b, VPA treatment [increased SSEA4] in the population across different T cell donors. + TRA-1-81 + CD30 + It significantly increased the percentage of iPSC cells, thereby demonstrating the benefits of VPA in enhancing T cell reprogramming with improved efficiency.

[0238] Clonal expansion of single cells dissociated from iPSC colonies generated using the above reprogramming system (Fig. 8a) was performed to induce stress, and the stability of the expanded pluripotent cultures was determined across different donors. As shown in Fig. 8b, fractions of the iPSC population increased over successive passages, representing stable, self-renewing pluripotent cultures derived from multiple donors. Flow cytometry of the passaged reprogramming pool confirmed the expression of iPSC pluripotency markers indicating sustained pluripotency after expansion (Fig. 8c).

[0239] Conventional FRMs, composed of ROCK inhibitors, WNT activators, MEK inhibitors, and TGFβ inhibitors, have been used for somatic cell reprogramming and are traditionally applied immediately after transfection. In the cells of the reprogramming system, the FRM exists from about day 1 until the iPSC pool is formed (a process of 12 to 16 days). Exposing somatic cells transfected with the STTR plasmid to small molecules including VPA and TGFβ inhibitors in a stage-specific manner can further improve the quality and efficiency of the reprogramming process during the 12 to 16-day process, as illustrated in FIG. 9, and this STTR + FRM containing stage-specific HDACi and TGFβi has been found to be also referred to as "STTR2 reprogramming" in this application.

[0240] In the STTR2 method and composition, in addition to the valproic acid (VPA) treatment as described above, exposure to a TGFβ inhibitor is delayed from about 1 day in the STTR method to about 6 to 8 days in the STTR2 method, around the time of expression of the exogenous gene in the vector plasmid until the time of iPSC colony appearance (about 2 to 3 days to 12 to 16 days after transfection), until the transfected somatic cells lose their T cell identity until iPSC colony formation. The ROCK inhibitor, WNT activator, and MEK inhibitor are retained in the medium after reprogramming, after taking cells via single-cell dissociation and single-cell sorting to establish iPSC clones. Screening criteria for fully reprogrammed iPSC clones included morphology, pluripotency marker expression, and clearance of the reprogramming plasmid. As described above, the allowed clones were expanded and cryopreserved into a Master Cell Bank (MCB) containing high-purity clonal iPS cells (>99%) using FMM2. Specifically, Activin A was added after sorting or after iPSC colony formation, and the concentrations of one or both of the MEK inhibitor and WNT activator were selectively reduced by about 30% to 60%. Karyotype analysis and pluripotency gene profiling were used to determine the stability of the iPSC clones after cryopreservation.

[0241] TaqMan probes (Fig. 10a; black bars) were used to detect the reprogramming vector in iPSC clones. Reprogramming different donor T cells using the STTR2 system was observed to induce the robust generation of 100% transplant gene-free iPSC clones with complete vector clearance (Figs. 10b and 10c), representing higher volumes and more reliable footprint-free results compared to the previous system. Furthermore, flow cytometry of iPSC clones produced with STTR2 showed uniform expression of iPSC surface markers (SSEA4, TRA-1-81, and CD30) (Fig. 11). All iPSC clones had identical and distinctly different gene expression profiles compared to the parent T cells, confirming that the STTR2 system induces the generation of high-quality pluripotent cells derived from finally differentiated T cells, which are particularly difficult to reprogram compared to, for example, fibroblasts or keratinocytes.

[0242] In addition, iPSC clones generated by STTR2 were found to maintain a high propensity to differentiate into cell types exhibiting all three germ layers. The pluripotency of iPSCs generated by STTR2 was evaluated by testing the trilineage differentiation potential. iPSC differentiation was performed using the STEMdiff™ Trilineage Differentiation Kit (Stem Cell Technologies). After one week of culture in the indicated media to induce lineage-specific differentiation, differentiated cells were harvested, and the expression of the indicated lineage markers (pancreatic progenitor marker SOX17 for the endoderm, mesenchymal marker CD56 for the mesoderm, and neural progenitor marker SOX2 for the ectoderm) was evaluated by flow cytometry (Fig. 12a).

[0243] The pluripotency of iPSCs generated by STTR2 was evaluated by testing their ability to differentiate into terminally differentiated cells, such as T lymphocytes. iPSCs were cultured in stage-specific media to induce hematopoietic characteristics and T cell differentiation. As shown in Figure 12b, flow cytometry analysis at the indicated time points demonstrated that iPSCs generated by STTR2 differentiated into mature T cells similarly to control iPSCs generated using a conventional episomal system.

[0244] In a separate experiment, the pluripotency of iPSCs obtained using STTR2 was evaluated by an in vivo teratoma formation assay. 500,000 to 2 million iPSCs generated by STTR2 were implanted into immunodeficient NSG mice via subcutaneous injection. Six to 10 weeks after injection, teratoma tissues were harvested, processed, and subjected to histological analysis including staining of paraffin-embedded tissue sections with heathoxylin and eosin. As shown in Fig. 12c, the pluripotency of iPSC clones generated using the STTR2 system was confirmed to be such that the teratomas contained tissues derived from each embryonic germ layer (endoderm, mesoderm, and ectoderm).

[0245] Collectively, the data demonstrate that footprint-free iPSCs can be easily generated by transiently and transiently expressing reprogramming genes using an enhanced STTR2 system that includes reprogramming stage-specific small molecules such as HDACi and TGFβi in addition to FMM's ROCKi, MEKi, and GSK3i. The enhanced platform supports the efficient and rapid generation of a substantially homogeneous footprint-free iPSC population, including TiPSCs, maintaining pluripotency over a wide range of passages.

[0246] Example 6 - iPSCs obtained using STTR2 maintain genomic stability and generate functional T cells after sequential manipulation

[0247] iPSC clones were thawed and expanded as described in Example 2. In this experiment, the manipulation was performed by electroporating iPSCs with a CRISPR RNP complex mediating the targeted insertion of a chimeric antigen receptor (CAR)-expression cassette at specific genomic loci. The manipulated cell populations were classified into single cells and expanded for screening of desired genetic modalities. Selected clones exhibiting a normal karyotype (46, XX) at the latest tested passage (i.e., passage 10 after iPSC thawing) were expanded, cryopreserved in FMM2, and genomic stability was tested by karyotype analysis after cryopreservation. As shown in Fig. 13, the flow cytometry profiles of the STTR2-generating, CAR-manipulated iPSC clones showed uniform expression of iPSC surface markers (SSEA4, TRA-1-81, and CD30).

[0248] In a separate experiment, iPSCs were cultured in stage-specific media to induce hematopoietic characteristics and T cell differentiation. At the end of T cell expansion, iPSC-derived T cells were analyzed by flow cytometry and in vitro apoptosis assay. As shown in Figure 14a, the flow cytometry profiles of T cells generated from STTR2-generating, CAR-engineered iPSC clones showed uniform expression of T identity markers (CD3ic and CD7). CAR expression was observed in >90% of iPSC-derived T cells. The lack of TCR expression confirmed that the T cell receptor alpha constant (TRAC) gene was destroyed by CRISPR engineering at the iPSC stage.

[0249] T cells differentiated from STTR2-generated, CAR-engineered iPSCs were evaluated for their ability to recognize and kill tumor target cells using a flow cytometry-based in vitro cytotoxicity assay. Primary CAR-T cells were included in the assay for comparison. Effector cells (primary CAR-T cells and iPSC CAR-T cells) were co-cultured with cancer cell lines expressing CAR-specific antigens (pos antigen tumors) and without CAR-specific antigen expression (negative antigen tumors) for approximately 4 hours at the indicated effector-to-target (E:T) ratios and analyzed by flow cytometry. As shown in Fig. 14b, percentage cytotoxicity for each effector-to-target (E:T) ratio was calculated according to the following formula: Percentage Cytotoxicity = 100 - (% of remaining live target cells with test sample / % of remaining live target cells without test sample x 100). Collectively, the data show that T cells differentiated from STTR2-generated, CAR-engineered iPSC clones exhibit similar antigen-specific killing function compared to CAR-engineered primary T cells.

[0250] Example 7 - Transitional and transient reprogramming system for generating a single-cell-derived iPSC bank as a source of derived cells for therapeutic use

[0251] The STTR2 reprogramming and FMM2 maintenance compositions and methods were used in tandem in this application to generate clonal master iPSC lines for use as a regenerative and reliable cell source for off-the-shelf immunotherapy. Donor consent fibroblasts or T cells were transfected with the plasmid combinations disclosed. Reprogrammed cells were sorted into 96-well plates at clonal density, and single-cell derived iPSC clones were expanded and screened for desired attributes including pluripotency, loss of the reprogramming plasmid, genomic stability, and differentiation potential. The selected clonal iPSC lines were manufactured and cryopreserved under strict manufacturing and process quality control, and the lines underwent extensive characterization and testing to qualify as a "master cell bank" as required by relevant regulations. The iPSCs in the manufactured iPSC bank were differentiated into natural killer (NK) or T lineage cells to a clinically relevant scale according to current Good Manufacturing Practice (GMP) standards. The derivative cells underwent extensive characterization and testing in accordance with relevant regulations to qualify as a "drug substance and drug product." iPSC-derived NK or T lineage cells are used, for example, at approximately 1 x 10⁶ units for adoptive cell therapy against hematological and solid tumors, either as monotherapy or in combination with immune checkpoint inhibitors. 8 It was cryopreserved to produce large doses per cell / volume. Typically, 1 x 10⁶ 8 The cell / dose ratio is 1.67 x 10 for a 60 kg patient. 6 It is converted to cells / kg. The formulation, route of administration, and administration regimen for each indication were designed and determined based on preclinical data from in vitro and in vivo Good Laboratory Practice (GLP) and non-GLP studies.

[0252] In addition to supporting iPSC-derived immune cells for the treatment of cancer and immune diseases, footprint-free and feeder cell-free master iPSC lines generated by the STTR2 reprogramming platform and / or FMM2 maintenance medium also have the potential to enable ready-made cell therapies for degenerative disorders ranging from macular degeneration, diabetes, and Parkinson's disease to blood disorders and cardiovascular diseases.

[0253] Those skilled in the art will readily recognize that the methods, compositions, and products described herein represent exemplary embodiments and are not intended to limit the scope of the invention. It will be readily apparent to those skilled in the art that various substitutions and modifications may be made to the disclosed herein without departing from the scope and spirit of the invention.

[0254] All patents and publications mentioned in this specification represent the level of those skilled in the art to which this disclosure relates. All patents and publications are incorporated herein by reference to the same extent as each individual publication is specifically and individually indicated by reference.

[0255] The disclosures described herein by way of example may be suitably practiced in the absence of any elements or elements, limitations or restrictions not specifically disclosed herein. Accordingly, for example, in each example, any of the terms “comprising,” “essentially made,” and “made” herein may be replaced by either of the other two terms. The terms and expressions used are used for descriptive rather than limiting purposes, and there is no intention in the use of such terms and expressions to exclude any equivalent or part thereof of the features shown and described, but it is recognized that various modifications are possible within the scope of the claimed disclosures. Accordingly, it should be understood that although the disclosures are specifically disclosed by preferred embodiments and optional features, modifications and variations of the concepts disclosed herein may be made by those skilled in the art, and such modifications and variations are deemed to be within the scope of the invention as defined by the appended claims.

Claims

Claim 1 As a composition for producing induced pluripotent stem cells (iPSCs), (i) TGFβ family proteins,(ii) ROCK inhibitors, and (iii) A composition effective in improving iPSC multipotency and genomic stability in long-term iPSC maintenance, comprising a MEK inhibitor and a WNT activator, and not comprising a TGFβ inhibitor. Claim 2 In paragraph 1, (a) Long-term iPSC maintenance comprises one or more of the stages including single-cell dissociation of iPSC colonies, single-cell sorting of dissociated iPSCs, iPSC single-cell clonal expansion, cryopreservation of a clonal iPSC master cell bank (MCB), thawing of the iPSC MCB, and optionally additional cryopreservation-thawing cycles of the iPSC MCB; or (b) TGFβ family proteins are selectively added to the composition at the single-cell dissociation of iPSC colonies, at the expansion of iPSC single-cell clones, or at any stage in between; (c) A composition in which the MEK inhibitor and / or WNT activator is 30 to 60% of the amount used in the reprogramming composition for reprogramming non-pluripotent cells into iPSCs. Claim 3 In paragraph 1, (i) TGFβ family proteins include at least one of activin A, TGFβ, nodal, and functional variants or fragments thereof; and / or include; (ii) A composition comprising a WNT activator, a GSK3 inhibitor. Claim 4 In paragraph 2, (i) Non-pluripotent cells include somatic cells, progenitor cells, or pluripotent cells; (ii) Non-pluripotent cells include T cells or; (iii) A reprogramming composition comprises a ROCK inhibitor, a MEK inhibitor, a WNT activator, a TGFβ inhibitor, and optionally an HDAC inhibitor, wherein the TGFβ inhibitor and the HDAC inhibitor are included in the reprogramming composition at a specific stage during reprogramming. Claim 5 In paragraph 1, (i) Improved long-term iPSC pluripotency is indicated by reduced pluripotency return or reduced spontaneous differentiation compared to iPSCs not in contact with the composition; (ii) The composition, with improved genomic stability indicated by a lower propensity for genomic abnormalities compared to iPSCs without contact with the composition. Claim 6 A composition according to claim 5, wherein improved genomic stability comprises the reduction or prevention of trisomy or karyotype abnormalities in iPSCs obtained by reprogramming T cells. Claim 7 A composition according to claim 1, further comprising iPSCs, optionally wherein the iPSCs comprise at least one genome edit. Claim 8 In paragraph 2, (i) iPSC maintenance further comprises iPSC genome editing to obtain an engineered iPSC pool, single-cell sorting of the engineered iPSC pool, single-cell clonal expansion of the engineered iPSC, cryopreservation of a cloned engineered iPSC master cell bank (MCB), thawing of the engineered iPSC MCB, and optionally additional cryopreservation-thawing cycles of the engineered iPSC MCB; (ii) A composition comprising at least one genome edit, wherein the engineered iPSC comprises at least one genome edit. Claim 9 As a composition for producing induced pluripotent stem cells (iPSCs), (i) ROCK inhibitors, MEK inhibitors, and WNT activators; (ii) HDAC inhibitors; and (iii) The composition comprises a TGFβ inhibitor and is effective in improving the reprogramming of non-pluripotent cells to obtain iPSCs with established pluripotency and improved genomic stability, and optionally, adding (i), (ii) or (iii) to the composition is stage-specific during the reprogramming of non-pluripotent cells for increased reprogramming efficiency. Claim 10 In Paragraph 9, (a) Reprogramming of non-pluripotent cells comprises one or more stages including somatic cell transfection (day 0), exogenous gene expression, increase in heterochromatin, loss of somatic identity, and iPSC colony formation; (b) Addition of the HDAC inhibitor is selectively performed at chromatin reconstruction or about 2 to 3 days (after transfusion); (c) A composition in which the addition of a TGFβ inhibitor is selectively performed at the time of loss of somatic identity, or about 6 to 8 days (after transfection), and one or more stages of reprogramming are indicated by cell morphological changes and / or marker gene profiling. Claim 11 In Paragraph 9, (i) HDAC inhibitors include valproic acid (VPA) or functional variants or derivatives thereof; and / or include; (ii) A composition comprising a WNT activator, a GSK3 inhibitor. Claim 12 In Paragraph 9, (i) Non-pluripotent cells include somatic cells, progenitor cells, or pluripotent cells; (ii) A composition comprising non-pluripotent cells, including T cells. Claim 13 In Paragraph 9, (i) Established plurality includes and / or ground state plurality; (ii) Established pluripotency is expressed by increased naive-specific gene expression including one or more of MAEL, KLF4, DNMT3L, DPPA5, PRDM14, FGF4, UTF1, TFCP2L1 and TBX3 and / or is expressed by; (iii) Improved genomic stability is indicated by a lower propensity for genomic abnormalities than iPSCs obtained without contact with the composition during reprogramming and / or; (iv) Increased reprogramming efficiency is indicated by a higher percentage of cells expressing pluripotency marker genes in the iPSC pool after reprogramming compared to the iPSC pool obtained without contact with the composition during reprogramming, the composition. Claim 14 A method for producing iPSCs comprising the step of cryopreserving a population of induced pluripotent stem cells (iPSCs), wherein the iPSCs are in contact with a composition of any one of claims 1 to 8, and the pluripotency and genomic stability of the iPSCs are maintained during cryopreservation; optionally, a population of iPSCs including homologous iPSCs is expanded from a single clonal iPSC cell. Claim 15 A method according to claim 14, further comprising the step of expanding a single-cell iPSC clone to obtain a population of cloned iPSCs, wherein the iPSCs are in contact with the composition of any one of claims 1 to 8, and the pluripotency and genomic stability of the iPSCs are maintained during expansion. Claim 16 A method according to claim 15, further comprising the step of single-cell sorting dissociated iPSCs to obtain single-cell iPSC clones, wherein the iPSCs are in contact with the composition of any one of claims 1 to 8, and the pluripotency and genomic stability of the iPSCs are maintained during single-cell sorting. Claim 17 A method according to claim 16, further comprising the step of dissociating an iPSC colony into a single-cell iPSC, wherein the iPSC is in contact with the composition of any one of claims 1 to 8, and the pluripotency and genomic stability of the iPSC are maintained during the iPSC single-cell dissociation. Claim 18 A method according to claim 17, further comprising the step of obtaining at least one colony comprising an iPSC generated from the reprogramming of a non-pluripotent cell. Claim 19 A method according to any one of claims 14 to 18, wherein the iPSC is reprogrammed from a somatic cell, a progenitor cell, or a pluripotent cell, or the iPSC is reprogrammed from a T cell. Claim 20 In any one of paragraphs 14 through 19, (i) Potentiality includes and / or includes ground state potency; (ii) Pluripotency is expressed by increased naive-specific gene expression including one or more of MAEL, KLF4, DNMT3L, DPPA5, PRDM14, FGF4, UTF1, TFCP2L1, and TBX3; (iii) A method in which genomic stability includes a lower propensity for genomic abnormalities than iPSCs in the above step without contact with the composition. Claim 21 As a method for producing induced pluripotent stem cells (iPSCs), (i) A step of initiating cell reprogramming by delivering one or more reprogramming factors to a non-pluripotent cell; and (ii) A method comprising the step of generating at least one colony containing iPSCs by contacting the cells after step (i) with the composition of any one of claims 9 to 13 for a sufficient period of time to reprogram the non-pluripotent cells. Claim 22 A method according to claim 21, wherein the delivery step comprises: (i) one or more first plasmids, each first plasmid comprising a polynucleotide encoding a replication origin and one or more reprogramming factors, but not a polynucleotide encoding EBNA or a variant thereof; one or more first plasmids collectively comprising at least OCT4, or at least OCT4, YAP1, SOX2, and large T antigen (LTag); and the introduction of one or more first plasmids induces a reprogramming process; and (ii) introducing one of (1) a second plasmid comprising a nucleotide sequence encoding EBNA, wherein the second plasmid does not contain polynucleotide(s) encoding a replication origin or reprogramming factors; (2) EBNA mRNA; and (3) EBNA protein. Claim 23 In claim 22, the method further comprises one or more first plasmids collectively additionally encoding one or both of SOX2 and KLF, or one or more of MYC, LIN28, ESRRB and ZIC3. Claim 24 A method according to claim 21, wherein the contact step further comprises the step of culturing cells in the presence of a ROCK inhibitor, a MEK inhibitor, a WNT activator, an HDAC inhibitor, and a TGFβ inhibitor. Claim 25 In claim 21, the contact step comprises: (a) selectively contacting cells after step (i) at the stage of exogenous reprogramming factor expression, or 1 to 2 days after reprogramming factor delivery (day 0) with a combination comprising a ROCK inhibitor, a MEK inhibitor, and a WNT activator; (b) selectively contacting the cells of step (a) at the chromatin restructuring stage, or about 2 to 3 days after reprogramming factor delivery with an HDAC inhibitor; and (c) a step of selectively contacting the cells of step (b) with a TGFβ inhibitor at the stage of loss of somatic identity or about 6 to 8 days (after transfection) to generate at least one colony containing iPSCs; said stages are indicated by cell morphological changes and / or marker gene profiling, and / or, the iPSCs are footprint-free, have established pluripotency and improved genomic stability, and are produced with higher efficiency compared to reprogramming without steps (a), (b) and (c). Claim 26 In Paragraph 21, (i) Non-pluripotent cells include somatic cells, progenitor cells, or pluripotent cells; (ii) A method in which non-pluripotent cells include T cells. Claim 27 In paragraph 25, (i) Established plurality includes and / or includes ground state plurality; (ii) Established pluripotency is expressed by increased naive-specific gene expression including one or more of MAEL, KLF4, DNMT3L, DPPA5, PRDM14, FGF4, UTF1, TFCP2L1 and TBX3 and / or is expressed by; (iii) Improved genomic stability includes and / or includes a lower propensity for genomic abnormalities than iPSCs from reprogramming without steps (a), (b) and (c); (iv) Increased reprogramming efficiency is indicated by a higher percentage of cells expressing pluripotency marker genes in the iPSC pool after reprogramming compared to the iPSC pool obtained without contact with the composition during reprogramming, method. Claim 28 In claim 26, the improved genomic stability further comprises the reduction or prevention of trisomy or karyotype abnormalities in iPSCs obtained by reprogramming T cells. Claim 29 As a method for producing induced pluripotent stem cells (iPSCs), (i) (ii) a step of initiating cell reprogramming by delivering one or more reprogramming factors to a non-pluripotent cell; Step (i) a step of contacting the cells after the subsequent step with a composition of any one of claims 9 to 13 for a sufficient period of time to generate at least one colony containing iPSCs, wherein the pluripotency and genomic stability of the iPSCs are established; (iii) A step of dissociating the iPSC colonies of step (ii) into dissociated iPSCs, wherein the iPSCs come into contact with a composition of any one of claims 1 to 8; (iv) A step of classifying dissociated iPSCs to obtain one or more single-cell iPSC clones, wherein the single-cell iPSC clones are in contact with a composition of any one of claims 1 to 8; and optionally, (v) A step of expanding a single-cell iPSC clone into a population of cloned iPSCs, wherein the population of cloned iPSCs comes into contact with a composition of any one of claims 1 to 8; and optionally, (vi) A method comprising the step of cryopreserving a population of cloned iPSCs, wherein the cryopreserved population is in contact with a composition of any one of claims 1 to 8; wherein the pluripotency and genomic stability of the iPSCs are maintained during the steps of dissociation, sorting, expansion, cryopreservation, or thawing. Claim 30 A method comprising the step of cryopreserving a population of cloned iPSCs in claim 29. Claim 31 In claim 29, a method wherein one or more reprogramming factors comprise at least OCT4. Claim 32 A method according to claim 29, wherein the step (i) of delivering to a non-pluripotent cell comprises: (a) one or more first plasmids, each first plasmid comprising a polynucleotide encoding a replication origin and one or more reprogramming factors, but not a polynucleotide encoding EBNA or a variant thereof; one or more first plasmids collectively comprising at least OCT4, or at least OCT4, YAP1, SOX2, and large T antigen (LTag); and the introduction of one or more first plasmids induces a reprogramming process; and (b) introducing one of (1) a second plasmid comprising a nucleotide sequence encoding EBNA, wherein the second plasmid does not contain polynucleotide(s) encoding a replication origin or reprogramming factors; (2) EBNA mRNA; and (3) EBNA protein. Claim 33 In claim 32, the method further comprises one or more first plasmids collectively additionally encoding one or both of SOX2 and KLF, or one or more of MYC, LIN28, ESRRB and ZIC3. Claim 34 In claim 29, the contact step (ii) further comprises the step of culturing cells in the presence of a ROCK inhibitor, a MEK inhibitor, a WNT activator, an HDAC inhibitor, and a TGFβ inhibitor. Claim 35 A method according to claim 29, wherein the contact step (ii) further comprises: (a) a step of selectively contacting cells after step (i) at the stage of exogenous reprogramming factor expression, or 1 to 2 days after reprogramming factor delivery (day 0) with a combination comprising a ROCK inhibitor, a MEK inhibitor, and a WNT activator; (b) a step of selectively contacting cells of step (a) at the chromatin restructuring stage, or about 2 to 3 days after reprogramming factor delivery with an HDAC inhibitor; and (c) a step of selectively contacting cells of step (b) at the stage of loss of somatic identity, or about 6 to 8 days (post-transplantation) with a TGFβ inhibitor to generate at least one colony comprising iPSCs; wherein the stages are indicated by cell morphological changes and / or marker gene profiling, and / or, iPSCs have established pluripotency and improved genomic stability and are produced with higher efficiency compared to reprogramming without steps (a), (b), and (c). Claim 36 In paragraph 29, (1) A step of contacting cells of the sorting step (iv), the expansion step (v), the cryopreservation step (vi), and optionally the dissociation step (iii) with a ROCK inhibitor, a MEK inhibitor, and a WNT activator, wherein the concentration of one or both of the MEK inhibitor and the WNT activator is 30% to 60% of the concentration in step (ii); (2) A method comprising an extension step (v) and a cryopreservation step (vi), and optionally a step of additionally contacting cells of the dissociation step (iii) and / or sorting step (iv) with TGFβ family proteins; wherein the cells of steps (iii), (iv), (v) and (vi) are not contacted with a TGFβ inhibitor or an HDAC inhibitor. Claim 37 In Paragraph 29, (i) Non-pluripotent cells include somatic cells, progenitor cells, or pluripotent cells; (ii) A method in which non-pluripotent cells include T cells. Claim 38 In Paragraph 29, (i) Potentiality includes and / or includes ground state potency; (ii) Pluripotency is expressed by increased naive-specific gene expression including one or more of MAEL, KLF4, DNMT3L, DPPA5, PRDM14, FGF4, UTF1, TFCP2L1, and TBX3; (iii) iPSCs comprise at least one genome edit and / or include; (iv) Genome stability includes a lower tendency toward genome abnormalities, method. Claim 39 A method according to claim 38, further comprising reducing or preventing trisomy or karyotype abnormalities in iPSCs obtained by reprogramming T cells, wherein genomic stability. Claim 40 In claim 29, the method further comprises genome editing of iPSCs to obtain a pool of engineered iPSCs, single-cell sorting of the pool of engineered iPSCs, single-cell clonal expansion of the engineered iPSCs, cryopreservation of a cloned engineered iPSC master cell bank (MCB), thawing of the engineered iPSC MCB, and optionally additional cryopreservation-thaw cycles of the engineered iPSC MCB; wherein the engineered iPSCs comprise at least one genome edit. Claim 41 A composition comprising induced pluripotent cells (iPSCs), a cell line, a clonal population, or a master cell bank thereof, wherein the iPSCs are contacted by a combination of a ROCK inhibitor, a MEK inhibitor, a WNT activator, and a TGFβ family protein, and the iPSCs have increased naive-specific gene expression including one or more of MAEL, KLF4, DNMT3L, DPPA5, PRDM14, FGF4, UTF1, TFCP2L1, and TBX3; optionally, the iPSCs have at least one of high clonality, genetic stability, and ground-state pluripotency. Claim 42 A composition according to claim 41, wherein the TGFβ family protein comprises at least one of activin A, TGFβ, nodal, and functional variants or fragments thereof; and the WNT activator comprises a GSK3 inhibitor. Claim 43 In paragraph 41, the composition, wherein the iPSC is generated from the reprogramming of non-pluripotent cells. Claim 44 A composition according to claim 43, wherein the non-pluripotent cells comprise somatic cells, progenitor cells, or multipotent cells; and the non-pluripotent cells comprise T cells. Claim 45 In paragraph 44, the composition comprises at least genome editing, iPSC. Claim 46 A composition according to claim 41, further comprising a culture medium, wherein the culture medium is feeder-free. Claim 47 In claim 41, the composition wherein the iPSC has at least one of high clonalability, genetic stability, and ground state pluripotency. Claim 48 Induced pluripotent cells (iPSCs), cell lines, clonal populations, or master cell banks produced by a method according to any one of claims 14 to 40. Claim 49 In paragraph 48, the iPSC is an induced pluripotent cell (iPSC) comprising at least genome editing, a cell line, clonal population, or master cell bank thereof. Claim 50 Non-natural cells or a population thereof derived from the in vitro differentiation of the pluripotent cells or cell lines of paragraph 48 or 49. Claim 51 In paragraph 50, the cell is an immune effector cell, and optionally the immune effector cell is a derived non-natural cell or population thereof comprising at least genome editing included in the iPSC. Claim 52 In paragraph 50, the cells are derived non-natural cells or populations thereof, including CD34 cells, hematopoietic endothelial cells, hematopoietic stem or progenitor cells, hematopoietic pluripotent progenitor cells, T cell progenitors, NK cell progenitors, T cells, NKT cells, NK cells, B cells, or immunomodulatory cells. Claim 53 In paragraph 50, the derived non-natural cell or population thereof is a rejuvenated cell comprising at least one of the following characteristics compared to its natural cell counterpart: overall increase in heterochromatin; improved mitochondrial function; increased DNA damage response; telomere elongation and a decrease in the percentage of short telomeres; a decrease in the proportion of senescent cells; and a higher potential for proliferation, survival, persistence, or memory-like function. Claim 54 A composition for use in manufacturing pluripotent cells for application in cell-based therapy, comprising pluripotent cells produced by a method according to any one of claims 14 to 40. Claim 55 A composition in which, in paragraph 54, the pluripotent cells are homologous or autologous cells. Claim 56 A pharmaceutical kit comprising pluripotent cells obtained by a method according to any one of claims 14 to 40. Claim 57 A pharmaceutical kit comprising the induced pluripotent cells of claim 48 or the induced non-natural cells of any one of claims 50 to 53. Claim 58 An in vitro system for initiating reprogramming in non-pluripotent cells, comprising one or more first plasmids—wherein each first plasmid comprises a polynucleotide encoding a replication origin and one or more reprogramming factors but not encoding EBNA or a derivative thereof; one or more first plasmids collectively comprise polynucleotides encoding OCT4, YAP1, SOX2, and LTag—; optionally comprising one of the following: (1) a second plasmid comprising a nucleotide sequence encoding EBNA, wherein the second plasmid does not comprise polynucleotide(s) encoding a replication origin or reprogramming factor(s); (2) EBNA mRNA; and (3) EBNA protein. Claim 59 In paragraph 58, the second plasmid has a high loss rate; the expression of EBNA is transient and temporary, system. Claim 60 A system according to claim 58 or 59 that does not provide EBNA replication and / or continuous expression in the nucleus. Claim 61 A system that enables transient / cytoplasmic expression of EBNA for a short period prior to the appearance of pluripotent cell forms and the induced expression of endogenous pluripotent genes in any one of claims 58 to 60. Claim 62 A system that enables the transient / cytoplasmic expression of one or more reprogramming factors contained in the first plasmid(s) for a short period and prior to the emergence of pluripotent cell forms and the induced expression of endogenous pluripotent genes, in any one of claims 58 to 61. Claim 63 A system in which, in any one of paragraphs 58 to 62, the replication origin is selected from the group consisting of poliomavirinae virus, papillomavirus and gamma herpesvirus. Claim 64 A system according to any one of claims 58 to 63, wherein the replication origin is selected from the group consisting of SV40, BK virus (BKV), bovine papillomavirus (BPV), and Epstein-Barr virus (EBV). Claim 65 A system in which, in any one of paragraphs 58 through 64, the replication origin corresponds to or is derived from the wild-type replication origin of EBV. Claim 66 In any one of paragraphs 58 through 65, EBNA is a system based on EBV. Claim 67 A system according to any one of claims 58 through 66, wherein one or more of the first plasmids collectively further comprise polynucleotides encoding reprogramming factor(s) comprising: (i) one or more of NANOG, KLF, LIN28, MYC, ECAT1, UTF1, ESRRB, HESRG, CDH1, TDGF1, DPPA4, DNMT3B, ZIC3, and L1TD1; or (ii) MYC, LIN28, ESRRB, and ZIC3. Claim 68 A system in which, in any one of paragraphs 58 to 67, the polynucleotide encoding the reprogramming factor is included in a polycistron construct or a non-polycistron construct. Claim 69 In paragraph 68, the polycistron construct comprises a single open read frame or multiple open read frames, a system. Claim 70 A system according to any one of claims 58 to 69, comprising two or more first plasmids, wherein each first plasmid comprises the same or different reprogramming factor coded by at least one polynucleotide copy. Claim 71 A system according to any one of claims 58 to 70, comprising four first plasmids, each first plasmid comprising the same or different reprogramming factor encoded by at least one polynucleotide copy. Claim 72 A system according to any one of claims 58 to 71, comprising four first plasmids, each first plasmid comprising at least one copy of a polynucleotide encoding OCT4 and YAP1, SOX2 and MYC, LIN28 and LTag, and ESRRB and ZIC3. Claim 73 A system according to any one of claims 58 to 72, wherein the first plasmid comprises one or more polynucleotides encoding a reprogramming factor, and adjacent polynucleotides are operably linked by a linker sequence encoding a self-cleaving peptide or an IRES. Claim 74 In paragraph 73, the self-cleaving peptide is a 2A peptide and is selected from the group comprising F2A, E2A, P2A and T2A, in a system. Claim 75 In paragraph 74, the 2A peptide included in the first plasmid construct may be the same or different in the system. Claim 76 In paragraph 74 or 75, the two 2A peptides in adjacent positions are different systems. Claim 77 A system according to any one of claims 58 to 76, wherein the first and second plasmids each comprise one or more promoters for the expression of a reprogramming factor and EBNA, and the one or more promoters comprise at least one of CMV, EF1α, PGK, CAG, UBC, and other suitable promoters that are constitutive, inducible, endogenous regulatory, or transient, tissue or cell type specific. Claim 78 A system according to any one of paragraphs 58 through 77, wherein the first and second plasmids each comprise a CAG promoter. Claim 79 A kit comprising the system of any one of paragraphs 58 through 78.